



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 256 348 A1**

(12) **EUROPEAN PATENT APPLICATION**
published in accordance with Art. 158(3) EPC

(43) Date of publication:
13.11.2002 Bulletin 2002/46

(21) Application number: **01904385.0**

(22) Date of filing: **13.02.2001**

(51) Int Cl.7: **A61K 31/737**, A61K 38/17,
A61K 39/395, A61K 45/00,
A61P 31/20, C07K 16/10,
C12N 15/09, G01N 33/50,
G01N 33/53, G01N 33/576

(86) International application number:
PCT/JP01/00967

(87) International publication number:
WO 01/058459 (16.08.2001 Gazette 2001/33)

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **14.02.2000 JP 2000034906**

(71) Applicants:
• **Mitsubishi Pharma Corporation**
Osaka-shi, Osaka 541-0046 (JP)
• **JAPAN as represented by DIRECTOR GENERAL**
OF NATIONAL INSTITUTE OF INFECTIOUS
DISEASES
Tokyo 162-8640 (JP)

(72) Inventors:
• **ITAMI, Seima c/o Mitsubishi Pharma Corporation**
Chuo-ku, Tokyo 103-8405 (JP)

- **SHIBUI, Taturou**
c/o Mitsubishi Pharma Corporation
Chuo-ku, Tokyo 103-8405 (JP)
- **SEKI, Makoto**
c/o Mitsubishi Pharma Corporation
Chuo-ku, Tokyo 103-8405 (JP)
- **YOTSUMOTO, Yoshihisa**
c/o Mitsubishi Pharma Corp.
Chuo-ku, Tokyo 103-8405 (JP)
- **MATSUURA, Yoshiharu**
Suita-shi, Osaka 565-0821 (JP)
- **MIYAMURA, Tatsuo**
Suginami-ku, Tokyo 168-0065 (JP)

(74) Representative:
Sternagel, Fleischer, Godemeyer & Partner
Patentanwälte
An den Gärten 7
51491 Overath (DE)

(54) **REMEDIES FOR HEPATITIS C**

(57) The present invention provides a substance which inhibits the binding between E2/NS1 protein of hepatitis C virus and a cell infectious with hepatitis C virus, a cell expressing CD81, or CD81. The present in-

vention can provide a novel medicament which has an anti-viral effects such as an inhibitory action against HCV infection.

EP 1 256 348 A1

Description

Technical Field

5 **[0001]** The present invention relates to various substances which bind to an envelope glycoprotein of hepatitis C virus (hereinafter sometimes referred to as "HCV"), and more particularly to proteins such as antibodies, sulfated polysaccharides and low molecular weight compounds, which have anti-viral effects such as inhibitory actions against HCV infection by binding to the envelope glycoprotein of HCV.

10 Background Art

[0002] In 1989, Chiron Corporation (U.S.A.) cloned a gene fragment of human hepatitis virus which had been heretofore referred to as "non-A non-B hepatitis virus," and the fragment was named "HCV" (SCIENCE, Vol. 244, 359-362, 1989). HCV is a virus, the genome of which is single strand (+) strand RNA. Besides Chiron Corporation, Shimotohno et al. of the National Cancer Center (Proc. Natl. Acad. Sci. USA, Vol. 87, 9524-9528, 1990) and Takamizawa et al. of the Research Institute for Microbial Diseases at Osaka University (J. Virol, Vol. 65, No. 3, 1105-1113, 1990) thereafter published the entire gene sequences of hepatitis C virus. Thereafter, it was found that HCV comprise three types of structural proteins, i.e., core protein, envelope 1 protein (hereinafter sometimes referred to as "E1" or "E1 protein") and envelope 2 protein (hereinafter sometimes referred to as "E2/NS1" or "E2/NS1 protein") and 6 types of non-structural proteins.

[0003] Once HCV is developed, acute hepatitis, chronic hepatitis, and hepatocir rhosis are highly likely to be developed, and the disease condition is eventually transited to liver cancer leading a patient to death. Conventionally, interferon, an anti-viral agent, has been typically used in the treatment. However, there are problems of variation in the therapeutic effects for each patient and side effects such as fever (J. Med. Virol., Vol. 42, 299-305, 1994) (Journal of Gastroenterology, Vol. 91, 995-1002, 1994).

[0004] Although a treatment using other anti-viral agents such as ribavirin has been also studied, this could not provide sufficient effect (Lancet, Vol. 337, 1058-1061, 1991), and therefore the development of a novel anti-HCV agent has been awaited.

[0005] HCV gene is considered to very easily undergo mutation and HCV, because of its high mutation ability, was presumed to escape from the immunity in the body of a patient. In particular, at the N-terminus of E2/NS1 of HCV, there is presumed to be a region of 25 to 30 amino acids, referred to as a "hyper variable region," which is rich in mutation, and Kato et al. deduce that an epitope of a human immune system is a hyper variable region (J. Virol., Vol. 67, No. 7, 3923-3930, 1993) (J. Virol., Vol. 68, No. 8, 4776-4784, 1994). More specifically, since the region which is recognized by the human immune system such as neutralizing antibody is in the hyper variable region, even though the neutralizing antibody is generated in the body of the infected patient, it is considered that the hyper variable region immediately undergoes mutation and viruses escape from the antibody. However, Ishii et al. have reported that an antibody which inhibits the binding between E2/NS1 and human T cell Molt-4 is present in a highly active state only in the blood of a patient who naturally recovered from HCV, and it is suggested that a humoral immunity is involved in the treatment of HCV in spite of the high mutation ability of HCV (Hepatology, Vol. 28, No. 4, 1117-1120, 1998).

[0006] In 1999, Chiron Corporation (U.S.A.) isolated CD81 as a protein on a cell surface to which E2/NS1 bound (SCIENCE, Vol. 282, 938-941, 1999). CD81 and E2/NS1 which were expressed in *Escherichia coli*, bound to each other in the same manner as reported by Ishii et al. and the serum of a patient who naturally recovered from HCV inhibited this binding. This result suggested that CD81 was a receptor of HCV.

[0007] From the foregoing, it has been considered that the use, as an agent, of a substance such as an antibody, which binds to an envelope protein that is presumably deeply involved in the infection of HCV to a cell and inhibits the binding to a human cell infectious with HCV, can inhibit HCV in the blood from infecting organs capable of being infected such as liver again, and can lead the HCV patient to the recovery. However, as yet, infection-inhibiting substances for HCV-derived diseases have not been sufficiently studied.

50 Disclosure of the Invention

[0008] HCV is known to be RNA virus and, thus, is highly likely to undergo mutation. This mutation causes mutation in many sites, both in the structural protein and the non-structural protein of HCV. Because of this mutation, the development of a substance for inhibiting HCV infection, for example, an antibody which recognizes a given protein sequence, has been considered to be difficult. However, the present inventors have focused on the point that the neutralizing antibody reported by Ishii et al. inhibits the binding to only one type of E2/NS1 even though the sequence of the infected virus are different for each recovered patient. More specifically, they have considered that a substance recognizing a specific region or a configuration of the antigen can inhibit the binding between E2/NS1 and a human

cell infectious with HCV, a CD81 expressing cell, or CD81 and prevent infection regardless of the diversity of viral sequences.

[0009] In the present invention, for the purpose of developing an agent for improving the symptoms of hepatitis C patients, the present inventors have conducted concentrated search on substances which inhibit the binding between E2/NS1 and the cell infectious with HCV, the cell expressing CD81, or CD81, and as a result, succeeded in obtaining a substance capable of inhibiting the binding and infection of HCV to a cell infectious with HCV.

[0010] Thus, the present invention provides a substance which inhibits the binding between E2/NS1 protein of hepatitis C virus and a cell infectious with hepatitis C virus, a cell expressing CD81, or CD81.

[0011] The preferred embodiment of the present invention provides: a substance which inhibits, upon binding to a region having a positively charged regions of E2/NS1 protein of hepatitis C virus, the binding between E2/NS1 protein of hepatitis C virus and a cell infectious with hepatitis C virus, a cell expressing CD81, or CD81; a substance in which E2/NS1 protein of hepatitis C virus is a protein prepared by adding a substance capable of recognizing E2/NS1 protein to E2/NS1 protein of hepatitis C virus; a substance in which E2/NS1 protein of hepatitis C virus is a protein prepared by adding a substance capable of detecting E2/NS1 protein by a fluorescence method or a luminescence method to E2/NS1 protein of hepatitis C virus; a substance in which E2/NS1 protein of hepatitis C virus is a protein prepared by adding a tag to E2/NS1 protein of hepatitis C virus; a substance in which E2/NS1 protein of hepatitis C virus is a protein prepared by adding a tag to the C-terminus of E2/NS1 protein of hepatitis C virus; a substance in which a cell expressing CD81 is a cell which expresses human CD81; a substance in which CD81 is human CD81 and expressed by solubilized form; a substance which has an association constant to E2/NS1 protein of hepatitis C virus is higher than 10^8 , or a dissociation constant to E2/NS1 protein of hepatitis C virus is lower than 10^{-8} ; a substance which has an association constant to E2/NS1 protein of hepatitis C virus is higher than 10^9 , or a dissociation constant to E2/NS1 protein of hepatitis C virus is lower than 10^{-9} ; a substance which is a protein, sulfated polysaccharide, or a low molecular weight compound; a substance in which a protein is an antibody; a substance in which an antibody is derived from the B cell of a patient who recovered from hepatitis C; a substance in which an antibody is derived from genes in the B cell of a patient who recovered from hepatitis C; and a substance in which a patient is recovered from hepatitis C without any antiviral treatment and the B cell is peripheral blood mononuclear cell.

[0012] Another aspect of the present invention provides:

an antibody in which CDR-1, CDR-2, and CDR-3 of a variable region of the H chain respectively comprise amino acid sequences shown by SEQ ID NOS: 1, 2, and 3 in the Sequence Listing or the amino acid sequences having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequences shown by SEQ ID NOS: 1, 2, and 3, and which has an affinity to E2/NS1 protein of hepatitis C virus;

said antibody which comprises an amino acid sequence shown by SEQ ID NO: 16 or 34 in the Sequence Listing or the amino acid sequence having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequence shown by SEQ ID NO: 16 or 34;

an antibody in which CDR-1, CDR-2, and CDR-3 of a variable region of the L chain respectively comprise amino acid sequences shown by SEQ ID NOS: 4, 5, and 6 in the Sequence Listing or the amino acid sequences having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequences shown by SEQ ID NOS: 4, 5, and 6, and which has an affinity to E2/NS1 protein of hepatitis C virus;

said antibody which comprises an amino acid sequence shown by SEQ ID NO: 17 in the Sequence Listing or the amino acid sequence having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequence shown by SEQ ID NO: 17;

an antibody in which CDR-1, CDR-2, and CDR-3 of a variable region of the L chain respectively comprise amino acid sequences shown by SEQ ID NOS: 7, 8, and 9 in the Sequence Listing or the amino acid sequences having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequences shown by SEQ ID NOS: 7, 8, and 9, and which has an affinity to E2/NS1 protein of hepatitis C virus;

said antibody which comprises an amino acid sequence shown by SEQ ID NO: 18 in the Sequence Listing or the amino acid sequence having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequence shown by SEQ ID NO: 18;

an antibody in which CDR-1, CDR-2, and CDR-3 of a variable region of the L chain respectively comprise amino acid sequences shown by SEQ ID NOS: 10, 11, and 12 in the Sequence Listing or the amino acid sequences having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequences shown by SEQ ID NOS: 10, 11, and 12, and which has an affinity to E2/NS1 protein of hepatitis C virus;

said antibody which comprises an amino acid sequence shown by SEQ ID NO: 19 in the Sequence Listing or the amino acid sequence having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequence shown by SEQ ID NO: 19;

an antibody in which CDR-1, CDR-2, and CDR-3 of a variable region of the L chain respectively comprise amino acid sequences shown by SEQ ID NOS: 13, 14, and 15 in the Sequence Listing or the amino acid sequences

having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequences shown by SEQ ID NOS: 13, 14, and 15, and which has an affinity to E2/NS1 protein of hepatitis C virus; and said antibody which comprises an amino acid sequence shown by SEQ ID NO: 20 in the Sequence Listing or the amino acid sequence having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequence shown by SEQ ID NO: 20;

[0013] A further aspect of the present invention provides:

an antibody in which CDR-1, CDR-2, and CDR-3 of a variable region of the L chain respectively comprise amino acid sequences shown by SEQ ID NOS: 42, 43, and 44 in the Sequence Listing or the amino acid sequences having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequences shown by SEQ ID NOS: 42, 43, and 44, and which has an affinity to E2/NS1 protein of hepatitis C virus;

said antibody which comprises an amino acid sequence shown by SEQ ID NO: 54 in the Sequence Listing or the amino acid sequence having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequence shown by SEQ ID NO: 54;

an antibody in which CDR-1, CDR-2, and CDR-3 of a variable region of the L chain respectively comprise amino acid sequences shown by SEQ ID NOS: 45, 46, and 47 in the Sequence Listing or the amino acid sequences having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequences shown by SEQ ID NOS: 45, 46, and 47, and which has an affinity to E2/NS1 protein of hepatitis C virus;

said antibody which comprises an amino acid sequence shown by SEQ ID NO: 55 in the Sequence Listing or the amino acid sequence having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequence shown by SEQ ID NO: 55;

an antibody in which CDR-1, CDR-2, and CDR-3 of a variable region of the L chain respectively comprise amino acid sequences shown by SEQ ID NOS: 48, 49, and 50 in the Sequence Listing or the amino acid sequences having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequences shown by SEQ ID NOS: 48, 49, and 50, and which has an affinity to E2/NS1 protein of hepatitis C virus;

said antibody which comprises an amino acid sequence shown by SEQ ID NO: 56 in the Sequence Listing or the amino acid sequence having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequence shown by SEQ ID NO: 56;

an antibody in which CDR-1, CDR-2, and CDR-3 of a variable region of the L chain respectively comprise amino acid sequences shown by SEQ ID NOS: 51, 52, and 53 in the Sequence Listing or the amino acid sequences having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequences shown by SEQ ID NOS: 51, 52, and 53, and which has an affinity to E2/NS1 protein of hepatitis C virus; and

said antibody which comprises an amino acid sequence shown by SEQ ID NO: 57 in the Sequence Listing or the amino acid sequence having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequence shown by SEQ ID NO: 57;

[0014] A further aspect of the present invention provides:

an antibody which comprises, as an amino acid sequence of a heavy chain, an amino acid sequences shown by SEQ ID NO: 40 in the Sequence Listing or the amino acid sequences having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequences shown by SEQ ID NO: 40, and which has an affinity to E2/NS1 protein of hepatitis C virus; and

an antibody which comprises, as an amino acid sequence of a light chain, an amino acid sequences shown by SEQ ID NO: 41 in the Sequence Listing or the amino acid sequences having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequences shown by SEQ ID NO: 41, and which has an affinity to E2/NS1 protein of hepatitis C virus;

[0015] A further aspect of the present invention provides a single-chain antibody having an affinity to E2/NS1 protein of hepatitis C virus, which comprises an amino acid sequence shown by SEQ ID NO: 26, 27, 28, or 29 in the Sequence Listing or the amino acid sequence having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequence shown by SEQ ID NO: 26, 27, 28, or 29.

[0016] A further aspect of the present invention provides a single-chain antibody having an affinity to E2/NS1 protein of hepatitis C virus, which comprises an amino acid sequence shown by SEQ ID NO: 36, 37, 38, or 39 in the Sequence Listing or the amino acid sequence having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequence shown by SEQ ID NO: 36, 37, 38, or 39.

[0017] A further aspect of the present invention provides a single-chain antibody having an affinity to E2/NS1 protein of hepatitis C virus, which comprises an amino acid sequence shown by SEQ ID NO: 62, 63, 64, or 65 in the Sequence

Listing or the amino acid sequence having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequence shown by SEQ ID NO: 62, 63, 64, or 65.

5 [0018] A further aspect of the present invention provides a nucleic acid which encodes the aforementioned antibody of the present invention. Preferably, there is provided: the nucleic acid which comprises a nucleotide sequence shown by any of SEQ ID NO: 21, 22, 23, 24, 25, 35, 58, 59, 60, or 61 in the Sequence Listing; the nucleic acid which comprises a nucleotide sequence shown by SEQ ID NO: 40 or 41 in the Sequence Listing; the nucleic acid which comprises a nucleotide sequence shown by any of SEQ ID NO: 26, 27, 28, or 29 in the Sequence Listing; the nucleic acid which comprises a nucleotide sequence shown by any of SEQ ID NO: 36, 37, 38, or 39 in the Sequence Listing; and the nucleic acid which comprises a nucleotide sequence shown by any of SEQ ID NO: 62, 63, 64, or 65 in the Sequence Listing.

10 [0019] A still further aspect of the present invention provides a method for producing an antibody using any of the above-described nucleic acids.

[0020] A further aspect of the present invention provides a recombinant antibody which can be obtained by the above method and has an affinity to E2/NS 1 protein of hepatitis C virus. Preferably, a recombinant antibody in which the Fc region is of a human type, and a recombinant antibody which is a single-strand antibody, are provided.

15 [0021] A further aspect of the present invention provides: a medicament which comprises the aforementioned substance of the present invention as an active ingredient; a medicament which comprises the aforementioned antibody of the present invention as an active ingredient; and a medicament which comprises the aforementioned recombinant antibody of the present invention as an active ingredient. Preferably, there are provided a medicament for treating and/or preventing hepatitis C and a medicament for diagnosing hepatitis C. Further, the present invention provides an anti-HCV agent which comprises the aforementioned substance of the present invention as an active ingredient, an anti-HCV agent which comprises the aforementioned antibody of the present invention as an active ingredient, and an anti-HCV agent which comprises the recombinant antibody of the present invention as an active ingredient.

20 [0022] A further aspect of the present invention provides a method for obtaining a sequence of the variable region of the antibody binding to E2/NS 1 in which the B cell of a patient who recovered from hepatitis C is stimulated to express mRNA of the antibody against E2/NS1 protein of hepatitis C virus, and thereby mRNA of the antibody and cDNA of the antibody are obtained from the B cell. Preferably, a method for obtaining a sequence of the variable region of the antibody is provided in which a patient who recovered from hepatitis C is one who recovered without antiviral treatment and the B cell is a peripheral blood mononuclear cell.

25 [0023] A further aspect of the present invention provides an antibody having a sequence of the variable region obtained by the above-described method.

30 [0024] A further aspect of the present invention provides a method for screening a substance which inhibits the binding between E2/NS1 of hepatitis C virus and a cell infectious with hepatitis C, a cell expressing CD81, or CD81, which comprises steps of: contacting E2/NS1 of hepatitis C virus with a cell infectious with hepatitis C, a cell expressing CD81, or CD81 in the presence and absence of a test substance; and comparing the bindings between E2/NS1 of hepatitis C virus and the cell infectious with hepatitis C, the cell expressing CD81, or CD81 in the presence and absence of a test substance. Preferably, there are provided: a screening method in which E2/NS1 protein of hepatitis C virus is a protein prepared by adding a substance capable of recognizing E2/NS1 protein to E2/NS1 protein of hepatitis C virus; a screening method in which E2/NS1 protein of hepatitis C virus is a protein prepared by adding a substance capable of detecting E2/NS1 protein by a fluorescence method or a luminescence method to E2/NS1 protein of hepatitis C virus; a screening method in which E2/NS1 protein of hepatitis C virus is a protein prepared by adding a tag to E2/NS1 protein of hepatitis C virus; a screening method in which E2/NS1 protein of hepatitis C virus is a protein prepared by adding a tag to the C-terminus of E2/NS1 protein of hepatitis C virus; a screening method in which the cell expressing CD81 is a cell which expresses human CD81; a screening method in which CD81 is human CD81 and expressed by solubilized form; and a screening method in which the test substance is a protein, sulfated polysaccharides, or a low molecular weight compound.

35 [0025] A still further aspect of the present invention provides a substance which inhibits the binding between E2/NS1 protein of hepatitis C virus and the cell infectious with hepatitis C, the cell expressing CD81, or CD81, which is obtained by any of the above screening methods.

40 [0026] A further aspect of the present invention provides a substance which inhibits a life cycle of hepatitis C virus, which is obtained by the screening method which comprises steps of assaying the binding between a cell infectious with HCV and a cell expressing HCV protein in the presence and absence of the test substance, and comparing it with the binding in the absence of the test substance; and a substance which inhibits a life cycle of hepatitis C virus, which is obtained by the screening method which comprises steps of, after the cell infectious with HCV has bound with the HCV protein expressing cell in the presence or absence of the test substance, assaying the fusion between the cell infectious with HCV and the HCV protein expressing cell, and comparing it with the fusion in the absence of the test substance. Preferably, the test substance is a protein, sulfated polysaccharides, or a low molecular weight compound.

45 [0027] A further aspect of the present invention provides: an anti-HCV agent which comprises the above substance

as an active ingredient, and a method for producing the anti-HCV agent which comprises formulating the anti-HCV agent using the above substance. The method for production preferably comprises a step of confirming the inhibition of proliferation of hepatitis C virus by the above screening method.

5 BRIEF DESCRIPTION OF THE DRAWINGS

[0028]

- 10 Fig. 1 is a diagram showing neutralizing activities of antibodies scFv1-1 and scFv1-4 according to the present invention.
- Fig. 2 is a diagram showing a neutralizing activity of heparin.
- Fig. 3 is a diagram showing a neutralizing activity of suramin.
- Fig. 4 is a diagram showing an NOB activity of modified scFv.
- Fig. 5 is a diagram showing an NOB activity of a whole antibody.
- 15 Fig. 6 is a diagram showing an inhibitory activity against cell fusion of the whole antibody.
- Fig. 7 is a diagram showing a construction of an expression plasmid, pEX gamma1 loxP-Hyg HCVI.
- Fig. 8 is a diagram showing a construction of an expression plasmid, pEX kappa Km HCVI.
- Fig. 9 is a diagram showing a construction of an expression plasmid, pEX loxp-Hyg HCV1 W.

20 Best Mode for Carrying out the Invention

[0029] The present invention is described in more detail below.

[0030] The substance according to the present invention is a substance which inhibits the binding between E2/NS1 protein of hepatitis C virus and a cell infectious with hepatitis C virus (hereinafter sometimes referred to as "HCV infectious cell"), a cell expressing CD81 (hereinafter sometimes referred to as "CD81 expressing cell"), or CD81.

[0031] A method for selecting such substances as described above and confirming whether or not each of these substances can inhibit the binding between E2/NS1 and the HCV infectious cell, the CD81 expressing cell, or CD81, is described below.

[0032] As described above, an HCV envelope protein comprises E1 and E2/NS1. A region in E2/NS1 which is rich in mutation, referred to as a "hyper variable region," is deduced to be an epitope of a human immune system. More specifically, E2/NS1 is deduced to be deeply involved in the binding to a cell, which is the first stage of viral infection. Therefore, in the present invention, a substance which inhibits the binding between E2/NS1 and the HCV infectious cell, the CD81 expressing cell, or CD81 has been developed as an inhibitor of binding of HCV to a cell or HCV infection.

[0033] E2/NS1 comprises the amino acids 384 to 746 in the protein expressed from the HCV genome. In the present invention, the binding of E2/NS1 to the HCV infectious cell was confirmed, for example, by expressing a protein prepared by adding a tag to the C-terminus of E2/NS1 of HCV genes in a solubilized state, binding it to the HCV infectious cell or the CD81 expressing cell, and confirming the binding of E2/NS1 to the above cell by a light-emission method or a luminescence method using an antibody against the tag. A substance which inhibits the binding was confirmed by mixing E2/NS1 with a substance for which the binding inhibition was to be confirmed before binding a solubilized E2/NS1 with the above cell in a system for confirming the binding, followed by the assay of changes in light emission or color development by mixing with the cells. Substances which inhibits the binding are described below in detail, and examples include an antibody which comprises amino acid sequences shown by SEQ ID NOS: 1 to 3 in the H chain and amino acid sequences shown by SEQ ID NOS: 4 to 6 in the L chain, heparin, and suramin. A substance is not limited to these as long as the substance inhibits the binding between E2/NS1 and the HCV infectious cell or the CD81 expressing cell. Since the binding between solubilized CD81 and E2 has also been reported (SCIENCE, Vol. 282, 938-941), it is easily deduced that the binding between solubilized CD81 and E2 can be inhibited by using the above substance.

[0034] Sulfated polysaccharides such as heparin are known to be of strong negative charge and are known to bind to a region having a strong positive charge in proteins such as antithrombin III and a fibroblast growth factor (FEBS Lett, Vol. 69, 51-54, 1976) (Cell, Vol. 64, 841-848, 1991). Further, as described in Examples below, in the present invention it was found that E2/NS1 bound to heparin. That is, among the substances described in Examples, because heparin couples to a region in E2/NS1 with a strong positive charge, it is easily deduced that it inhibits the binding between E2/NS1 and the HCV infectious cell, the CD81 expressing cell, or CD81. Any substance which binds to the region having a positive charge in E2/NS1 can inhibit the binding between E2/NS1 and the HCV infectious cell, the CD81 expressing cell, or CD81.

[0035] Since sulfated polysaccharides such as heparin could affect the charge on the surface of the protein and impart a structural change upon binding to a glycoprotein, the binding between sulfated polysaccharides and E2/NS1 was confirmed in the present invention. A structural change as described above is deduced to be involved in the binding

between E2/NS1 and the HCV infectious cell, the CD81 expressing cell, or CD81.

[0036] "Negative charge" and "positive charge" used herein refer to charged sites which are present on the protein or the sugar chain bound thereto. In the present invention, the site is a domain in which E2/NS1 binds to Heparin sepharose CL-6B (Pharmacia) and binds to a column when it is not eluted by 10 mM phosphate buffer containing 0.15 M NaCl.

[0037] According to the present invention, "a substance which can recognize E2/NS1 protein of hepatitis C virus" refers to a tagged protein as described below and a substance capable of detecting E2/NS1 protein by an antibody such as hapten.

[0038] "A protein prepared by adding a tag to E2/NS1 protein of hepatitis C virus" used herein is not particularly limited, as long as the protein is prepared by adding a sequence which can be recognized by a specific antibody and has at least 5 amino acids such as known Etag (Pharmacia), Histag, myctag, FLAGtag, HAtag, GST and IgG Fc regions to for example the C-terminus of a protein of the amino acids 384 to 711 on the HCV genome. As described above, an epitope of an immune system, referred to as a "hyper variable region," is considered to be present at the N-terminus of E2/NS1 of HCV. Accordingly, when E2/NS1 is expressed after binding a tag thereto, use of those having a tag bound to the C-terminus is preferred. Proteins thus obtained are soluble. This soluble E2/NS1 can be used without particular limitation as long as the outermembrane domain of E2/NS1 between the amino acid 384 and the amino acid 746 is expressed. A tagged and solubilized E2/NS1 protein can be expressed in cells capable of adding a sugar chain to proteins, such as animal cells, insect cells, and yeast.

[0039] The protein prepared by adding a substance detectable by antibodies such as hapten to E2/NS1 protein of hepatitis C virus refers to a substance prepared by expressing an outermembrane domain of E2/NS1 between the amino acid 384 and the amino acid 746 of E2/NS1, and binding it with a low molecular weight compound which can be recognized by antibodies, such as biotin, fluorescein or DIG. Regarding the substances which recognize a low molecular weight compound, in the case of the exemplified biotin, for example, the substance can be recognized by proteins such as avidin and streptoavidin in addition to antibodies. Therefore, it is not particularly limited to an antibody and a protein, as long as it is capable of recognizing the substance.

[0040] The protein prepared by adding a substance detectable by a fluorescent method or a luminescence method to E2/NS1 protein of hepatitis C virus, refers to, for example, a substance prepared by expressing an outermembrane domain of E2/NS1 between the amino acid 384 and the amino acid 746 of E2/NS1, and binding it with a fluorescence-emitting substance or a substance prepared by binding the substance to certain substance, for example, a substance which develops a color upon mixing with an enzyme substrate, such as FITC, alkali phosphatase or HRP.

[0041] In the present invention, "HCV infectious cell" refers to human hepatic cells such as Huh7, HepG2, and WRL68 and lymphocyte cells such as Molt-4, MT-2, and Daudi as cells in which HCV could proliferate or infect. The cells are not limited to these as long as the cell shows the HCV infectivity.

[0042] Examples of cells expressing CD81 include those prepared by introducing a vector which is obtained by inserting human CD81 genes (GenBank Registration No. M33680) into a multicloning site of pCDNA3.1(+) (Invitrogen), in the NIH3T3 cell using Lipofectin (GIBCO BRL). In the present invention, a vector for expressing CD81, an expression cell, and a method for introducing a gene are not particularly limited, as long as the human CD81 expression can be confirmed in the cell constructed by a conventional gene recombination technique by means of a method for detecting protein or mRNA such as Western blotting, a fluorescence detection method using an anti-CD81 antibody or Northern blotting.

[0043] When a substance which inhibits the binding between E2/NS1 and CD81 is selected in the present invention, CD81 used herein can be a solubilized human CD81. Any solubilized human CD81 can be used without particular limitation so far as the outermembrane domain of CD81 is expressed. The solubilized CD81 can be expressed in accordance with a conventional gene recombination technique using animal cells, insect cells, yeast, *Escherichia coli*, and the like. Further, it is not necessary that the solubilized CD81 is one obtained by expressing only the outermembrane domain. For example, a tagged one or a modified one can be used without any problem for the purpose of purification or detection.

[0044] Examples of the light emission method and the luminescence method mentioned in the method for detecting the binding between E2/NS1 and the HCV infectious cell, the CD81 expressing cell, or CD81 using an antibody against a tag preferably include flow cytometry, cell ELISA, and ELISA. The methods are not particularly limited so far as the binding between E2/NS1 and the CD81 expressing cell or CD81 can be detected.

[0045] The "antibody" used herein includes, in addition to an antibody normally existing in a living organism, a peptide comprising at least one antigen binding site formed by the variable region in the H chain or L chain of the antibody or a combination thereof, Fab composed of a set of H chain fragment and L chain fragment, F(ab')₂ composed of two sets of H chain fragments and L chain fragments, and a single-chain antibody composed of H chain fragment and L chain fragment bound in series to the same peptide (hereinafter sometimes referred to as "scFv"). In the present invention, the whole antibody is most preferred.

[0046] In the present invention, a monoclonal antibody was prepared by obtaining a gene of an antibody from the

B-cell of a patient who recovered from hepatitis C. Conventional methods for isolating only the genes of antibody of interest from a plurality of B-cells derived from human include a method in which EBV is transformed into the B-cell of a patient to immortalize the B cell, followed by the cloning of only the cells which produce the antibody of interest. As a result of concentrated studies, the present inventors have succeeded in obtaining scFv by the phage display method.

5 [0047] For example, an antibody was obtained by the phage display method by sampling heparin blood from a patient who recovered from hepatitis C, obtaining peripheral blood mononuclear cells by the Ficoll method, and purifying the B-cells only using an anti-CD19 antibody support. Thereafter, human IL-2, human IL-10, E2/NS1 antigen(1 ng/ml), and anti-human CD40 antibody (1 μ g/ml) were used to stimulate the B-cell for the transcription of genes of antibody to mRNA. The purification of B-cell is not particularly limited as long as the B-cells can be specifically separated. The stimulation of B-cell can be carried out in a manner different from the above method and can be carried out in an appropriately abbreviated manner without problem. Thereafter, antibody mRNA and antibody cDNA were obtained from the B-cell. Further, a frame of a gene of a single chain antibody was prepared which was capable of incorporating genes in the H chain and the L chain variable regions into scFv expression plasmid, and gene 3 gene of M13 phage was ligated to the downstream thereof. An H chain and an L chain randomly obtained from the cDNA by PCR were incorporated into the sites into which the variable regions of the H chain and the L chain were to be incorporated. Using this plasmid, a single chain antibody which was incorporated in the form of fused protein with gene 3 protein at the end of M13 phage was expressed, and only those bound to E2/NS1 were selected therefrom. Thus, a single chain antibody scFv1-1 and a phage expressing the scFv1-1 in which CDR-1, CDR-2, and CDR-3 of the variable region of the H chain were, respectively, the amino acid sequences shown by SEQ ID NOS: 1, 2, and 3 in the Sequence Listing and CDR-1, CDR-2, and CDR-3 in the variable region of the L chain were, respectively, the amino acid sequences shown by SEQ ID NOS: 4, 5, and 6 in the Sequence Listing, were obtained. It was found that scFv1-1 and a phage expressing the scFv1-1 had a particularly strong affinity to E2/NS1 and strongly inhibited the binding between E2/NS1 and the HCV infectious cell, the CD81 expressing cell, or CD81.

15 [0048] The method for screening a single-chain antibody using the M13 phage system was described above. In the present invention, any method can be used without particular limitation so far as the "antibody" and the protein expressed on the surface of the phage can be expressed in the form of a fusion protein.

20 [0049] In the present invention, "a patient who recovered from hepatitis C" refers to a patient whose mRNA of HCV in the blood became lower than the lower limit of the detection limit and for whom a measured value of liver function such as the ALT value, has been in a normalized state for 6 months or longer after having been in what is called a "hepatitis C condition" with mRNA of HCV being detected in the blood and abnormality observed in a value for measuring the liver function such as ALT.

25 [0050] scFv1-1, which was exemplified as a representative example of the antibody according to the present invention, showed the binding constant K_a to E2/NS1 of 4.5×10^8 (M) and the dissociation constant K_d of 2.2×10^{-9} (1/M) as a result of measurement using BIACORE (BIACORE). The present inventors obtained a plurality of single chain antibodies having the same variable region of the H chain as that of scFv1-1 and a variable region of the L chain that was different from that of scFv1-1, and for each single chain antibody the binding ability and the ability of inhibiting the binding between E2/NS1 and the HCV infectious cell and the human CD81 expressing cell were compared. As a result, there was a correlation between the binding ability and the ability of inhibiting the binding between E2/NS1 and cells. Among those, a single-chain antibody scFv1-1 having a binding constant of 10^8 (M) or more and a dissociation constant of 10^{-8} (1/M) or less can be judged as being satisfactory as a medicament from the viewpoint of the inhibitory activity. That is, an antibody having a binding constant to E2/NS1 of 10^8 (M) or more and a dissociation constant of 10^{-8} (1/M) or less as a result of measurement using BIACORE is more preferred as a medicament for inhibiting infection to the HCV infectious cell. In order to further enhance the ability of the antibody, an antibody having a binding constant of 10^9 (M) or more and a dissociation constant of 10^{-9} (1/M) or less is further preferred.

30 [0051] In general, an antibody comprises two types of polypeptides, i.e., a large polypeptide and a small polypeptide, and a larger subunit is referred to as an "H chain" and a smaller subunit is referred to as an "L chain." The peptides respectively comprise a "variable region" which is present at the N-terminal side and forms an antigen binding site and a "constant region" which is defined by each antibody class. The variable region is further divided into complementarity-determining regions "CDRs" which are deeply involved in the formation of the antigen binding site and "frameworks" which are present therebetween. A CDR is known to have three regions, "CDR-1," "CDR-2," and "CDR-3" from the N-terminal side for each of the H chain and the L chain.

35 [0052] The antibodies ScFv1-1, ScFv1-2, ScFv1-3, and ScFv1-4 of the present invention are described below as examples. The amino acid sequences of the antibodies ScFv1-1, ScFv1-2, ScFv1-3, and ScFv1-4 are shown in SEQ ID NOS: 1 to 20 in the Sequence Listing, and the DNA sequences are shown in SEQ ID NOS: 21 to 25.

40 [0053] The amino acids which constitute a variable region of the antibody often vary depending on the antibody. The amino acid sequence in the H chain portion of ScFv1-1 is shown in SEQ ID NO: 16. SEQ ID NO: 16 represents a sequence for expressing scFv in *Escherichia coli*, i.e., a sequence having 2 amino acids added to the N terminus of the H chain of scFv1-1. Accordingly, considered in terms of an antibody framework, the amino acids 3 to 32 in SEQ

ID NO: 16 represent framework 1, the amino acids 33 to 37 represent "CDR-1," the amino acids 38 to 51 represent framework 2, the amino acids 52 to 68 represent "CDR-2," the amino acids 69 to 100 represent framework 3, the amino acids 101 to 117 represent "CDR-3," and the amino acids 118 to 128 represent framework 4. The amino acid sequence in the L chain portion of ScFv1-1 is shown in SEQ ID NO: 17. The amino acids 1 to 23 in SEQ ID NO: 17 represent framework 1, the amino acids 24 to 34 represent "CDR-1," the amino acids 35 to 49 represent framework 2, the amino acids 50 to 56 represent "CDR-2," the amino acids 57 to 88 represent framework 3, the amino acids 89 to 97 represent "CDR-3," and the amino acids 98 to 111 represent framework 4. The amino acid sequences of the H chain of ScFv1-2, 1-3, and 1-4 are all shown in SEQ ID NO: 16. The L chain is as described below. The amino acid sequence in the L chain portion of ScFv1-2 is shown in SEQ ID NO: 18. The amino acids 1 to 23 in SEQ ID NO: 18 represent framework 1, the amino acids 24 to 34 represent "CDR-1," the amino acids 35 to 49 represent framework 2, the amino acids 50 to 56 represent "CDR-2," the amino acids 57 to 88 represent framework 3, the amino acids 89 to 97 represent "CDR-3," and the amino acids 98 to 111 represent framework 4. The amino acid sequence in the L chain portion of ScFv1-3 is shown in SEQ ID NO: 19. The amino acids 1 to 23 in SEQ ID NO: 19 represent framework 1, the amino acids 24 to 34 represent "CDR-1," the amino acids 35 to 49 represent framework 2, the amino acids 50 to 56 represent "CDR-2," the amino acids 57 to 88 represent framework 3, the amino acids 89 to 97 represent "CDR-3," and the amino acids 98 to 111 represent framework 4. The amino acid sequence in the L chain portion of ScFv1-4 is shown in SEQ ID NO: 20. The amino acids 1 to 22 in SEQ ID NO: 20 represent framework 1, the amino acids 23 to 36 represent "CDR-1," the amino acids 37 to 51 represent framework 2, the amino acids 52 to 58 represent "CDR-2," the amino acids 59 to 90 represent framework 3, the amino acids 91 to 102 represent "CDR-3," and the amino acids 103 to 116 represent framework 4. The boundary between these frameworks and CDRs was determined based on Kabat et al., "Immunologically useful protein sequence" (National Institutes of Health, Bethesda, MD, (1987) and (1991)).

[0054] ScFv can be prepared using, for example, Recombinant Phage Antibody System (Pharmacia). When the single-chain antibody is toxic to *Escherichia coli* as a production host and causes extinction of *Escherichia coli* or decomposition of the single-chain antibody, the kit cannot be effectively used and a lot of contrivances are required. The single-chain antibody can be prepared by selecting inducible vectors such as pSE380 plasmid (Invitrogen) or pET24d(+) plasmid (Novagen) and host bacterial cells. In addition to the above method, in the production of the single-chain antibody, an animal cell expression system, an insect cell expression system, and a yeast cell expression system can be effectively utilized. In Examples, 15 amino acid residues of 3 repeats of (Gly-Gly-Gly-Gly-Ser) were used as a linker for linking the H chain and the L chain. In the present invention, however, any linker can be used without being limited to this sequence.

[0055] SEQ ID NO: 21 in the Sequence Listing represents the nucleotide sequence of the nucleic acid corresponding to the amino acids 1 to 128 of SEQ ID NO: 16 in the Sequence Listing. SEQ ID NO: 22 in the Sequence Listing represents the nucleotide sequence of the nucleic acid corresponding to the amino acids 1 to 111 of SEQ ID NO: 17 in the Sequence Listing. SEQ ID NO: 23 in the Sequence Listing represents the nucleotide sequence of the nucleic acid corresponding to the amino acids 1 to 111 of SEQ ID NO: 18 in the Sequence Listing. SEQ ID NO: 24 in the Sequence Listing represents the nucleotide sequence of the nucleic acid corresponding to the amino acids 1 to 111 of SEQ ID NO: 19 in the Sequence Listing. SEQ ID NO: 25 in the Sequence Listing represents the nucleotide sequence of the nucleic acid corresponding to the amino acids 1 to 116 of SEQ ID NO: 20 in the Sequence Listing. Regarding these nucleotide sequences, a nucleotide sequence having a deletion, a substitution, or an addition of one or several nucleotides is included in the scope of the present invention as long as the sequence exhibits the effects as described in the present application.

[0056] The fact that the antigen-specificity of the antibody and the binding intensity to the antigen are mainly determined by the amino acid sequences of the CDR is demonstrated by the humanization of the mouse antibody (Methods in Enzymology, 203, 99-121, 1991).

[0057] Further, an antibody of a form which is usually present in a living organism can be prepared from scFv. For example, only the variable regions of the H chain and the L chain are amplified by PCR from scFv plasmid which binds to E2/NS1. Each fragment is, for example, integrated into a plasmid having the H chain gene and/or the L chain gene of the human antibody, thereby forming an antibody having a variable region on the scFv and being a form usually present in a living organism. More specifically, for example, suitable restriction enzyme cleavage sites are introduced at both ends of the gene fragment obtained when amplifying the variable regions of the H chain and the L chain from the plasmid, and they are combined with a suitable restriction enzyme cleavage site on the plasmid having the H chain and/or the L chain of the human antibody, thereby replacing genes in the variable region without causing frame-shift. Thus, an antibody of a form usually present in a living organism which has a sequence of the variable region on a plasmid as it is, can be prepared. Further, a peptide containing at least one antigen binding site formed by the variable region of the H chain or L chain of the antibody or a combination thereof, Fab composed of a set of an H chain fragment and an L chain fragment, and (Fab'2) composed of 2 sets of H chain fragments and L chain fragments can also be prepared from the antibody.

[0058] Further, substitution of sequences of antibodies mentioned below can enhance the binding force to E2/NS1

and the neutralizing activity; an antibody in which CDR-1, CDR-2, and CDR-3 in the variable region of the H chain in the present invention are, respectively, amino acid sequences shown by SEQ ID NOS: 1, 2, and 3 in the Sequence Listing and CDR-1, CDR-2, and CDR-3 in the variable region of the L chain are, respectively, amino acid sequences shown by SEQ ID NOS: 4, 5, and 6 in the Sequence Listing; an antibody in which CDR-1, CDR-2, and CDR-3 in the variable region of the H chain are, respectively, amino acid sequences shown by SEQ ID NOS: 1, 2, and 3 in the Sequence Listing and CDR-1, CDR-2, and CDR-3 in the variable region of the L chain are, respectively, amino acid sequences shown by SEQ ID NOS: 7, 8, and 9 in the Sequence Listing; an antibody in which CDR-1, CDR-2, and CDR-3 in the variable region of the H chain are, respectively, amino acid sequences shown by SEQ ID NOS: 1, 2, and 3 in the Sequence Listing and CDR-1, CDR-2, and CDR-3 in the variable region of the L chain are, respectively, amino acid sequences shown by SEQ ID NOS: 10, 11, and 12 in the Sequence Listing; or an antibody in which CDR-1, CDR-2, and CDR-3 in the variable region of the H chain are, respectively, amino acid sequences shown by SEQ ID NOS: 1, 2, and 3 in the Sequence Listing and CDR-1, CDR-2, and CDR-3 in the variable region of the L chain are, respectively, amino acid sequences shown by SEQ ID NOS: 13, 14, and 15 in the Sequence Listing. For example, the sequence of CDR-3 can be randomly substituted to obtain another antibody. A highly active antibody can be also obtained by substituting the amino acid sequences and gene sequences of CDR-1, CDR-2, and CDR-3 of the H chain and the L chain. In this case, an antibody having a modified amino acid sequence has no problem unless the neutralizing activity is deteriorated. That is, in the present invention, an amino acid sequence having modifications such as a substitution, a deletion, or an insertion is included in the scope of the present invention as long as the sequence has ability to inhibit the binding between E2/NS1 and the HCV infectious cell, the CD81 expressing cell, or CD81.

[0059] The antibodies of the present invention, ScFv2-1, ScFv2-2, ScFv2-3, and ScFv2-4, are antibodies having amino acid substitutions in the H chains of the above-described antibodies ScFv1-1, ScFv1-2, ScFv1-3, and ScFv1-4. The amino acid sequences and the DNA sequences of the H chains of the antibodies ScFv2-1, ScFv2-2, ScFv2-3, and ScFv2-4 are shown in SEQ ID NOS: 34 and 35 in the Sequence Listing.

[0060] Further, the amino acid sequences and the DNA sequences of the antibodies ScFv3-1, ScFv3-2, ScFv3-3, and ScFv3-4 of the present invention are shown in SEQ ID NOS: 42 to 65 in the Sequence Listing.

[0061] The descriptions on the antibodies ScFv2-1, ScFv2-2, ScFv2-3, ScFv2-4, ScFv3-1, ScFv3-2, ScFv3-3, and ScFv3-4 are the same as those given on the antibodies ScFv1-1, ScFv1-2, ScFv1-3, and ScFv1-4.

[0062] In the present invention, a full-length antibody is preferably used.

[0063] The expression of antibody in the present invention can be carried out by employing *Escherichia coli*, yeast, insect cells, animal cells, and the like. If the antibody is to be administered to a human as a medicament, an animal cell showing a sugar chain modification which is closer to that of human, is preferably used. For example, when an antibody is expressed in COS cell or CHO cell, pCDNA3.1(+) or pMAMneo (CLONETECH) can be used. For example, a gene of the H chain of the antibody obtained in the above method is incorporated into a multicloning site of pCDNA3.1(+), and a gene of the L chain is incorporated into pMAMneo. An expression unit having a gene of the L chain between a promoter and poly A is then incorporated into an adequate site of the vector having the H chain incorporated therein. Introduction of this vector into a COS cell, a CHO-K1, or a CHO DG44 by a conventional genetic engineering technique enables the production of the antibody of interest. Further, the expression unit of the DHFR gene is cleaved out from for example, pSV2/DHFR (Nature, 1981. Vol. 294, Lee F. et al.) into the above prepared vector, and is incorporated into a vector which expresses the H chain and the L chain. This vector is introduced into the CHO DG44 by a conventional genetic engineering technique. The thus selected cells can be used to significantly improve the producibility of antibodies by utilizing the DHFR gene amplification system using MTX. In the COS cell, the antibody can be expressed only in the transient manner. In the CHO cell, the antibody can be expressed in a state in which the antibody genes are incorporated into a chromosome. Also, the above-described DHFR gene amplification system can be used to express an antibody at a high level, and the use of the CHO cell is more preferred in the industrial production since the antibody can be produced in a serum-free medium.

[0064] The COS cell is generally cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) under 5% CO₂ at 37°C. The method for breeding and producing cells after gene introduction into the COS cell is described in protocols such as "Bio Manual Series 4, Gene Introduction and Expression - Analytical Method"; Takashi Yokota, Ken-ichi Arai" (YODOSHA Co., Ltd., 1994). A method for introducing a gene into the COS cell may be electroporation, as well as a DEAE-dextran method and a method using a transfection reagent such as lipofectin.

[0065] CHO K-1 cell and CHO-DG44 cell can be cultured in DMEM supplemented with 10% FBS, as well as a commercially available serum-free medium such as CHO S SFM2 (GIBCO), under 5% CO₂ at 37°C. As in the case of COS cells, gene introduction into the CHO cell can be carried out by electroporation, as well as a DEAE-dextran method and a method using a transfection reagent such as lipofectin. In particular, in the case of the CHO DG44, the producibility of the antibody can be enhanced by gene amplification by culturing the cell in a medium free from hypoxanthine or thymidine and adding a DHFR inhibitor, i.e., MTX, in the medium.

[0066] At the time of production of antibody in the present invention, the cells are preferably cultured in a serum-free

medium in order to prevent the contamination of a serum-derived bovine antibody. COS and CHO cells which are not acclimatized in a serum-free medium but are cultured in serum media, are preferably cultured in DMEM free from serum. The antibody of the present invention, which is thus obtained in the culture supernatant, can be easily purified by a conventional method for purifying IgG antibodies using, for example, Protein A column and Protein G column.

5 [0067] The antibody produced in the present invention can be used in the treatment of HCV. As a form of the antibody, the produced antibody molecules can be used as it is. It is also possible to use Fab, F(ab')₂, Fv, or Fd, which are fragments containing antigen binding sites obtained by various protease treatments, and the whole antibody is most preferred. These fragments are described in detail in "Introductory Antibody Engineering" (Chijinshokan Co., Ltd.).
10 Fragmented peptides can be obtained by enzymatic treatment of antibody molecules. Alternatively, fragmented peptides can be produced by bacteria, yeast, or the like by a genetic engineering technique. By the combination of the thus obtained monoclonal antibody, monoclonal antibody-derived antibody fragment, peptide and the like, stronger binding properties can be made.

[0068] The antibody produced in the present invention can be used to decrease HCV particles in the blood of an HCV infected patient. For example, by administering the antibody produced in the present invention to a patient where
15 mRNA of HCV or the anti-HCV antibody is observed by a commercially available HCV diagnostic agent, the amount of HCV particles in the blood can be decreased, thereby preventing re-infection with HCV and leading the patient to recovery from HCV. Further, upon administration to the HCV patient, this antibody can bind in particular to cells which present E2/NS1 on the cell surface among HCV infected cells in the body of the HCV patient. It can also be expected that this binding and the activation of an immune system such as a complement in the living organism will result in
20 killing ability against HCV infected cells. Further, combination with a gene of a variable region derived from other antibodies enables the production of a bispecific antibody and a multispecific antibody. A "multispecific antibody" refers to an antibody which has at least two antigen binding sites which recognize different antigens or different epitopes of the same antigen. Among them, a "bispecific antibody" refers to an antibody which has at least two antigen binding sites which recognize different antigens or epitopes. For example, it is considered that a bispecific antibody wherein
25 the antigen binding site of a general antibody is different from the other antigen binding site can bind more strongly to an antigen, and can bind to HCV of broad sequences as compared to a general antibody. Further, an antibody which recognizes an antigen in a more multivalent manner as IgM can also be prepared. In addition to the procedure to make the antibody bispecific at the time of production, a bispecific or multispecific antibody can be produced by producing and purifying monoclonal antibodies and then binding the antibodies to each other. This procedure to make the antibody
30 bispecific can be carried out by combining not only with the same antigen, but also with another antigen. For example, an antibody against E1 which is considered to be presented on the surface of the HCV particles can be used to prepare a bispecific antibody and a multispecific antibody.

[0069] The amino acid sequences of the single-chain antibodies ScFv1-1, ScFv1-2, ScFv1-3, and ScFv1-4 are shown in SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, and SEQ ID NO: 29 in the Sequence Listing. Examples of nucleic
35 acid sequences encoding those are shown together with the amino acid sequences. The amino acids 1 to 22 of the amino acid sequence shown by SEQ ID NO: 26 represent a sequence containing a secretion signal from *Escherichia coli*, the amino acids 23 to 148 represent a variable region of the H chain, the amino acids 149 to 165 represent a linker, the amino acids 166 to 276 represent a variable region of the L chain, and the amino acids 277 to 299 represent a sequence containing a tag. The amino acids 1 to 22 of the amino acid sequence shown by SEQ ID NO: 27 represent
40 a sequence containing a secretion signal from *Escherichia coli*, the amino acids 23 to 148 represent a variable region of the H chain, the amino acids 149 to 165 represent a linker, the amino acids 166 to 276 represent a variable region of the L chain, and the amino acids 277 to 299 represent a sequence containing a tag. The amino acids 1 to 22 of the amino acid sequence shown by SEQ ID NO: 28 represent a sequence containing a secretion signal from *Escherichia coli*, the amino acids 23 to 148 represent a variable region of the H chain, the amino acids 149 to 165 represent a linker, the amino acids 166 to 276 represent a variable region of the L chain, and the amino acids 277 to 299 represent
45 a sequence containing a tag. The amino acids 1 to 22 of the amino acid sequence shown by SEQ ID NO: 29 represent a sequence containing a secretion signal from *Escherichia coli*, the amino acids 23 to 148 represent a variable region of the H chain, the amino acids 149 to 165 represent a linker, the amino acids 166 to 281 represent a variable region of the L chain, and the amino acids 282 to 304 represent a sequence containing a tag.

50 [0070] It is also possible to delete the amino acids 1 to 22 of the amino acid sequences shown by SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, and SEQ ID NO: 29 and express a single-chain antibody in the cells of *Escherichia coli*. The amino acids 277 to 299 of the amino acid sequences shown by SEQ ID NO: 26, SEQ ID NO: 27, and SEQ ID NO: 28 represent a sequence for detecting and purifying the single-chain antibody, and this sequence can be deleted or substituted with any sequence. Similarly, the amino acids 282 to 304 of the amino acid sequence shown by SEQ
55 ID NO: 29 are a sequence for detecting and purifying the single-chain antibody, and the sequence can be deleted or substituted with any sequence. A vector comprising a secretion signal from *Escherichia coli* and a sequence for purification is prepared in a manner described in Examples. The linker sequences of the amino acids 149 to 165 of the amino acid sequences shown by SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, and SEQ ID NO: 29 can be

substituted with any sequence as long as the sequence can maintain the steric structure of the variable regions of the H chain and the L chain substantially the same as scFv1-1. The single-chain antibody can be produced in animal cells, insect cells, and yeast cells, as well as *Escherichia coli*.

5 [0071] The amino acid sequences of single-chain antibodies ScFv2-1, ScFv2-2, ScFv2-3, and ScFv2-4 are shown in SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, and SEQ ID NO: 39 in the Sequence Listing, and examples of nucleic acid sequences encoding those are shown together with the amino acid sequences.

[0072] Further, the amino acid sequences of single-chain antibodies ScFv3-1, ScFv3-2, ScFv3-3, and ScFv3-4 are shown in SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, and SEQ ID NO: 65 in the Sequence Listing. Examples of nucleic acid sequences encoding those are shown together with the amino acid sequences.

10 [0073] The descriptions on single-chain antibodies ScFv2-1, ScFv2-2, ScFv2-3, ScFv2-4, ScFv3-1, ScFv3-2, ScFv3-3, and ScFv3-4 are the same as those given on ScFv1-1, ScFv1-2, ScFv1-3, and ScFv1-4.

[0074] A single-chain antibody can be made bispecific and multispecific. For example, it can be produced by repeatedly arranging the H chains and the L chains of a plurality of combinations of antigen recognition sites in a peptide. Ligation after production and purification is also possible. The H chain or the L chain can be used alone instead of a combined use of the H chain and the L chain. The type of the antibody can be selected depending on the application for use, and can be selected based on a binding intensity, an antigen binding site, and the like.

15 [0075] The present invention further provides a medicament which comprises, as an active ingredient, the above-described antibody, a substance having the function equivalent thereto and inhibiting the binding between E2/NS1 and the HCV infectious cell, the CD81 expressing cell, or CD81 as defined in the present invention, for example, a pharmaceutical composition comprising the above substance and a pharmaceutically acceptable carrier. More particularly, the anti-E2/NS1 antibody gene of the present invention can efficiently produce the anti-E2/NS1 antibody, and provides various forms of therapeutic preparations. The recombinant antibodies thus produced may be contained in the pharmaceutical composition together with the substance which is used for sustaining the activity of the antibody at the time of administration to human, such as a carrier having a pharmaceutically acceptable composition and a stabilizer. Examples of such carriers and stabilizers include human serum albumin and gelatin. The term "pharmaceutically acceptable" means that neither undesirable side-effects accompanying administration, such as nausea, vertigo and retching, nor an immune response to the preparation at a time of frequent administration occurs. Further, the antibody prepared by binding a substance such as a toxin to the antibody of the present invention can be used as a medicament. A liquid pharmaceutical composition dissolved with a pharmaceutically acceptable suitable solvent, diluent, or stabilizer, may also be used. In addition to the above pharmaceutical composition, in the case of parenteral administration (injection) of microsphere and liposome for the purpose of controlling concentration in the living organism, 1 µg to 50 mg/kg (body weight) of an antibody and a single-chain antibody is suitable, although it is not limited to this range.

25 [0076] In the foregoing, the antibody was described as a representative example. Applicable examples of a substance which inhibits the binding between E2/NS1 and the HCV infectious cell, CD81 expression cell, or CD81 in the present invention include the antibody, as well as a protein other than an antibody, sulfated polysaccharides, or low molecular weight compounds, unless the activity of the present invention is deteriorated.

[0077] Proteins other than the antibody include lactoferrin, and the preparation as a pharmaceutical composition and the administration method can be selected in accordance with those in the case of the aforementioned antibody.

30 [0078] "Sulfated polysaccharides" used in the present invention refers to, for example, what are called glycosaminoglycans and dextran sulfate, such as heparin, heparan sulfate, chondroitin sulfate A, chondroitin sulfate C, dermatan sulfate, keratan sulfate 1, and keratan sulfate 2, having an average molecular weight of 5,000 Da to 1,000,000 Da. Heparin having a size of about 5,000 Da to 30,000 Da is preferred. Examples of administration methods include, but are not limited to: intravenous drip of 10,000 to 30,000 units diluted with 5% liquid glucose, physiological saline, or Ringer's solution; intermittent intravenous infusion administering 5,000 to 10,000 units per dose every 4 to 8 hours, from 3 hours after the initiation of injection, every 2 to 4 hours; and subcutaneous/intramuscular injection of 15,000 to 20,000 units of concentrated solution preparation initially, followed by administration of a maintenance dosage twice a day of 10,000 to 15,000 units per dose.

[0079] The low molecular weight compound used in the present invention is sumarin and the like described below in the Examples, but it is not limited thereto as long as the substance can inhibit the infection of E2/NS1 of HCV and HCV.

35 [0080] Various binding sites of the low molecular weight compound can be considered. If the substance binds to a site to which the heparin binds, a compound having a sulfate group added thereto is preferred.

[0081] When proteins such as an antibody, sulfated polysaccharides, and low molecular weight compounds cited herein are used as a medicament, they are not necessarily used alone. A plurality of substances can be administered in an amount within the range described in the present specification regarding each substance.

40 [0082] In the case of the single-chain antibody, it can be preferably used for diagnosing hepatitis C virus.

45 [0083] The present invention relates to a substance which inhibits a life cycle of hepatitis C virus, which is obtained by the screening method which comprises steps of assaying the binding between a cell infectious with HCV and a cell expressing HCV protein in the presence and absence of the test substance, and comparing it with the binding in the

absence of the test substance; and a substance which inhibits a life cycle of hepatitis C virus, which is obtained by the screening method which comprises steps of, after the cell infectious with HCV has bound with the HCV protein expressing cell in the presence or absence of the test substance, assaying the fusion between the test substance and the cell infectious with HCV or the HCV protein expressing cell, and comparing it with the fusion in the absence of the test substance. Examples of a life cycle of hepatitis C virus referred to herein include infection and proliferation of hepatitis C virus.

[0084] The literature by Takikawa et al. (Takikawa et al., J. Virol., 74, 5066-5074, 2000) describes an assay system capable of assaying the binding and the fusion of the HCV infectious cells (HepG2) and CHO cells expressing HCV protein and a mechanism of HCV infection using the same.

[0085] The antibody obtained in the present invention is a novel substance which can competitively neutralize the assay system.

[0086] The cell fusion assay system is a system used in the assay of the cell fusion activity of viruses in HTLV-1 and the like. The assay system of the present invention is a system which falsely exhibits cell fusion of HCV. Thus, it is expected that a substance which inhibits this assay system has an effect of inhibiting HCV infection, particularly inhibiting the binding to cells and the enucleation.

Examples

[0087] The present invention is described below in more detail with reference to the examples, but the present invention is not limited to the following examples.

1. Expression of E2

(Construction of E2tag expression vector)

[0088] 100 ng of a region of 711 amino acids from the amino acid 384 in HCV genome of E2/NS1 of HCV J1 clone gene (Genbank Registration No: D89815) was used, and the DNA (tPA signal + E2(384-711) + tag) fragment was amplified by PCR using a PCR primer for the 5' side of the gene (5'CCC AAG CTT ACC ATG GAT GCA ATG AAG AGA GGG CTC TGC TGT GTG CTG CTG CTG TGT GGA GCA GTC TTC GTT TCG GCT AGC CAT ACC CGC GTG ACG GGG GGG GTG CAA GG 3'; SEQ ID NO: 30) having a signal peptide sequence for promoting secretion in animal cells and a PCR primer for 3' side of the gene (5'CCC CCT CGA GTC TAG ATT AAC GCG GTT CCA GCG GAT CCG GAT ACG GCA CCG GCG CAC CGG AGA CGA CCG CCG ACC CTA TAC C 3'; SEQ ID NO: 31) having an E-tag sequence as primers for PCR amplification. PCR reaction was performed using Perkin Elmer Cetus DNA Thermal Cycler and KOD polymerase (purchased from Toyobo Co., Ltd., the reaction conditions were in accordance with the instructions). Thereafter, a desired DNA fragment was purified by 5% acrylamide electrophoresis in accordance with the method described in "Molecular Cloning, Section 6.46-6.48, Cold Spring Harbor." 1 µg of the purified DNA fragment was reacted in 50 µL of system M (10 mM Tris-HCl, 50 mM NaCl, 2 mM MgCl₂) using 1 unit of HindIII and XbaI at 37°C for 2 hours and cleaved. The enzyme was deactivated by heating at 70°C for 10 minutes. The product and 1 µg of expression vector pCDNA3.1(+) for animal cells (purchased from Invitrogen) was reacted in 50 µL of system M (10 mM Tris-HCl, 50 mM NaCl, 2 mM MgCl₂) using 1 unit of HindIII and XbaI at 37°C for 2 hours and cleaved, and the enzyme was deactivated by heating at 70°C for 10 minutes. A solution containing phenol, chloroform and isoamyl alcohol at a ratio of 25:24:1, the amount of which is the same as that of the enzyme solution, was added thereto and mixed. The resultant mixture was centrifuged, and only a water layer was collected (this operation is hereinafter referred to as "phenol-chloroform extraction"). Further, 1/10 volume of 3M sodium acetate and 2.5x volume of ethanol were mixed with the collected water layer, and the mixture was allowed to stand at -20°C overnight or at -80°C for 15 minutes. The mixture was centrifuged to collect a DNA fragment. After the addition of 70% ethanol, decantation was performed and vacuum drying was conducted (this series of operations of adding ethanol followed by collection of DNA fragments is hereinafter referred to as "ethanol precipitation"). Thereafter, the collected DNA fragments were dissolved in 5 µL of sterilized water. These purified DNA fragments were ligated to each other using a ligase kit (purchased from Takara Shuzo Co., Ltd., the reaction was in accordance with the instructions), and *Escherichia coli* strain JM109 (purchased from Takara Shuzo Co., Ltd., the reaction was in accordance with the instructions) was transformed to obtain the desired E2tag expression plasmid, pE2tag.

(Expression of E2tag in animal cell)

[0089] *Escherichia coli* carrying plasmid pE2tag was cultured in a 50 mL baffled flask overnight. Bacterial cells were collected by centrifugation at 8,000 rpm for 10 minutes and a plasmid was purified using QIAGEN Plasmid Midi kit (purchased from QIAGEN) in accordance with the instructions.

EP 1 256 348 A1

[0090] The purified plasmid was transfected to strain CHO DG44 cultured in EX-CELL302 (purchased from JRH) supplemented with 5% FBS by using lipofectin (purchased from LIFETECH) in accordance with the instructions. CHO DG44 was cultured in 5% CO₂ at 37°C. 2 days after the transfection, cells were treated with 0.25% trypsin, and the cells were then inoculated in EX-CELL302 supplemented with G418 at 400 µg/mL. Media were exchanged using G418-added media for about 2 weeks and the rise of colonies was observed.

[0091] E2tag expression in the obtained cell was observed by Western blotting of the cell supernatant. Western blotting was performed in accordance with the instructions of Anti-E Tag Antibody purchased from Pharmacia. HRP-bound goat anti-mouse IgG antibody was used as a detection antibody. The light emission reaction was performed using ECL Western blotting detection reagents (purchased from Amersham Pharmacia Biotech) in accordance with the instructions by exposing X-ray film. Among the selected clones, the cell expressing the highest amount of E2tag was used in the later experiments.

(Purification of E2tag)

[0092] The clone expressing E2tag which obtained by the above method was cultured in EX-CELL302 so as to obtain a necessary amount of supernatant. When the logarithmic growth phase of the cell was terminated, the cells were removed by centrifugation and the supernatant was collected. Contaminant was further removed from the supernatant using a 0.45 µm filter. The supernatant thus obtained was subjected to affinity purification using RPAS Purification Module (purchased from Pharmacia). Purification was performed in accordance with the instructions attached to RPAS Purification Module. E2tag was substituted into PBS since E2tag can be obtained in the Elution buffer attached to RPAS Purification Module. More specifically, the elution fraction containing the above E2tag was added to the upper portion of the filter of Centricon 30 (purchased from Amicon), and centrifugation was performed at 5,000 rpm until the amount of the buffer contained therein became 100 µL or below. About 2 mL of PBS was added thereto and centrifugation was performed in the same manner. This procedure was repeated four times or more to collect E2tag dissolved in PBS.

2. Construction of NOB assay system

(Construction of CD81 expression vector)

[0093] In order to obtain the full length DNA of human CD81 gene (Genbank Registration No. M33680), cDNA was synthesized from 1 µg of mRNA purified from Hela cell using RT-PCR kit ver 2.1 (TAKARA) in accordance with the attached information and using a random primer. Subsequently, in accordance with the information attached to this kit, PCR reaction was carried out by setting GCGCCGCCATGGGAGTGGAGGGCTGC (SEQ ID NO: 32) for the 5'-side and CTCAGTACACGGAGCTGTTCCGGA (SEQ ID NO: 33) for the 3'-side as primers for PCR amplification. The PCR product was subjected to 0.8% agarose gel electrophoresis, and the band of interest was purified using QIAEX II Gel Extraction Kit (purchased from QIAGEN) in accordance with the attached instructions. By using TOPO TA Cloning KIT with TOP10F' Cells (purchased from Invitrogen), pCR2.1-TOPO was ligated with the fragment of the CD81 of interest, and *Escherichia coli* was transformed with the ligation product in accordance with the attached instructions, thereby obtaining pCRhCD81 of interest. Further, 1 µg of pCRhCD81 was reacted using 1 unit of EcoRI in 50 µL of system H (10 mM Tris-HCl, 100 mM NaCl, 2 mM MgCl₂) at 37°C for 2 hours and cleaved, and the enzyme was deactivated by heating at 70°C for 10 minutes. Then, the fragment containing CD81 genes was purified using QIAEXII Gel Extraction Kit (purchased from QIAGEN) in accordance with the attached instructions. Separately, pCDNA3.1(+) was also treated with EcoRI in the similar system and the enzyme was deactivated. Thereafter, 1 µL of bacterial alkali phosphatase (purchased from Toyobo Co., Ltd.) was added, and the mixture was incubated at 65°C for 1 hour. After purification by phenol-chloroform extraction and ethanol precipitation, the collected DNA fragments were dissolved in 5 µL of sterilized water. Further, both fragments were ligated to each other using a ligase kit (purchased from Takara Shuzo Co., Ltd., the reaction was in accordance with the instructions), and *Escherichia coli* strain JM109 (purchased from Takara Shuzo Co., Ltd., the reaction was in accordance with the instructions) was transformed to obtain the desired CD81 expression plasmid, pCDNA3.1(+)/CD81.

(Construction of CD81 expression cell)

[0094] *Escherichia coli* carrying plasmid pCDNA3.1(+)/CD81 was cultured in a 50 mL baffle flask overnight. Bacterial cells were centrifuged at 8,000 rpm and a plasmid was purified using QIAGEN Plasmid Midi kit (purchased from QIAGEN) in accordance with the instructions.

[0095] The purified plasmid was transfected into NIH3T3 strain cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% FBS using lipofectin (purchased from LIFETECH) in accordance with the instructions.

EP 1 256 348 A1

NIH3T3 was hereinafter cultured in 5% CO₂ at 37°C. 2 days after the transfection, the cells were treated with 0.25% trypsin and the cells were then inoculated in DMEM supplemented with 10% FBS and 800 µg/mL of G418. The medium was exchanged using G418-added medium for about 2 weeks, and the rise of colonies was confirmed.

[0096] CD81 expression in the obtained cell lines was confirmed in accordance with the following procedure. The obtained cell lines were cultured in the selective medium on the 6-well plate until the cell lines became confluent. The cells were washed once with PBS/0.05% EDTA, then detached using PBS/0.05% EDTA, and suspended in 20 µL of PBS containing 0.1% BSA and 0.1% azide (hereinafter referred to as "FACS buffer"). An anti-CD81 antibody (purchased from Pharmingen) was added in the final concentration of 0.025 mg/mL and mixed, and the mixture was then incubated on ice for 1 hour. 200 µL of FACS buffer was added and the cells were then collected by centrifugation at 3,000 rpm. This procedure was repeated twice. The collected cells were suspended in 30 µL of FACS buffer, FITC-labeled rabbit anti-mouse Igs antibody (purchased from Cappel) was added in the final concentration of 0.05 mg/mL, followed by mixing. The mixture was incubated under a shaded condition on ice for 1 hour. 200 µL of FACS buffer was added, and the cells were then collected by centrifugation at 3,000 rpm. After this procedure was repeated twice, the cells were suspended in 200 µL of FACS buffer, and the fluorescence level of the cells was measured using FACScan (Becton Dickinson Company, Ltd.). The cell showing the highest fluorescence level was selected, and was designated "NIH3T3/CD81."

(Confirmation of binding between E2tag and Molt-4 or NIH3T3/CD81)

[0097] The final concentration of Molt-4 (RIKEN, RCB No. 0206) or NIH3T3/CD81 was set at 5×10^6 cell/mL, and mixed with E2tag by separately setting the concentrations so as to bring the final concentration of E2tag to 50 µg/mL or below, and the mixture was incubated in RPMI 1640 containing 1% FBS in 20 µL of system on ice for 1 hour. 200 µL of PBS containing 5% FBS was added and the cells were then collected by centrifugation at 3,000 rpm. This procedure was repeated twice. The anti-Etag antibody was diluted to 10 µg/mL with RPMI 1640 containing 1% FBS, and 10 µL of the diluted antibody was added to each sample and mixed. Thereafter, the mixture was incubated on ice for 1 hour. 200 µL of PBS containing 5% FBS was added, and the cells were then collected by centrifugation at 3,000 rpm. This procedure was repeated twice. 10 µL of solution prepared by diluting FITC-labeled rabbit anti-mouse Igs (purchased from Cappel) to a final concentration of 25 µg/mL with PBS containing 5% FBS was added to each sample and mixed. Thereafter, the mixture was incubated on ice for 1 hour. 200 µL of PBS containing 5% FBS was added, and the cells were then collected by centrifugation at 3,000 rpm. This procedure was repeated twice. The sample was suspended in 200 µL of PBS containing 5% FBS, and the change in the fluorescence level of cells was measured by FACScan (Becton Dickinson Company, Ltd.). Thus, the binding between E2tag and Molt-4 or NIH3T3/CD81 was confirmed.

(Confirmation of inhibitor of binding between E2tag and Molt-4 or NIH3T3/CD81)

[0098] A solution prepared by diluting E2tag with RPMI 1640 containing 1% FBS to the final concentration of 50 µg/mL was mixed with 10 µL each of a solution prepared by diluting scFv (the antibody obtained by the screening method described below in the present specification) in the range of 0.125 µg/mL to 12.5 µg/mL, a solution prepared by diluting heparin (SIGMA, H3393) in the range of 4 µg/mL to 400 µg/mL, and a solution prepared by diluting suramin (SIGMA, S2671) in the range of 50 µg/mL to 5,000 µg/mL, with RPMI 1640 containing 1% FBS, respectively. The resultant mixtures were incubated at 37°C for 30 minutes. 10 µL of solution prepared by suspending Molt-4 or NIH3T3/CD81 in RPMI 1640 containing 1% FBS at a concentration of 1×10^7 cell/mL was mixed therewith and the resultant mixture was incubated on ice for 1 hour. 200 µL of PBS containing 5% FBS was added and the cells were then collected by centrifugation at 3,000 rpm. This procedure was repeated twice. The anti-Etag antibody was diluted to 10 µg/mL with RPMI 1640 containing 1% FBS, 10 µL thereof was added to each sample, and mixed. The mixture was then incubated on ice for 1 hour. 200 µL of PBS containing 5% FBS was added and the cells were then collected by centrifugation at 3,000 rpm. This procedure was repeated twice. 10 µL of solution prepared by diluting FITC-labeled anti-mouse Igs (purchased from Cappel) with PBS containing 5% FBS to a final concentration of 25 µg/mL was added to each sample and mixed. Thereafter, the mixture was incubated on ice for 1 hour. 200 µL of PBS containing 5% FBS was added, and the cells were then collected by centrifugation at 3,000 rpm. This procedure was repeated twice. The sample was suspended in 200 µL of PBS containing 5% FBS, and the change in the fluorescence level of the cells was then measured by FACScan (Becton Dickinson Company, Ltd.). Thus, it was confirmed that the binding between E2tag and Molt-4 or NIH3T3/CD81 was inhibited by the added patient's serum or antibody.

[0099] Results are shown in Figs. 1 to 3. Fig. 1 shows the neutralizing activity of the antibody shown by the aforementioned amino acid sequence. In Fig. 1, scFv1-1 and scFv1-4 correspond to antibodies shown by the aforementioned amino acid sequence, and the control shows a single-chain antibody which recognizes VLA 4. Fig. 2 shows the neutralizing activity when heparin is used, and Fig. 3 shows the neutralizing activity when suramin is used.

3. Preparation of antibody library

(Purification of mRNA from patient who recovered from HCV)

5 **[0100]** From a patient who had recovered from HCV and has an antibody in the collected serum capable of inhibiting the binding between E2tag and Molt-4 or NIH3T3/CD81 expression cell, 40 mL heparin blood was sampled to collect blood. In order to separate peripheral blood lymphocyte, specific gravity centrifugation (Ficoll-Paque: Pharmacia) was performed to obtain 4×10^7 of lymphocytes. B-cell purification by anti-CD19 antibody using MACS (manufactured by Daiichi Pure Chemicals Co., Ltd.; Miltenyi Biotech GmbH) was performed to obtain 2.8×10^6 of cells. In order to confirm the purity of B-cells in the purified cells, the cells purified by the anti-CD19 antibody were stained to confirm by flow cytometry that the level of purification was 95% or higher. The purified B-cells were cultured for 72 hours under the stimulation of 200 unit/mL of human IL-2 (Genzyme), 10 ng/mL of human IL-10 (Genzyme), 1 ng/mL of E2/NS1 antigen and 1 μ g/mL of anti-human CD40 antibody (Genzyme) in the condition of 5×10^5 B-cell/ml of 10% FCS RPMI. Activation of B-cells was confirmed using a microscope, the cells were washed with PBS twice, and mRNA was obtained and purified from B-cells using RNeasy (Qiagen) in accordance with the instructions.

(Preparation of antibody library)

20 **[0101]** The antibody library was prepared in accordance with the method described in "By-Passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage (Journal of Molecular Biology 1991 222 582-597)." cDNA was synthesized from 1 μ g of purified mRNA using RT-PCR kit ver 2.1 (TAKARA) in accordance with the attached information by using random primer. In accordance with the information attached to this kit, H chain and L chain (λ chain, κ chain) of the antibody were then amplified by PCR using this cDNA as a template. The primer and the linker for cloning antibody genes were prepared and used in accordance with the description in the above literature. The PCR product was subjected to 1% agarose gel electrophoresis, and the bands of H chain and L chain of the antibody were cut out. From the agarose gel which was cut out, DNA was extracted using QIAEX II Gel extraction kit (QIAGEN). Subsequently, the extracted H chain, L chain, and linker were mixed so that their moles became equivalent to each other, and PCR was performed using a primer for ligation. PCR was performed in 50 μ L of system using 1 unit of Taq polymerase (Perkin Elmer) by heating at 94°C for 5 minutes, repeating 30 cycles of 94°C for 30 seconds, 55°C for 30 seconds and 72°C for 30 seconds, and then heating at 72°C for 5 minutes. The PCR product was subjected to 1% agarose gel electrophoresis, and a band having H chain, L chain and the linker ligated to each other in single band was cut out. From the agarose gel which was cut out, DNA was extracted using QIAEX II Gel extraction kit (QIAGEN). Subsequently, the extracted DNA was reacted with a restriction enzyme SfiI in 50 μ L of system M (10mM Tris-HCl, 50 mM NaCl, 2 mM MgCl₂) at 55°C for 2 hours and cleaved, and the enzyme was deactivated by heating at 70°C for 10 minutes. The restriction enzyme NotI was further added, and the DNA was reacted in 50 μ L of system M (10mM Tris-HCl, 50mM NaCl, 2 mM MgCl₂) at 37°C for 2 hours and cleaved, and the enzyme was deactivated by heating at 70°C for 10 minutes. The DNA was successively purified by phenol-chloroform extraction and ethanol precipitation and then dissolved in 50 μ L of sterilized water. 100 ng of this DNA fragment and 50 ng of pCantab5MycHis (a vector prepared by substituting Etag sequence of pCantab5E (Amersham Pharmacia) with Myc-Histag) were ligated to each other using a ligase kit (TAKARA) in accordance with the instructions. The ligation sample was successively purified by phenol-chloroform extraction and ethanol precipitation and then dissolved in 10 μ L of sterilized water. A half aliquot thereof was used to perform transformation in accordance with Molecular Cloning (1982) p249, Cold Spring Harbor Labs. Thus, 1×10^6 colonies were obtained. This colony was hereinafter used as a single-chain antibody library.

45 4. Screening of library phage

(Preparation of phage)

50 **[0102]** *Escherichia coli* grown on the plate was collected with 2 ml of 2x TY liquid medium, and 20 μ l thereof was added to 20 ml of 2x TY liquid medium (containing 100 μ g/L ampicillin and 2% glucose). The *Escherichia coli* was cultured until the absorbance at 600 nm became 1.0 while shaking at 37°C at 200 rpm. 1×10^{11} pfu/mL helper phage M13KO7 was added to the culture solution, and the mixture was allowed to stand at 37°C for 30 minutes. Subsequently, the mixture was shaken at 37°C at 200 rpm. 30 minutes later, the solution was centrifuged at 3,000 rpm for 10 minutes to collect *Escherichia coli*. The supernatant was discarded, and *Escherichia coli* was suspended in 20 ml of 2x TY liquid medium (containing 100 μ g/L ampicillin and 50 μ g/L kanamycin), and cultured overnight while shaking at 37°C at 200 rpm. On the following day, the culture solution was centrifuged at 15,000 rpm to precipitate *Escherichia coli*, and the supernatant was collected. This supernatant was used as a phage solution.

EP 1 256 348 A1

(Screening operation)

5 **[0103]** 1 ml of E2 antigen (10 µg/ml) dissolved in a solution of 50 mM NaHCO₃ (pH 9.6) was added to a plastic tube (Nunc Maxisorp Tube) and allowed to stand at 4°C overnight. On the following day, the antigen solution was discarded, and the tube was then washed with 5 mL of PBS solution. This procedure was repeated 3 times. 5 ml of 5% BSA was then added, and the mixture was allowed to stand at 37°C. 2 hours later, the BSA solution was discarded and the tube was washed with 5 ml of PBS solution. Subsequently, 250 µL of the prepared phage solution was mixed with 750 µL of 5% BSA solution, the mixture was added to the tube, and then allowed to stand at 37°C. 1 hour later, the added solution was discarded and the tube was washed with 5 ml of PBST (0.1%) solution. This procedure was repeated 20
10 times. Subsequently, the tube was washed with 5 mL of PBS solution. This procedure was repeated 20 times. 1 mL of 100 mM triethylamine was added to the tube and the tube was allowed to stand at room temperature for 10 minutes. Thereafter, the triethylamine solution was collected, and 500 µL of 1M Tris-HCl (pH 7.5) was added thereto, followed by thorough mixing. 750 µL of this solution was added to 10 mL of *Escherichia coli* TG-1 which had been cultured until the absorbance at 600 nm became 0.6, and the mixture was allowed to stand at 37°C for 30 minutes. Subsequently,
15 the mixture was shaken at 37°C at 200 rpm. 30 minutes later, the solution was centrifuged at 3,000 rpm for 10 minutes to collect *Escherichia coli*. This *Escherichia coli* was inoculated on the 2x TY plate medium (containing 100 µg/L ampicillin and 2% glucose) and incubated at 37°C overnight. On the following day, phages were collected from *Escherichia coli* grown on the plate in accordance with the operation described in (Preparation of phage), and the operation described in (Screening operation) was repeated. This screening operation was repeated 3 times.

20 **[0104]** As a result, the antibodies ScFv1-1, ScFv1-2, ScFv1-3, and ScFv1-4 having amino acid sequences shown by SEQ ID NOS: 1 to 29 in the Sequence Listing were obtained.

[0105] SEQ ID NOS: 1 to 3 in the Sequence Listing represent amino acid sequences of CDR-1, CDR-2, and CDR-3 of the H chains of the antibodies ScFv1-1, ScFv1-2, ScFv1-3, and ScFv1-4.

25 **[0106]** SEQ ID NOS: 4 to 6 in the Sequence Listing represent amino acid sequences of CDR-1, CDR-2, and CDR-3 of the L chain of the antibody ScFv1-1.

[0107] SEQ ID NOS: 7 to 9 in the Sequence Listing represent amino acid sequences of CDR-1, CDR-2, and CDR-3 of the L chain of the antibody ScFv1-2.

[0108] SEQ ID NOS: 10 to 12 in the Sequence Listing represent amino acid sequences of CDR-1, CDR-2, and CDR-3 of the L chain of the antibody ScFv1-3.

30 **[0109]** SEQ ID NOS: 13 to 15 in the Sequence Listing represent amino acid sequences of CDR-1, CDR-2, and CDR-3 of the L chain of the antibody ScFv1-4.

[0110] SEQ ID NO: 16 in the Sequence Listing represents the amino acid sequence of the H chains of the antibodies ScFv1-1, ScFv1-2, ScFv1-3, and ScFv1-4.

35 **[0111]** SEQ ID NOS: 17 to 20 in the Sequence Listing respectively represent the amino acid sequences of the L chains of the antibodies ScFv1-1, ScFv1-2, ScFv1-3, and ScFv1-4.

[0112] SEQ ID NO: 21 in the Sequence Listing represents the nucleotide sequence of the H chains of the antibodies ScFv1-1, ScFv1-2, ScFv1-3, and ScFv1-4.

[0113] SEQ ID NOS: 22 to 25 in the Sequence Listing respectively represent the nucleotide sequences of the L chains of the antibodies ScFv1-1, ScFv1-2, ScFv1-3, and ScFv1-4.

40 **[0114]** SEQ ID NOS: 26 to 29 in the Sequence Listing respectively represent the nucleotide sequences and the amino acid sequences of the antibodies ScFv1-1, ScFv1-2, ScFv1-3, and ScFv1-4.

[0115] The antibodies ScFv2-1, ScFv2-2, ScFv2-3, and ScFv2-4 in which the amino acid sequence of the H chain was the amino acid sequence shown by SEQ ID NO: 34 in the Sequence Listing, were obtained.

45 **[0116]** SEQ ID NO: 34 in the Sequence Listing represents the amino acid sequence of the H chains of the antibodies ScFv2-1, ScFv2-2, ScFv2-3, and ScFv2-4.

[0117] SEQ ID NO: 35 in the Sequence Listing represents the nucleotide sequence of the H chains of the antibodies ScFv2-1, ScFv2-2, ScFv2-3, and ScFv2-4.

[0118] SEQ ID NOS: 36 to 39 in the Sequence Listing represent the nucleotide sequences and the amino acid sequences of the antibodies ScFv2-1, ScFv2-2, ScFv2-3, and ScFv2-4.

50 5. ScFv rearrangement

(Preparation of antibody library)

55 **[0119]** The antibody library was prepared in the same manner as described in the above section of "Preparation of antibody library".

[0120] At first, a vector was prepared in which the L chain region of pCantab5scFv3-1MycHis (wherein the scFv1-1 gene described in Example is inserted between the SfiI site and the NotI site of pCantab5MycHis, and Alw44I is provided

EP 1 256 348 A1

at the 5'-terminus of the L chain and NotI site is provided at the 3'-terminus of the L chain) had been replaced with the HCV antigen-unreactive L chain. This was designated "pCantab5scFv3-1/L-/MycHis."

[0121] cDNA was synthesized from 1 µg of purified mRNA using RT-PCR kit ver 2.1 (TAKARA) in accordance with the attached information and using a random primer. In accordance with the information attached to this kit, L chain (λ chain, κ chain) of the antibody were then amplified by PCR using this cDNA as a template. The primer for cloning antibody genes was prepared and used in accordance with the description in the above literature. The PCR product was subjected to 1% agarose gel electrophoresis, and the bands of H chain and L chain of the antibody were cut out. From the agarose gel which was cut out, DNA was extracted using QIAEX II Gel extraction kit (QIAGEN).

[0122] Subsequently, the DNA was reacted with a restriction enzyme Alw44I in 50 µL of system M (10 mM Tris-HCl, 50 mM NaCl, 2 mM MgCl₂) at 37°C for 2 hours and cleaved, and the enzyme was deactivated by heating at 70°C for 10 minutes. The restriction enzyme NotI was further added, and the DNA was reacted in 100 µL of system H (10 mM Tris-HCl, 50 mM NaCl, 2 mM MgCl₂) at 37°C for 2 hours and cleaved, and the enzyme was deactivated by heating at 70°C for 10 minutes. The DNA was successively purified by phenol-chloroform extraction and ethanol precipitation and then dissolved in 50 µL of sterilized water. 100 ng of this DNA fragment and 50 ng of pCantab5scFv3-1/L-/MycHis which was treated with Alw44I and NotI in the same manner, were ligated to each other using a ligase kit (TAKARA) in accordance with the instructions. The ligation sample was successively purified by phenol-chloroform extraction and ethanol precipitation, and then dissolved in 10 µL of sterilized water. A half aliquot thereof was used to perform transformation in accordance with Molecular Cloning (1982) p249, Cold Spring Harbor Labs. Thus, 1 x 10⁶ colonies were obtained. The resultant colonies were hereinafter used as a single-chain antibody library.

(Screening of library phage)

[0123] Preparation of phages and screening operations were performed in the same manner as described above.

[0124] As a result, the antibodies ScFv3-1, ScFv3-2, ScFv3-3, and ScFv3-4 having amino acid sequences shown by SEQ ID NOS: 42 to 65 in the Sequence Listing were obtained.

[0125] SEQ ID NOS: 42 to 44 in the Sequence Listing represent amino acid sequences of CDR-1, CDR-2, and CDR-3 of the L chain of the antibody ScFv3-1.

[0126] SEQ ID NOS: 45 to 47 in the Sequence Listing represent amino acid sequences of CDR-1, CDR-2, and CDR-3 of the L chain of the antibody ScFv3-2.

[0127] SEQ ID NOS: 48 to 50 in the Sequence Listing represent amino acid sequences of CDR-1, CDR-2, and CDR-3 of the L chain of the antibody ScFv3-3.

[0128] SEQ ID NOS: 51 to 53 in the Sequence Listing represent amino acid sequences of CDR-1, CDR-2, and CDR-3 of the L chain of the antibody ScFv3-4.

[0129] SEQ ID NOS: 54 to 57 in the Sequence Listing respectively represent amino acid sequences of the L chains of the antibodies ScFv3-1, ScFv3-2, ScFv3-3, and ScFv3-4.

[0130] SEQ ID NOS: 58 to 61 in the Sequence Listing respectively represent nucleotide sequences of the L chains of the antibodies ScFv3-1, ScFv3-2, ScFv3-3, and ScFv3-4.

[0131] SEQ ID NOS: 62 to 65 in the Sequence Listing respectively represent nucleotide sequences and amino acid sequences of the antibodies ScFv3-1, ScFv3-2, ScFv3-3, and ScFv3-4.

6. Preparation of scFv from screened phages

[0132] A candidate colony was inoculated on 100 mL of 2x TY liquid medium (containing 100 µg/L ampicillin and 2% glucose), and the colony was cultured at 30°C at 200 rpm overnight. On the following day, the culture solution was added to 900 ml of 2x TY liquid medium (containing 100 µg/L ampicillin and 0.1% glucose), and cultured for 1 hour at 30°C at 200 rpm. 1 mL of 1M IPTG (isopropyl-β-D-thio-galactopyranoside) was added, and the mixture was further cultured under the same condition for 5 hours. The culture solution was centrifuged at 8,000 rpm for 10 minutes to precipitate bacteria. The supernatant was discarded, the precipitate was suspended in 50 ml of 50 mM Tris-HCl (pH 8), 20% sucrose and 1 mM EDTA solution, and then allowed to stand in ice for 15 minutes. Subsequently, the suspension was centrifuged at 10,000 rpm for 15 minutes, the supernatant was collected, and MgCl₂ was added to bring the solution to 1 mM.

7. Purification of ScFv

[0133] ScFv obtained from the *Escherichia coli* was purified using Ni-NTA agarose (purchased from QIAGEN) in accordance with the instructions. 1 mL of Ni-NTA agarose was washed by adding 30 ml of solution A (50 mM Na-phosphate, 300 mM NaCl, pH 7.4), stirred and centrifuged at 1,000 rpm for 2 minutes, and the supernatant was then discarded. The above-described supernatant was added to the Ni-NTA agarose. The mixture was stirred for 45 minutes

EP 1 256 348 A1

at 4°C, and His tag site of ScFv was bound to Ni-NTA agarose. Thereafter, the product was centrifuged at 1,000 rpm for 2 minutes, and the supernatant was discarded. 30 ml of solution A was added to wash Ni-NTA agarose, the mixture was centrifuged at 1,000 rpm for 2 minutes, and the supernatant was discarded. Further, Ni-NTA agarose was washed with 30 ml of solution B (solution A + 10 mM imidazole) in the same manner. The Ni-NTA agarose was then suspended in 10 ml of solution B, and the suspension was added to poly-prep column (Bio-Rad). Further, 10 ml of solution B was added, and the Ni-NTA agarose was washed. After the washing buffer was completely removed from the column, ScFv bound to Ni-NTA agarose was eluted using 2 ml of solution C (solution A + 250 mM imidazole). Subsequently, the eluate was added to PD10 column (Amersham Pharmacia) washed with 25 ml of PBS (10 mM phosphate pH 7.4, 150 mM NaCl), eluted with a PBS solution, and buffers were exchanged. The absorbance at 280 nm of each elution fraction was measured, and the ScFv elution fractions was taken together into one solution, and used in the later experiments.

8. Confirmation of binding ability between ScFv and E2

[0134] 1 mL of E2tag (1 µg/ml) dissolved in a 50 mM NaHCO₃ (pH 9.6) solution was added to 96-well plates (FALCON) in an amount of 50 µL respectively, and was incubated at 37°C for 1 hour. At this time, the same number of wells containing a buffer only and no E2tag, were also prepared as blank wells. The solution in each well was discarded by decantation, and 200 µL of PBS containing 0.1% Tween 20 was added to each well, followed by discard by decantation. This procedure was repeated 5 times. After the water content in each well was removed, PBS solution containing 5% BSA was added to each well in an amount of 200 µL, and the mixture was incubated at 37°C for 1 hour. The solution in each well was discarded by decantation, and 200 µL of PBS containing 0.1% Tween 20 was added to each well, followed by discard by decantation. This procedure was repeated 5 times. The obtained scFv was diluted with PBS containing 1% BSA to bring the concentration to 10 µg/mL or below and added to each of the wells with E2tag and the wells without E2tag in amounts of 50 µL each, and was incubated at 37°C for 1 hour. The solution in each well was discarded by decantation, and 200 µL of PBS containing 0.1% Tween 20 was added to each well, followed by discard by decantation. This procedure was repeated 5 times. After the water content in each well was removed, the anti-myc-tag antibody (purchased from Santa Cruz Biotechnology, Inc.) was diluted with PBS containing 1% BSA so as to bring the final concentration to 10 µg/mL, added to each well in amounts of 50 µL each, and the mixture was incubated at 37°C for 1 hour. The solution in each well was discarded by decantation, and 200 µL of PBS containing 0.1% Tween 20 was added to each well, followed by discard by decantation. This procedure was repeated 5 times. HRP-labeled anti-mouse Igs was diluted with PBS containing 1% BSA so as to bring the final concentration to 1 µg/mL, added to each well in amounts of 50 µL each, and the mixture was incubated at room temperature for 1 hour. The solution in each well was discarded by decantation, and 200 µL of PBS containing 0.1% Tween 20 was added to each well, followed by discard by decantation. This procedure was repeated 5 times. A solution of 10 mg of orthophenylenediamine and 12.5 µL of 30% hydrogen peroxide solution in 25 mL of OPD buffer was added to each well in amounts of 100 µL each, and the mixture was incubated at room temperature until color sufficiently developed. 100 µL of 4N sulfuric acid was added to terminate the reaction, and the absorbance at 490 nm was measured to confirm whether or not scFv bound to E2tag.

9. Construction of antibody expression vector

[0135] A region containing CMV promoter of pRC/CMV (purchased from Invitrogen), a multi-cloning site, a poly(A) signal sequence region (nucleotide 209 to 1250 in the gene map of Invitrogen) were amplified by PCR. The sequences of the used primers are 5'CCC TGA TCA GAA TTC GCA GGA TCC CTC GAG ACT AGT GAT GAT CGG GCC AGA TAT ACG CG 3' (SEQ ID NO: 66) for the 5'-side and 5'CCC TGA TCA AGA TCT GCT AGC GTC GAC TCC CCA GCA TGC CTG CTG CTA TTG 3' (SEQ ID NO: 67) for the 3'-side. The primers were synthesized using Applied Biosystems Model 394 and then prepared by a conventional method. PCR was performed using Perkin Elmer Cetus DNA Thermal Cycler and KOD polymerase (purchased from Toyobo Co., Ltd., the reaction conditions were set in accordance with the instructions). Thereafter, the desired about 1.0 Kbp DNA fragment was purified by 5% acrylamide electrophoresis in accordance with the method described in Molecular Cloning, sections 6.46-6.48, Cold Spring Harbor. About 1 µg of purified DNA fragment was reacted in 50 µl of system H using 1 unit of BclI at 37°C for 2 hours and cleaved. Separately, 1 µg of ppUC119 (purchased from Takara Shuzo Co., Ltd.) DNA was reacted using 1 unit of BamHI in 50 µl of system H at 37°C for 2 hours and cleaved. The cleaved DNA fragment and the cleaved plasmid were ligated to each other using a ligase kit (purchased from Takara Shuzo Co., Ltd., the reaction was carried out in accordance with the instructions), *Escherichia coli* strain JM109 (purchased from Takara Shuzo Co., Ltd., the reaction was carried out in accordance with the instructions) was transformed, and the desired expression plasmid pKS 1 was obtained.

[0136] The above-obtained pKS1 (1 µg) was reacted using 1 unit of SpeI in 50 µl of system M at 37°C for 2 hours and cleaved.

[0137] The loxP-Hygromycin fused gene was amplified by PCR using pcDNA3.1/Hygro(+) (purchased from Invitro-

gen). The sequences of the used primers were Hyg-stop: cccagatctctattccttgcctcggacgag (SEQ ID NO: 68) for the 5'-side and Hy-atg: cccaagcttatgaaaagcctgaactaccgcg 3' (SEQ ID NO: 69) for the 3'-side. The synthesis was ordered to SciMedia Ltd. and purchased therefrom. PCR was performed using Perkin Elmer Cetus DNA Thermal Cycler and KOD polymerase (purchased from Toyobo Co., Ltd., the reaction conditions were set in accordance with the instructions). Thereafter, the desired DNA fragment was purified by 5% acrylamide electrophoresis in accordance with the method described in Molecular Cloning, sections 6.46-6.48, Cold Spring Harbor. About 1 µg of purified DNA fragment was reacted in 50 µl of system M using 1 unit of NheI and NaeI at 37°C for 2 hours and cleaved.

[0138] DNA containing TK(A)n was amplified by PCR using pNeo-gal (purchased from Stratagene). The sequences of the used primers were cccgccggctgggtgtggcggaccg3' (SEQ ID NO: 70) for the 5'-side and 5'cccctctagaagatag-gaactcaagc 3' (SEQ ID NO: 71) for the 3'-side. The primers were synthesized using Applied Biosystems Model 394 and then prepared by a conventional method. PCR reaction was performed using Perkin Elmer Cetus DNA Thermal Cycler and KOD polymerase (purchased from Toyobo Co., Ltd., the reaction conditions were set in accordance with the instructions). Thereafter, a desired DNA fragment was purified by 5% acrylamide electrophoresis in accordance with the method described in Molecular Cloning, Section 6.46-6.48, Cold Spring Harbor. About 1 µg of purified DNA fragment was reacted in 50 µL of system M using 1 unit of XbaI and NaeI at 37°C for 2 hours and cleaved.

[0139] The cleaved plasmid, the cleaved loxP-hygromycin DNA fragment, and the Tk(A)nDNA fragment were ligated to each other using a ligase kit (purchased from Takara Shuzo Co., Ltd., the reaction was carried out in accordance with the instructions), *Escherichia coli* strain JM109 (purchased from Takara Shuzo Co., Ltd., the reaction was carried out in accordance with the instructions) was transformed, and the desired expression plasmid, pEX loxP-Hyg was obtained.

[0140] A DNA fragment containing a heavy chain constant region was amplified by PCR using pEX1-3-1W (Japanese Patent Application No. 2000-172684). The sequences of the used primers were 5'cccaagctctcagactagtagtaccaggccatcggtcttccc3' (SEQ ID NO: 72) for the 5'-side and 5'cccggggccctctagtagctttcattaccggagacaggg3' (SEQ ID NO: 73) for the 3'-side. The synthesis was ordered to SciMedia Ltd. and purchased therefrom. PCR reaction was performed using Perkin Elmer Cetus DNA Thermal Cycler and KOD polymerase (purchased from Toyobo Co., Ltd., the reaction conditions were set in accordance with the instructions). Thereafter, the desired DNA fragment was purified by 5% acrylamide electrophoresis in accordance with the method described in Molecular Cloning, sections 6.46-6.48, Cold Spring Harbor. About 1 µg of purified DNA fragment was reacted in 50 µl of system M using 1 unit of HindIII and ApaI at 37°C for 2 hours and cleaved.

[0141] 1 µg of pEX loxP-Hyg DNA was reacted using 1 unit of HindIII and ApaI in 50 µl of system M at 37°C for 2 hours and cleaved.

[0142] The cleaved plasmid and the cleaved DNA fragment containing a heavy chain constant region were ligated to each other using a ligase kit (purchased from Takara Shuzo Co., Ltd., the reaction was carried out in accordance with the instructions), *Escherichia coli* strain JM109 (purchased from Takara Shuzo Co., Ltd., the reaction was carried out in accordance with the instructions) was transformed, and the desired expression plasmid, pEX gamma1 loxP-Hyg, was obtained.

[0143] A DNA fragment containing a heavy chain variable region was amplified by PCR using ScFv1-1. The sequences of the used primers were HB1-N 5'cccaagctcaccATGAAACACCTGTGGTTCTTCTCCTGCTGGT-GGCAGCTCCC AGATGGGTCTGTCCCAGGTGCAGCtggtgcagtctg3' (SEQ ID NO: 74) and HB1-C 5'cccgctagcACTCGAGACGGTGACCAGGGTGCC3' (SEQ ID NO: 75). The synthesis was ordered to SciMedia Ltd. and purchased therefrom. PCR reaction was performed using Perkin Elmer Cetus DNA Thermal Cycler and KOD polymerase (purchased from Toyobo Co., Ltd., the reaction conditions were set in accordance with the instructions). Thereafter, the desired DNA fragment was purified by 5% acrylamide electrophoresis in accordance with the method described in Molecular Cloning, sections 6.46-6.48, Cold Spring Harbor. About 1 µg of purified DNA fragment was reacted in 50 µl of system M using 1 unit of HindIII and NheI at 37°C for 2 hours and cleaved.

[0144] 1 µg of pEX gamma1 loxP-Hyg DNA was reacted using 1 unit of HindIII and SspI in 50 µl of system M at 37°C for 2 hours.

[0145] The cleaved plasmid and the cleaved DNA fragment containing a heavy chain variable region were ligated to each other using a ligase kit (purchased from Takara Shuzo Co., Ltd., the reaction was carried out in accordance with the instructions), *Escherichia coli* strain JM109 (purchased from Takara Shuzo Co., Ltd., the reaction was carried out in accordance with the instructions) was transformed, and the desired expression plasmid, pEX gamma1 loxP-Hyg HCV1 was obtained (Fig. 7).

[0146] A DNA fragment containing kanamycin-resistant genes was amplified by PCR using pEGFPN2 (purchased from Clontech). The sequences of the used primers were 5'cccagagctagctctcaggcgggaaatgtgcggaaccct3' (SEQ ID NO: 76) for the 5'-side of the H chain and 5'cccgcctagcctgcaagtcatttcaacccagcgtccc3' (SEQ ID NO: 77) for the 3'-side. The synthesis was ordered to SciMedia Ltd. and purchased therefrom. PCR reaction was performed using Perkin Elmer Cetus DNA Thermal Cycler and KOD polymerase (purchased from Toyobo Co., Ltd., the reaction conditions were set in accordance with the instruction). Thereafter, the desired DNA fragment was purified by 5% acrylamide

EP 1 256 348 A1

electrophoresis in accordance with the method described in Molecular Cloning, sections 6.46-6.48, Cold Spring Harbor. About 1 µg of purified DNA fragment was reacted in 50 µl of system M using 1 unit of SpeI and NheI at 37°C for 2 hours, and then reacted at 37°C for 2 hours to be cleaved.

[0147] 1 µg of pKS1 DNA was reacted using 1 unit of NheI in 50 µl of system M at 37°C for 2 hours.

[0148] The cleaved plasmid and the cleaved DNA fragment containing kanamycin-resistant genes were ligated to each other using a ligase kit (purchased from Takara Shuzo Co., Ltd., the reaction was carried out in accordance with the instructions), *Escherichia coli* strain JM109 (purchased from Takara Shuzo Co., Ltd., the reaction was carried out in accordance with the instructions) was transformed, and the desired expression plasmid, pEX-1 Km, Amp, was obtained.

[0149] 1 µg of pEX-1 Km, Amp 1 DNA was reacted using 1 unit of DraI and ScaI in 50 µl of system H at 37°C for 2 hours and cleaved.

[0150] The cleaved plasmid was ligated using a ligase kit (purchased from Takara Shuzo Co., Ltd., the reaction was carried out in accordance with the instructions), *Escherichia coli* strain JM109 (purchased from Takara Shuzo Co., Ltd., the reaction was carried out in accordance with the instructions) was transformed, and the desired expression plasmid, pEX-1 Km, was obtained.

[0151] A DNA fragment containing a light chain constant region was amplified by PCR using pCZ0k (described in Shibui, T., et al., Appl. Microbiol. Biotechnol. (1993) 38, 770-775). The sequences of the used primers were 5'ccccagctctagagtcgacggtaccgtggaaatcaaacgaactgtgg3' (SEQ ID NO: 78) for the 5'-side of the H chain and 5'ccccggccctctagcggcgcctaactctcccctgtgaagc3' (SEQ ID NO: 79) for the 3'-side. The synthesis was ordered to SciMedia Ltd. and purchased therefrom. PCR reaction was performed using Perkin Elmer Cetus DNA Thermal Cycler and KOD polymerase (purchased from Toyobo Co., Ltd., the reaction conditions were set in accordance with the instructions). Thereafter, the desired DNA fragment was purified by 5% acrylamide electrophoresis in accordance with the method described in Molecular Cloning, sections 6.46-6.48, Cold Spring Harbor. About 1 µg of purified DNA fragment was reacted in 50 µl of system M using 1 unit of HindIII and ApaI at 37°C for 2 hours and cleaved.

[0152] 1 µg of pEX-1 Km DNA was reacted using 1 unit of HindIII and ApaI in 50 µl of system M at 37°C for 2 hours and cleaved.

[0153] The cleaved plasmid and the cleaved DNA fragment containing a light chain constant region were ligated to each other using a ligase kit (purchased from Takara Shuzo Co., Ltd., the reaction was set in accordance with the instructions), *Escherichia coli* strain JM109 (purchased from Takara Shuzo Co., Ltd., the reaction was carried out in accordance with the instructions) was transformed, and the desired expression plasmid, pEX kappa Km, was obtained.

[0154] A DNA fragment containing a light chain variable region was amplified by PCR using scFv1-1. The sequences of the used primers were LK1-N 5'ccaagctcaccATGGCGTTGCAGACCCAGGTCTTCATTTCTCTGTTGCTCTGGATCTCTGGTGCCTACGGGgacatccagatgaccagctctcc3' (SEQ ID NO: 80) and LK1-C 5'CcccgtagcTTTGATTTCCACCTTGGTCCCCCG3' (SEQ ID NO: 81). The synthesis was ordered to SciMedia Ltd. and purchased therefrom. PCR reaction was performed using Perkin Elmer Cetus DNA Thermal Cycler and KOD polymerase (purchased from Toyobo Co., Ltd., the reaction conditions were set in accordance with the instructions). Thereafter, the desired DNA fragment was purified by 5% acrylamide electrophoresis in accordance with the method described in Molecular Cloning, sections 6.46-6.48, Cold Spring Harbor. About 1 µg of purified DNA fragment was reacted in 50 µl of system M using 1 unit of HindIII and BsiWI at 37°C for 2 hours, and reacted at 50°C for 2 hours to be cleaved.

[0155] 1 µg of pEX kappa Km DNA was reacted using 1 unit of HindIII and Asp187I in 50 µl of system M at 37°C for 2 hours and cleaved.

[0156] The cleaved plasmid and the cleaved DNA fragment containing a heavy chain variable region were ligated to each other using a ligase kit (purchased from Takara Shuzo Co., Ltd., the reaction was carried out in accordance with the instructions), *Escherichia coli* strain JM109 (purchased from Takara Shuzo Co., Ltd., the reaction was carried out in accordance with the instruction) was transformed, and the desired expression plasmid, pEX kappa Km HCV1, was obtained (Fig. 8).

[0157] 1 µg of pEX kappa Km HCV1 DNA was reacted using 1 unit of SpeI and NheI in 50 µl of system M at 37°C for 2 hours and cleaved.

[0158] 1 µg of pEX gamma1 loxP-Hyg HCV1 DNA was reacted using 1 unit of NheI in 50 µl of system M at 37°C for 2 hours and cleaved.

[0159] The above described cleaved plasmids were ligated to each other using a ligase kit (purchased from Takara Shuzo Co., Ltd., the reaction was carried out in accordance with the instructions), *Escherichia coli* strain JM109 (purchased from Takara Shuzo Co., Ltd., the reaction was carried out in accordance with the instructions) was transformed, and the desired plasmid, pEX loxP-Hyg HCV1 W Km, was obtained.

[0160] 1 µg of pEX loxP-Hyg HCV1 W Km 1 DNA was reacted using 1 unit of Sse8387 in 50 µl of system M at 37°C for 2 hours and cleaved.

[0161] The cleaved plasmid was ligated using a ligase kit (purchased from Takara Shuzo Co., Ltd., the reaction was

EP 1 256 348 A1

carried out in accordance with the instructions), *Escherichia coli* strain JM109 (purchased from Takara Shuzo Co., Ltd., the reaction was carried out in accordance with the instructions) was transformed, and the desired expression plasmid, pEX loxp-Hyg HCV1 W, was obtained (Fig. 9).

5 10. Site-specific introduction of antibody gene into the high expression site searching strain

[0162] pBS185 (site-specific recombinant enzyme expression plasmid, purchased from Lifetech) and pEX loxp-Hyg HCV1 W were transfected (1.0 µg each of DNA was used for 2,000,000 cells) using strain MKamp1 (strain described in Japanese Patent Application No. 2000-172684) in accordance with the instructions. The cells were cultured in the CHO-S-SFM-II medium containing 5% FBS (fetal bovine serum, purchased from Lifetech) at 37°C under 5% CO₂ for 48 hours. Then, the cells were selectively cultured in the same medium supplemented with 200 mg/l hygromycin (purchased from SIGMA) at 37°C under 5% CO₂ for 25 days, and a hygromycin-resistant colony was selected (strain MkampHCV1).

15 11. Measurement of production amount of antibody using ELISA assay

[0163] A solution of anti-human immunoglobulin goat antibody (diluted to 10 µg/ml with solution 1; purchased from Zymed) was added to a 96-well plate at 50 µl/well, and the plate was treated at 37°C for 2 hours. Thereafter, the solution in the well was discarded, 250 µl of solution 2 was added to each well, and incubated at 4°C for 16 hours or longer. After the solution was removed, each well was washed with solution 3 five times. An antibody (standard) diluted with solution 4 or a sample solution (a culture supernatant was optionally diluted with solution 4) was added at 50 µl/well, and incubated at 37°C for 2 hours. After the removal of the solution and washing with solution 3 five times, solution 5 was added at 50 µl/well, and the mixture was incubated at 20°C for 40 minutes. After the removal of the solution and washing with PBS five times, solution 9 was added at 100 µl/well, and reaction was performed at room temperature under a shaded condition for about 5 minutes. An equal amount of 10% sulfuric acid was added to terminate the reaction, the absorbance A1 and A2 at 11 = 490 nm and 12 = 650 nm in each well were then measured using an immunoreader (manufactured by Inter Med, Immuno Reader NJ-2000) to determine (A1-A2). A calibration curve was prepared using a diluted standard solution to measure the concentration of the 1-3-1 antibody (used as a standard) in the sample.

[0164] Formulation of each solution is as follows.

Solution 1: PBS containing 0.1% sodium azide

Solution 2: PBS containing 1% BSA and 0.1% sodium azide

Solution 3: PBS containing 0.05% Tween 20

35 Solution 4: PBS containing 1% BSA

Solution 5: a solution of 2 µl of stock solution of HRP-labeled anti-human immunoglobulin goat antibody (purchased from Zymed) in 10 ml of solution 4 (prepared at the time of using)

Solution 6: 500 ml of solution prepared by adding water to 14.2 g of sodium hydrogenphosphate

Solution 7: 500 ml of solution prepared by adding water to 10.5 g of citric monohydrate

40 Solution 8: 1,000 ml of solution prepared by adding water to the mixture of 257 ml of solution 5 and 243 ml of solution 6

Solution 9: a solution prepared by dissolving 4.0 mg of O-phenylenediamine (purchased from Wako Pure Chemicals Industries, Ltd.) in 10 ml of solution 7 and 5 µl of 30%(v/v) hydrogen peroxide solution (used within 10 minutes after preparation)

45 12. Antibody productivity of the strain prepared by site-specifically introducing an antibody expression gene into strain MKamp

[0165] The following production amount was observed by the above ELISA assay.

Parent strain	Fluorescence	Antibody gene-introduced strain Hygromycin-resistance	Antibody productivity
Mkamp 1	None	Resistant	10 mg/l

55 13. Characterization of recombinant whole antibody

[0166] In the same manner as employed in the assay of the affinity and the neutralizing activity against the antigen of a single-chain antibody, the values were measured for the obtained and purified recombinant whole antibody.

EP 1 256 348 A1

$$K_d = 2 \times 10^{-9} \quad \text{neutralizing activity IC}_{50} = 25 \text{ mg/l}$$

5 **[0167]** The obtained recombinant whole antibody was designated "whole antibody 1-1" and the amino acid sequence and the nucleotide sequence of the heavy chain and the light chain are shown in SEQ ID NOS: 40 and 41 in the Sequence Listing.

14. Cell fusion assay

10 **[0168]** Cell fusion assay was performed in accordance with the method of Takikawa et al. (Takikawa et al., J. Virol., 74, 5066-5074, 2000). 20,000 CHO cells (Matsuura et al., unpublished) expressing recombinant E1 and E2 proteins on cell surfaces were respectively inoculated in each well on a collagen-coated 96-well plate and cultured under 5% CO₂ at 37°C. In the preparation of cells, without using trypsin, the cells were immersed in 10 mM EDTA-added phosphate buffer saline (PBS) for 5 minutes, a flask was shaken to disperse the cells as much as possible, and the cells were detached while slowly pipetting. After culturing for 24 hours, the cells were washed with 200 µL of Opti-MEM (Gibco BRL) twice. Then, a reporter plasmid pT7EMCLuc (Aoki et al., Virology, 250, 140-150, 1998) having a firefly luciferase gene incorporated downstream of T7 promoter and pRL-CMV (Promega) having a sea pansy luciferase gene incorporated downstream of CMV promoter for standardizing the gene-introducing efficiency were introduced into cells using Trans IT-LT1 (Mirus). The medium was prepared in the following formulation for each plate. After the media were allowed to stand for 15 minutes, 30 µL each thereof was added to each well. 2 hours later, 150 µL of D-MEM (Gibco) supplemented with 10% serum was added, and culturing is continued.

Opti-MEM	3 ml
Trans IT-LT1	50 µL
pT7EMCLuc	9 µg
pRL-CMV	0.6 µg

25
30 **[0169]** HepG2 cells derived from human hepatocellular cancer were used as receptor cells for cell fusion. HepG2 cells were inoculated in each well on a 6-well plate at 8.0×10^5 cells and cultured under 5% CO₂ at 37°C. After culturing for 24 hours, plasmid pCAGT7pol (Ishii et al., unpublished) expressing T7 RNA polymerase was introduced into the cell in the following formulation per well, and 2 hours later, 1.5 ml of D-MEM supplemented with 10% serum was added. After culturing for 24 to 36 hours, cells were trypsinized, suspended in 25 to 30 ml of D-MEM supplemented with 10% serum, transferred to 50 ml centrifugation tube, and the suspension culturing was performed under 5% CO₂ at 37°C on a shaking apparatus overnight.

Opti-MEM	100 µL
Trans IT-LT1	5 µL
pCAGT7pol	1 µg

35
40
45 **[0170]** On the CHO cells (48 hours after transfection) which was provided on the 96-well plate, had a reporter plasmid introduced therein and expressed an HCV envelope protein, were added 2×10^4 cells/100 µL per well of HepG2 cells which had a plasmid expressing T7RNA polymerase introduced therein and was subjected to suspension culture overnight. After culturing for 5 hours, the medium was discarded and the cells were immersed in 100 µL of PBS (pH 5.0) for 2 minutes. Immediately after that, the solution was discarded, and 200 µL of D-MEM supplemented with 10% serum was added to each well, and culturing was continued. After culturing for 5 hours, the cells were assayed for the luciferase activity using dual-luciferase reporter assay system (Promega) in accordance with the attached protocol. Thus, the cell fusion activity was evaluated.

50 15. Cell fusion inhibition assay

55 **[0171]** The assay of the cell fusion inhibitory activity by the antibody was performed in basically the same manner as in the above cell fusion assay except that, before the addition of HepG2 cells to the CHO cells, HepG2 cells were washed with Opti-MEM twice, reacted with the test antibody (whole antibody 1-1) which was stepwisely diluted with Opti-MEM for 60 minutes, and then co-culture was performed. Thereafter, the luciferase activity was measured in the same manner, and the cell fusion inhibitory activity was evaluated. As a result, a substance which specifically inhibits the cell fusion by the envelope protein of HCV was observed in the complete antibodies which were prepared based

on the single-chain antibody which exhibited the NOB activity.

16. Measurement of binding constant using BIACORE X

5 [0172] The binding constant of the obtained ScFv was measured using BIACORE X in accordance with the attached instructions.

[0173] E2tag was substituted with 10 mM acetate buffer (pH = 5.0) using Centricon 30. This E2tag (100 µg/mL, 20 µL) was injected into separate lanes on sensor chip CM5 (purchased from BIACORE) at 5 µL/min to be immobilized by amino binding. Thus, an E2tag immobilized sensor chip was obtained. ScFv1-1 was substituted with HBS buffer (10 mM HEPES (pH 7.4), 0.15 M NaCl, 3.4 mM EDTA, 0.005% Tween 20) using Centricon 30. This scFv1-1 solution was injected onto the previously prepared E2tag sensor chip using BIACORE X (BIACORE) at 5 µL/min to obtain a sensorgram at the time of binding. Thereafter, only the HBS solution was injected onto the sensor chip at 5 µL/min to obtain a sensorgram at the time of dissociation. By analysis of these sensorgrams, a binding constant of 4.5×10^8 (M) and a dissociation constant of 2.2×10^{-9} (M) between E2tag and scFv1-1 were obtained.

15

17. Confirmation of binding between E2tag and heparin

[0174] As a method for confirming the presence of the site in E2tag for binding with sulfated polysaccharide, the binding between a column Heparin-Sepharose CL-6B (purchased from Pharmacia) to which heparin is covalently bound and E2tag was confirmed. Heparin-Sepharose CL-6B was equilibrated using 0.15 M NaCl, 10 mM phosphate buffer (pH 7.0).

[0175] 2 µg of E2tag dissolved in PBS and 300 µg of high molecular weight heparin (purchased from SIGMA) or 300 µg of Heparin (purchased from SIGMA) were mixed in 50 µL of system, and the mixture was incubated at 37°C for 1 hour while stirring. As a control, a sample which was incubated with E2tag only was also prepared. Centrifugation was performed at 10,000 rpm for 5 minutes, and only the supernatant was fractionated into another container. 100 µL of 0.15 M NaCl, 10 mM phosphate buffer (pH 7.0) was added, and the mixture was centrifuged. The supernatant was then transferred to another container. This procedure was repeated 5 times. 50 µL of 0.5 M NaCl, 10 mM phosphate buffer (pH 7.0) was added, and the mixture was stirred at room temperature for 5 minutes and centrifuged. The supernatant was then transferred to another container. 50 µL of 1.5 M NaCl and 10 mM phosphate buffer (pH 7.0) was added, and the mixture was stirred at room temperature for 5 minutes and centrifuged. The supernatant was then transferred to another container. 50 µL of sample buffer was added, and the mixture was incubated at 100°C for 5 minutes, centrifuged, and the supernatant was transferred to another container.

25

30

35

40

[0176] The elution samples transferred to the other containers were subjected to 10% polyacrylamide gel electrophoresis, and Western blotting was performed in the same manner as employed in the section regarding construction of E2tag expression strain, thereby confirming which of the elution fractions contained E2tag. As a result, it was found that E2tag was all bound to the column when only the E2tag was mixed with Heparin-Sepharose CL-6B, and it was confirmed that the binding of E2tag to the column was inhibited when incubated with high molecular weight heparin or heparin before mixing with Heparin-Sepharose CL-6B. These results indicate that E2tag and E2 have sites which strongly bind to heparin.

Industrial Applicability

45

[0177] The present invention can provide a novel medicament which has an anti-viral effects such as an inhibitory action against HCV infection.

50

55

SEQUENCE LISTING

5 <110> Mitsubishi-Tokyo Pharmaceutical, Co.

<120> A therapeutic agent for hepatitis type C

<130> A11037MA

10 <160> 81

<210> 1

15 <211> 5

<212> PRT

<213> Homo sapiens

20 <400> 1

Asp Gln Pro Ile Gly

25 1 5

<210> 2

<211> 17

30 <212> PRT

<213> Homo sapiens

35 <400> 2

Gly Ile Ile Pro Leu Ser Gly Pro Pro His Tyr Ala Gln Lys Phe Gln

40 1 5 10 15

Gly

<210> 3

45 <211> 17

<212> PRT

<213> Homo sapiens

50 <400> 3

Val Leu Arg Gly Tyr Cys Arg Arg Gly Ser Cys Tyr Asp Trp Leu Asp

55 1 5 10 15

Pro

<210> 4

<211> 11

<212> PRT

<213> Homo sapiens

<400> 4

Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn

1 5 10

<210> 5

<211> 7

<212> PRT

<213> Homo sapiens

<400> 5

Ala Thr Ser Arg Leu Tyr Ser

1 5

<210> 6

<211> 9

<212> PRT

<213> Homo sapiens

<400> 6

Gln Gln Thr Lys Ser Phe Pro Leu Thr

1 5

<210> 7

<211> 11

<212> PRT

<213> Homo sapiens

<400> 7

Arg Ala Ser Gln Asp Ile Ser Thr Trp Leu Ala

1 5 10

5

<210> 8

<211> 7

10

<212> PRT

<213> Homo sapiens

15

<400> 8

Ala Ala Ser Ser Leu Gln Ser

1 5

20

<210> 9

<211> 9

25

<212> PRT

<213> Homo sapiens

<400> 9

30

Leu Gln His Asp Ser Tyr Pro Phe Ser

1 5

35

<210> 10

<211> 8

40

<212> PRT

<213> Homo sapiens

<400> 10

45

Arg Ala Ser Gln Ser Ile Ser Asn

1 5

50

<210> 11

<211> 7

55

<212> PRT

<213> Homo sapiens

<400> 11

Ala Ala Ser Arg Leu Gln Arg

5

1 5

<210> 12

10

<211> 9

<212> PRT

<213> Homo sapiens

15

<400> 12

Gln Gln Ser Tyr Ser Thr Asn Pro Thr

20

1 5

<210> 13

25

<211> 14

<212> PRT

<213> Homo sapiens

30

<400> 13

Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His

35

1 5 10

<210> 14

40

<211> 7

<212> PRT

<213> Homo sapiens

45

<400> 14

Gly Asn Asn Asn Arg Pro Ser

50

1 5

<210> 15

<211> 11

55

<212> PRT

<213> Homo sapiens

<400> 15

Gln Ser Tyr Asp Ser Ser Leu Ser Gly Phe Glu

1 5 10

<210> 16

<211> 128

<212> PRT

<213> Homo sapiens

<400> 16

Met Ala Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro

1 5 10 15

Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Tyr Ile

20 25 30

Asp Gln Pro Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu

35 40 45

Trp Met Gly Gly Ile Ile Pro Leu Ser Gly Pro Pro His Tyr Ala Gln

50 55 60

Lys Phe Gln Gly Lys Val Ser Ile Thr Ala Asp Glu Ser Thr Ser Thr

65 70 75 80

Ala Tyr Leu Glu Leu Thr Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Ala Arg Val Leu Arg Gly Tyr Cys Arg Arg Gly Ser Cys Tyr

100 105 110

Asp Trp Leu Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser

115 120 125

<210> 17

<211> 111

<212> PRT

<213> Homo sapiens

<400> 17

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr
 20 25 30
 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Leu
 35 40 45
 Tyr Ala Thr Ser Arg Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Lys Ser Phe Pro Leu
 85 90 95
 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala
 100 105 110

<210> 18

<211> 111

<212> PRT

<213> Homo sapiens

<400> 18

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Thr Trp
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Arg Ala Pro Lys Leu Leu Ile

<213> Homo sapiens

<400> 22

5
gac atc cag atg acc cag tct cca tcc tcc ctg tct gca tct gta gga 48
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
10
1 5 10 15
gac aga gtc acc atc act tgc cag gcg agt cag gac att agc aac tat 96
Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr
15
20 25 30
tta aat tgg tat cag cag aaa cca ggg aaa gcc cct aag ctc ctg ctc 144
20
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Leu
35 40 45
tat gct aca tcc aga ttg tac agt ggg gtc cca tcc agg ttc agt ggc 192
25
Tyr Ala Thr Ser Arg Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
30
agt gga tct ggg aca gat ttc act ctc agc atc agc agc ctg cag cct 240
Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Ser Ser Leu Gln Pro
35
65 70 75 80
gaa gat ttt gca act tac tat tgt caa cag act aag agt ttc ccc ctc 288
40
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Lys Ser Phe Pro Leu
85 90 95
act ttc ggc ggg ggg acc aag gtg gaa atc aaa cgt gcg gcc gca 333
45
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala
100 105 110

<210> 23

<211> 333

<212> DNA

<213> Homo sapiens

<400> 23

5 gac atc cag atg acc cag tct cca tct tcc gtg tct gct tct gta ggg 48
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
 1 5 10 15
 10 gac aga gtc acc atc act tgt cgg gcg agt cag gat att agc acc tgg 96
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Thr Trp
 20 25 30
 15 tta gcc tgg tat cag cag aaa cca ggg aga gcc cct aag ctc ctg atc 144
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Arg Ala Pro Lys Leu Leu Ile
 20 35 40 45
 25 tat gct gca tcc agt ttg caa agt ggg gtc cca tca agg ttc agc ggc 192
 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 30 agt ggg tct ggg aca gaa ttc act ctc aca atc agc agc ctg cag cct 240
 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 35 gaa gat ttt gca act tat tac tgt cta cag cat gat agt tac ccc ttc 288
 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asp Ser Tyr Pro Phe
 85 90 95
 40 tct ttc ggc cct ggg acc aag gtg gaa atc aaa cgt gcg gcc gca 333
 Ser Phe Gly Pro Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala
 45 100 105 110

<210> 24

<211> 333

<212> DNA

<213> Homo sapiens

<400> 24

gac atc gtg atg acc cag tct cca tcc tcc ctg tct gca tct gta gga 48
 Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 5 1 5 10 15
 gac aca gtc acc atc tct tgc cgg gca agt cag agc att tcc aac ttt 96
 Asp Thr Val Thr Ile Ser Cys Arg Ala Ser Gln Ser Ile Ser Asn Phe
 10 20 25 30
 tta aac tgg tat cgg cag aaa cca gga aag gcc cct gaa ctg atg att 144
 Leu Asn Trp Tyr Arg Gln Lys Pro Gly Lys Ala Pro Glu Leu Met Ile
 15 35 40 45
 tat gct gcg tcc aga ctg caa cgt ggg gac cca tca agg ttt agt ggc 192
 Tyr Ala Ala Ser Arg Leu Gln Arg Gly Asp Pro Ser Arg Phe Ser Gly
 20 50 55 60
 agt gga tct ggg aca gaa ttc agt ctc acc atc agc ggt ctg cag cct 240
 Ser Gly Ser Gly Thr Glu Phe Ser Leu Thr Ile Ser Gly Leu Gln Pro
 25 65 70 75 80
 gag gat tct gca acc tat cac tgt caa cag agt tac agt acc aat ccc 288
 Glu Asp Ser Ala Thr Tyr His Cys Gln Gln Ser Tyr Ser Thr Asn Pro
 30 85 90 95
 acg ttc ggc ggg ggg acc aag gtg gag atc aaa cgt gcg gcc gca 333
 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala
 35 100 105 110
 <210> 25
 <211> 348
 <212> DNA
 <213> Homo sapiens
 <400> 25
 40
 45
 50
 55 cag gct gtg etc act cag cgg tcc tca gtg tct ggg ccc cca ggg cag 48

EP 1 256 348 A1

	Gln	Ala	Val	Leu	Thr	Gln	Pro	Ser	Ser	Val	Ser	Gly	Pro	Pro	Gly	Gln	
5	1				5					10					15		
	agg	gtc	acc	atc	tcc	tgc	act	ggg	agc	agc	tcc	aac	atc	ggg	gca	ggt	96
10	Arg	Val	Thr	Ile	Ser	Cys	Thr	Gly	Ser	Ser	Ser	Asn	Ile	Gly	Ala	Gly	
				20				25						30			
	tat	gat	gta	cac	tgg	tac	cag	cag	ctt	cca	gga	aca	gcc	ccc	aaa	ctc	144
15	Tyr	Asp	Val	His	Trp	Tyr	Gln	Gln	Leu	Pro	Gly	Thr	Ala	Pro	Lys	Leu	
			35				40					45					
	ctc	atc	tat	ggt	aac	aac	aat	cgg	ccc	tca	ggg	gtc	cct	gac	cga	ttc	192
20	Leu	Ile	Tyr	Gly	Asn	Asn	Asn	Arg	Pro	Ser	Gly	Val	Pro	Asp	Arg	Phe	
			50				55					60					
25	tct	ggc	tcc	aag	tct	ggc	acc	tca	gcc	tcc	ctg	gcc	atc	act	ggg	ctc	240
	Ser	Gly	Ser	Lys	Ser	Gly	Thr	Ser	Ala	Ser	Leu	Ala	Ile	Thr	Gly	Leu	
30		65			70					75					80		
	cag	gct	gag	gat	gag	gct	gat	tat	tac	tgc	cag	tcc	tat	gac	agc	agc	288
	Gln	Ala	Glu	Asp	Glu	Ala	Asp	Tyr	Tyr	Cys	Gln	Ser	Tyr	Asp	Ser	Ser	
35				85						90				95			
	ctg	agt	ggg	ttt	gag	gtc	ttc	gga	acc	ggg	acc	aag	gtg	gag	atc	aaa	336
40	Leu	Ser	Gly	Phe	Glu	Val	Phe	Gly	Thr	Gly	Thr	Lys	Val	Glu	Ile	Lys	
				100						105				110			
	cgt	gcg	gcc	gca													348
45	Arg	Ala	Ala	Ala													
				115													
50	<210>	26															
	<211>	900															
	<212>	DNA															
55	<213>	Homo sapiens															

<400> 26

5 gtg aaa aaa tta tta ttc gca att cct tta gtt gtt cct ttc tat gcg 48
 Val Lys Lys Leu Leu Phe Ala Ile Pro Leu Val Val Pro Phe Tyr Ala
 1 5 10 15
 10 gcc cag ccg gcc atg gcc cag gtg cag ctg gtg cag tct ggg gct gag 96
 Ala Gln Pro Ala Met Ala Gln Val Gln Leu Val Gln Ser Gly Ala Glu
 20 25 30
 15 gtg aag aag cct ggg tcc tcg gtg aag gtc tcc tgc aag gct tct gga 144
 Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly
 35 40 45
 20 ggc acc tac atc gac caa cct atc ggc tgg gtg cga cag gcc cct gga 192
 Gly Thr Tyr Ile Asp Gln Pro Ile Gly Trp Val Arg Gln Ala Pro Gly
 50 55 60
 25 caa ggg ctt gag tgg atg gga ggg atc atc cct ctc tct ggt ccg cca 240
 Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Leu Ser Gly Pro Pro
 65 70 75 80
 30 cac tac gca cag aag ttc cag ggc aaa gtc tcg att acc gcg gac gag 288
 His Tyr Ala Gln Lys Phe Gln Gly Lys Val Ser Ile Thr Ala Asp Glu
 85 90 95
 35 tcc acg agc aca gct tac ctg gaa ctg acc agc ctc aca tct gag gac 336
 Ser Thr Ser Thr Ala Tyr Leu Glu Leu Thr Ser Leu Thr Ser Glu Asp
 100 105 110
 40 acg gcc gta tat tac tgt gcg agg gtc ctt agg ggt tat tgt cgt cgt 384
 Thr Ala Val Tyr Tyr Cys Ala Arg Val Leu Arg Gly Tyr Cys Arg Arg
 115 120 125
 45 ggc tcc tgc tat gac tgg ctc gac ccc tgg ggc cag ggc acc ctg gtc 432
 Gly Ser Cys Tyr Asp Trp Leu Asp Pro Trp Gly Gln Gly Thr Leu Val
 50 Gly Ser Cys Tyr Asp Trp Leu Asp Pro Trp Gly Gln Gly Thr Leu Val

EP 1 256 348 A1

130 135 140
 5 acc gtc tcg agt gga ggc ggc ggt tca ggc gga ggt ggc tct ggc ggt 480
 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
 145 150 155 160
 10 ggc gga agt gca ctt gac atc cag atg acc cag tct cca tcc tcc ctg 528
 Gly Gly Ser Ala Leu Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu
 15 165 170 175
 tct gca tct gta gga gac aga gtc acc atc act tgc cag gcg agt cag 576
 Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln
 20 180 185 190
 gac att agc aac tat tta aat tgg tat cag cag aaa cca ggg aaa gcc 624
 25 Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala
 195 200 205
 cct aag ctc ctg ctc tat gct aca tcc aga ttg tac agt ggg gtc cca 672
 30 Pro Lys Leu Leu Leu Tyr Ala Thr Ser Arg Leu Tyr Ser Gly Val Pro
 210 215 220
 35 tcc agg ttc agt ggc agt gga tct ggg aca gat ttc act ctc agc atc 720
 Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile
 225 230 235 240
 40 agc agc ctg cag cct gaa gat ttt gca act tac tat tgt caa cag act 768
 Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr
 45 245 250 255
 aag agt ttc ccc ctc act ttc ggc ggg ggg acc aag gtg gaa atc aaa 816
 Lys Ser Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 50 260 265 270
 cgt gcg gcc gca gag cag aag ctg atc agc gaa gag gat ctg ggc tcg 864
 55 Arg Ala Ala Ala Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Gly Ser

EP 1 256 348 A1

	275	280	285	
5	agg tcg acc cac cat gcg cat cac cac gcc gca tag			900
	Arg Ser Thr His His Ala His His His Ala Ala			
	290	295		
10	<210> 27			
	<211> 900			
15	<212> DNA			
	<213> Homo sapiens			
	<400> 27			
20	gtg aaa aaa tta tta ttc gca att cct tta gtt gtt cct ttc tat gcg			48
	Val Lys Lys Leu Leu Phe Ala Ile Pro Leu Val Val Pro Phe Tyr Ala			
25	1 5 10 15			
	gcc cag ccg gcc atg gcc cag gtg cag ctg gtg cag tct ggg gct gag			96
	Ala Gln Pro Ala Met Ala Gln Val Gln Leu Val Gln Ser Gly Ala Glu			
30	20 25 30			
	gtg aag aag cct ggg tcc tcg gtg aag gtc tcc tgc aag gct tct gga			144
35	Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly			
	35 40 45			
40	ggc acc tac atc gac caa cct atc ggc tgg gtg cga cag gcc cct gga			192
	Gly Thr Tyr Ile Asp Gln Pro Ile Gly Trp Val Arg Gln Ala Pro Gly			
	50 55 60			
45	caa ggg ctt gag tgg atg gga ggg atc atc cct ctc tct ggt ccg eca			240
	Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Leu Ser Gly Pro Pro			
50	65 70 75 80			
	cac tac gca cag aag ttc cag ggc aaa gtc tcg att acc gcg gac gag			288
	His Tyr Ala Gln Lys Phe Gln Gly Lys Val Ser Ile Thr Ala Asp Glu			
55	85 90 95			

tcc acg agc aca gct tac ctg gaa ctg acc agc ctc aca tct gag gac 336
 Ser Thr Ser Thr Ala Tyr Leu Glu Leu Thr Ser Leu Thr Ser Glu Asp
 5 100 105 110
 acg gcc gta tat tac tgt gcg agg gtc ctt agg ggt tat tgt cgt cgt 384
 10 Thr Ala Val Tyr Tyr Cys Ala Arg Val Leu Arg Gly Tyr Cys Arg Arg
 115 120 125
 ggt tcc tgc tat gac tgg ctc gac ccc tgg ggc cag ggc acc ctg gtc 432
 15 Gly Ser Cys Tyr Asp Trp Leu Asp Pro Trp Gly Gln Gly Thr Leu Val
 130 135 140
 acc gtc tcg agt gga ggc ggc ggt tca ggc gga ggt ggc tct ggc ggt 480
 20 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
 145 150 155 160
 ggc gga agt gca ctt gac atc cag atg acc cag tct cca tct tcc gtg 528
 Gly Gly Ser Ala Leu Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val
 30 165 170 175
 tct gct tct gta ggg gac aga gtc acc atc act tgt cgg gcg agt cag 576
 35 Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln
 180 185 190
 gat att agc acc tgg tta gcc tgg tat cag cag aaa cca ggg aga gcc 624
 40 Asp Ile Ser Thr Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Arg Ala
 195 200 205
 cct aag ctc ctg atc tat gct gca tcc agt ttg caa agt ggg gtc cca 672
 45 Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro
 210 215 220
 tca agg ttc agc ggc agt ggg tct ggg aca gaa ttc act ctc aca atc 720
 50 Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile
 225 230 235 240
 55

agc agc ctg cag cct gaa gat ttt gca act tat tac tgt cta cag cat 768
 Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His
 5 245 250 255
 gat agt tac ccc ttc tct ttc ggc cct ggg acc aag gtg gaa atc aaa 816
 10 Asp Ser Tyr Pro Phe Ser Phe Gly Pro Gly Thr Lys Val Glu Ile Lys
 260 265 270
 cgt gcg gcc gca gag cag aag ctg atc agc gaa gag gat ctg ggc tcg 864
 15 Arg Ala Ala Ala Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Gly Ser
 275 280 285
 agg tcg acc cac cat gcg cat cac cac gcc gca tag 900
 20 Arg Ser Thr His His Ala His His His Ala Ala
 25 290 295
 <210> 28
 <211> 900
 30 <212> DNA
 <213> Homo sapiens
 35 <400> 28
 gtg aaa aaa tta tta ttc gca att cct tta gtt gtt cct ttc tat gcg 48
 Val Lys Lys Leu Leu Phe Ala Ile Pro Leu Val Val Pro Phe Tyr Ala
 40 1 5 10 15
 gcc cag ccg gcc atg gcc cag gtg cag ctg gtg cag tct ggg gct gag 96
 45 Ala Gln Pro Ala Met Ala Gln Val Gln Leu Val Gln Ser Gly Ala Glu
 20 25 30
 gtg aag aag cct ggg tcc tcg gtg aag gtc tcc tgc aag gct tct gga 144
 50 Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly
 35 40 45
 55 ggc acc tac atc gac caa cct atc ggc tgg gtg cga cag gcc cct gga 192

Gly Thr Tyr Ile Asp Gln Pro Ile Gly Trp Val Arg Gln Ala Pro Gly
 5 50 55 60
 caa ggg ctt gag tgg atg gga ggg atc atc cct ctc tct ggt ccg cca 240
 Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Leu Ser Gly Pro Pro
 10 65 70 75 80
 cac tac gca cag aag ttc cag ggc aaa gtc tcg att acc gcg gac gag 288
 His Tyr Ala Gln Lys Phe Gln Gly Lys Val Ser Ile Thr Ala Asp Glu
 15 85 90 95
 tcc acg agc aca gct tac ctg gaa ctg acc agc ctc aca tct gag gac 336
 Ser Thr Ser Thr Ala Tyr Leu Glu Leu Thr Ser Leu Thr Ser Glu Asp
 20 100 105 110
 acg gcc gta tat tac tgt gcg agg gtc ctt agg ggt tat tgt cgt cgt 384
 Thr Ala Val Tyr Tyr Cys Ala Arg Val Leu Arg Gly Tyr Cys Arg Arg
 25 115 120 125
 ggt tcc tgc tat gac tgg ctc gac ccc tgg ggc cag ggc acc ctg gtc 432
 Gly Ser Cys Tyr Asp Trp Leu Asp Pro Trp Gly Gln Gly Thr Leu Val
 30 130 135 140
 acc gtc tgc agt gga ggc ggc ggt tca ggc gga ggt ggc tct ggc ggt 480
 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
 35 145 150 155 160
 ggc gga agt gca ctt gac atc gtg atg acc cag tct cca tcc tcc ctg 528
 Gly Gly Ser Ala Leu Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu
 40 165 170 175
 tct gca tct gta gga gac aca gtc acc atc tct tgc cgg gca agt cag 576
 Ser Ala Ser Val Gly Asp Thr Val Thr Ile Ser Cys Arg Ala Ser Gln
 45 180 185 190
 agc att tcc aac ttt tta aac tgg tat cgg cag aaa cca gga aag gcc 624

Ser Ile Ser Asn Phe Leu Asn Trp Tyr Arg Gln Lys Pro Gly Lys Ala
 5 195 200 205
 cct gaa ctg atg att tat gct gcg tcc aga ctg caa cgt ggg gac cca 672
 Pro Glu Leu Met Ile Tyr Ala Ala Ser Arg Leu Gln Arg Gly Asp Pro
 10 210 215 220
 tca agg ttt agt ggc agt gga tct ggg aca gaa ttc agt ctc acc atc 720
 Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Ser Leu Thr Ile
 15 225 230 235 240
 agc ggt ctg cag cct gag gat tct gca acc tat cac tgt caa cag agt 768
 Ser Gly Leu Gln Pro Glu Asp Ser Ala Thr Tyr His Cys Gln Gln Ser
 20 245 250 255
 tac agt acc aat ccc acg ttc ggc ggg ggg acc aag gtg gag atc aaa 816
 Tyr Ser Thr Asn Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 30 260 265 270
 cgt gcg gcc gca gag cag aag ctg atc agc gaa gag gat ctg ggc tcg 864
 Arg Ala Ala Ala Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Gly Ser
 35 275 280 285
 agg tcg acc cac cat gcg cat cac cac gcc gca tag 900
 Arg Ser Thr His His Ala His His His Ala Ala
 40 290 295
 <210> 29
 45 <211> 915
 <212> DNA
 50 <213> Homo sapiens
 <400> 29
 55 gtg aaa aaa tta tta ttc gca att cct tta gtt gtt cct ttc tat gcg 48
 Val Lys Lys Leu Leu Phe Ala Ile Pro Leu Val Val Pro Phe Tyr Ala

	1	5	10	15	
5	gcc cag ccg gcc atg gcc cag gtg cag ctg gtg cag tct ggg gct gag				96
	Ala Gln Pro Ala Met Ala Gln Val Gln Leu Val Gln Ser Gly Ala Glu				
		20	25	30	
10	gtg aag aag cct ggg tcc tcg gtg aag gtc tcc tgc aag gct tct gga				144
	Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly				
15		35	40	45	
	ggc acc tac atc gac caa cct atc ggc tgg gtg cga cag gcc cct gga				192
	Gly Thr Tyr Ile Asp Gln Pro Ile Gly Trp Val Arg Gln Ala Pro Gly				
20		50	55	60	
	caa ggg ctt gag tgg atg gga ggg atc atc cct ctc tct ggt ccg cca				240
25	Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Leu Ser Gly Pro Pro				
	65	70	75	80	
30	cac tac gca cag aag ttc cag ggc aaa gtc tcg att acc gcg gac gag				288
	His Tyr Ala Gln Lys Phe Gln Gly Lys Val Ser Ile Thr Ala Asp Glu				
		85	90	95	
35	tcc acg agc aca gct tac ctg gaa ctg acc agc ctc aca tct gag gac				336
	Ser Thr Ser Thr Ala Tyr Leu Glu Leu Thr Ser Leu Thr Ser Glu Asp				
40		100	105	110	
	acg gcc gta tat tac tgt gcg agg gtc ctt agg ggt tat tgt cgt cgt				384
	Thr Ala Val Tyr Tyr Cys Ala Arg Val Leu Arg Gly Tyr Cys Arg Arg				
45		115	120	125	
	ggt tcc tgc tat gac tgg ctc gac ccc tgg ggc cag ggc acc ctg gtc				432
50	Gly Ser Cys Tyr Asp Trp Leu Asp Pro Trp Gly Gln Gly Thr Leu Val				
	130	135	140		
55	acc gtc tcg agt gga ggc ggc ggt tca ggc gga ggt ggc tct ggc ggt				480
	Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly				

	145	150	155	160	
5	ggc gga agt gca ctt cag gct gtg ctc act cag ccg tcc tca gtg tct				528
	Gly Gly Ser Ala Leu Gln Ala Val Leu Thr Gln Pro Ser Ser Val Ser				
		165	170	175	
10	ggg ccc cca ggg cag agg gtc acc atc tcc tgc act ggg agc agc tcc				576
	Gly Pro Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser				
		180	185	190	
15	aac atc ggg gca ggt tat gat gta cac tgg tac cag cag ctt cca gga				624
	Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly				
		195	200	205	
20	aca gcc ccc aaa ctc ctc atc tat ggt aac aac aat cgg ccc tca ggg				672
	Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Asn Asn Arg Pro Ser Gly				
		210	215	220	
25	gtc cct gac cga ttc tct ggc tcc aag tct ggc acc tca gcc tcc ctg				720
	Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu				
		225	230	235	240
30	gcc atc act ggg ctc cag gct gag gat gag gct gat tat tac tgc cag				768
	Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln				
		245	250	255	
35	tcc tat gac agc agc ctg agt ggg ttt gag gtc ttc gga acc ggg acc				816
	Ser Tyr Asp Ser Ser Leu Ser Gly Phe Glu Val Phe Gly Thr Gly Thr				
		260	265	270	
40	aag gtg gag atc aaa cgt gcg gcc gca gag cag aag ctg atc agc gaa				864
	Lys Val Glu Ile Lys Arg Ala Ala Ala Glu Gln Lys Leu Ile Ser Glu				
		275	280	285	
45	gag gat ctg ggc tcg agg tcg acc cac cat gcg cat cac cac gcc gca				912
	Glu Asp Leu Gly Ser Arg Ser Thr His His Ala His His His Ala Ala				
50					
55					

	290	295	300	
5	tag			915
	<210> 30			
10	<211> 110			
	<212> DNA			
	<213> Artificial Sequence			
15	<220>			
	<223> Primer			
20	<400> 30			
	cccaagctta ccatggatgc aatgaagaga gggctctgct gtgtgctgct gctgtgtgga			60
	gcagtcttcg tttcggctag ccataccgc gtgacggggg ggtgcaagg			110
25	<210> 31			
	<211> 82			
30	<212> DNA			
	<213> Artificial Sequence			
	<220>			
35	<223> Primer			
	<400> 31			
40	ccccctcgag tctagattaa cgcggttcca gcgatccgg atacggcacc ggcgcaccgg			60
	agacgaccgc cgacctata cc			82
45	<210> 32			
	<211> 36			
	<212> DNA			
50	<213> Artificial Sequence			
	<220>			
	<223> Primer			
55	<400> 32			

gcgccgcat gggagtggag ggctgc

36

<210> 33

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 33

ctcagtacac ggagctgttc cgga

24

<210> 34

<211> 128

<212> PRT

<213> Homo sapiens

<400> 34

Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro

1 5 10 15

Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Tyr Ile

20 25 30

Asp Gln Pro Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu

35 40 45

Trp Met Gly Gly Ile Ile Pro Leu Ser Gly Pro Pro His Tyr Ala Gln

50 55 60

Lys Phe Gln Gly Lys Val Ser Ile Thr Ala Asp Glu Ser Thr Ser Thr

65 70 75 80

Ala Tyr Leu Glu Leu Thr Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Ala Arg Val Leu Arg Gly Tyr Cys Arg Arg Gly Ser Cys Tyr

	100	105	110	
5	Asp Trp Leu Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser			
	115	120	125	
	<210> 35			
10	<211> 380			
	<212> DNA			
15	<213> Homo sapiens			
	<400> 35			
20	atg gcc gag gtg cag ctg gtg gag tct ggg gct gag gtg aag aag cct	48		
	Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro			
	1 5 10 15			
25	ggg tcc tcg gtg aag gtc tcc tgc aag gct tct gga ggc acc tac atc	96		
	Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Tyr Ile			
	20 25 30			
30	gac caa cct atc ggc tgg gtg cga cag gcc cct gga caa ggg ctt gag	144		
	Asp Gln Pro Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu			
35	35 40 45			
	tgg atg gga ggg atc atc cct ctc tct ggt ccg cca cac tac gca cag	192		
40	Trp Met Gly Gly Ile Ile Pro Leu Ser Gly Pro Pro His Tyr Ala Gln			
	50 55 60			
	aag ttc cag ggc aaa gtc tcg att acc gcg gac gag tcc acg agc aca	240		
45	Lys Phe Gln Gly Lys Val Ser Ile Thr Ala Asp Glu Ser Thr Ser Thr			
	65 70 75 80			
50	gct tac ctg gaa ctg acc agc ctc aca tct gag gac acg gcc gta tat	288		
	Ala Tyr Leu Glu Leu Thr Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr			
	85 90 95			
55	tac tgt gcg agg gtc ctt agg ggt tat tgt cgt cgt ggt tcc tgc tat	336		

Tyr Cys Ala Arg Val Leu Arg Gly Tyr Cys Arg Arg Gly Ser Cys Tyr
 5 100 105 110
 gac tgg ctc gac ccc tgg ggc cag ggc acc ctg gtc acc gtc tcg agt 384
 Asp Trp Leu Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 10 115 120 125
 <210> 36
 15 <211> 900
 <212> DNA
 <213> Homo sapiens
 20 <400> 36
 gtg aaa aaa tta tta ttc gca att cct tta gtt gtt cct ttc tat gcg 48
 25 Val Lys Lys Leu Leu Phe Ala Ile Pro Leu Val Val Pro Phe Tyr Ala
 1 5 10 15
 gcc cag ccg gcc atg gcc gag gtg cag ctg gtg gag tct ggg gct gag 96
 30 Ala Gln Pro Ala Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu
 20 25 30
 35 gtg aag aag cct ggg tcc tcg gtg aag gtc tcc tgc aag gct tct gga 144
 Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly
 35 40 45
 40 ggc acc tac atc gac caa cct atc ggc tgg gtg cga cag gcc cct gga 192
 Gly Thr Tyr Ile Asp Gln Pro Ile Gly Trp Val Arg Gln Ala Pro Gly
 45 50 55 60
 caa ggg ctt gag tgg atg gga ggg atc atc cct ctc tct ggt ccg cca 240
 50 Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Leu Ser Gly Pro Pro
 65 70 75 80
 cac tac gca cag aag ttc cag ggc aaa gtc tcg att acc gcg gac gag 288
 55 His Tyr Ala Gln Lys Phe Gln Gly Lys Val Ser Ile Thr Ala Asp Glu

	85	90	95	
5	tcc acg agc aca gct tac ctg gaa ctg acc agc ctc aca tct gag gac			336
	Ser Thr Ser Thr Ala Tyr Leu Glu Leu Thr Ser Leu Thr Ser Glu Asp			
	100	105	110	
10	acg gcc gta tat tac tgt gcg agg gtc ctt agg ggt tat tgt cgt cgt			384
	Thr Ala Val Tyr Tyr Cys Ala Arg Val Leu Arg Gly Tyr Cys Arg Arg			
15	115	120	125	
	ggt tcc tgc tat gac tgg ctc gac ccc tgg ggc cag ggc acc ctg gtc			432
	Gly Ser Cys Tyr Asp Trp Leu Asp Pro Trp Gly Gln Gly Thr Leu Val			
20	130	135	140	
	acc gtc tcg agt gga ggc ggc ggt tca ggc gga ggt ggc tct ggc ggt			480
25	Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly			
	145	150	155	160
30	ggc gga agt gca ctt gac atc cag atg acc cag tct cca tcc tcc ctg			528
	Gly Gly Ser Ala Leu Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu			
	165	170	175	
35	tct gca tct gta gga gac aga gtc acc atc act tgc cag gcg agt cag			576
	Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln			
40	180	185	190	
	gac att agc aac tat tta aat tgg tat cag cag aaa cca ggg aaa gcc			624
	Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala			
45	195	200	205	
	cct aag ctc ctg ctc tat gct aca tcc aga ttg tac agt ggg gtc cca			672
50	Pro Lys Leu Leu Leu Tyr Ala Thr Ser Arg Leu Tyr Ser Gly Val Pro			
	210	215	220	
55	tcc agg ttc agt ggc agt gga tct ggg aca gat ttc act ctc agc atc			720
	Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile			

	225	230	235	240	
5	agc agc ctg cag cct gaa gat ttt gca act tac tat tgt caa cag act				768
	Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr				
		245	250	255	
10	aag agt ttc ccc ctc act ttc ggc ggg ggg acc aag gtg gaa atc aaa				816
	Lys Ser Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys				
		260	265	270	
15	cgt gcg gcc gca gag cag aag ctg atc agc gaa gag gat ctg ggc tcg				864
	Arg Ala Ala Ala Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Gly Ser				
		275	280	285	
20	agg tcg acc cac cat gcg cat cac cac gcc gca tag				900
	Arg Ser Thr His His Ala His His His Ala Ala				
		290	295		
25	<210> 37				
	<211> 900				
	<212> DNA				
30	<213> Homo sapiens				
	<400> 37				
35					
40	gtg aaa aaa tta tta ttc gca att cct tta gtt gtt cct ttc tat gcg				48
	Val Lys Lys Leu Leu Phe Ala Ile Pro Leu Val Val Pro Phe Tyr Ala				
	1 5 10 15				
45	gcc cag ccg gcc atg gcc gag gtg cag ctg gtg gag tct ggg gct gag				96
	Ala Gln Pro Ala Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu				
		20	25	30	
50	gtg aag aag cct ggg tcc tcg gtg aag gtc tcc tgc aag gct tct gga				144
	Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly				
		35	40	45	
55					

5 ggc acc tac atc gac caa cct atc ggc tgg gtg cga cag gcc cct gga 192
 Gly Thr Tyr Ile Asp Gln Pro Ile Gly Trp Val Arg Gln Ala Pro Gly
 50 55 60

10 caa ggg ctt gag tgg atg gga ggg atc atc cct ctc tct ggt ccg cca 240
 Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Leu Ser Gly Pro Pro
 65 70 75 80

15 cac tac gca cag aag ttc cag ggc aaa gtc tgc att acc gcg gac gag 288
 His Tyr Ala Gln Lys Phe Gln Gly Lys Val Ser Ile Thr Ala Asp Glu
 85 90 95

20 tcc acg agc aca gct tac ctg gaa ctg acc agc ctc aca tct gag gac 336
 Ser Thr Ser Thr Ala Tyr Leu Glu Leu Thr Ser Leu Thr Ser Glu Asp
 25 100 105 110

30 acg gcc gta tat tac tgt gcg agg gtc ctt agg ggt tat tgt cgt cgt 384
 Thr Ala Val Tyr Tyr Cys Ala Arg Val Leu Arg Gly Tyr Cys Arg Arg
 115 120 125

35 ggt tcc tgc tat gac tgg ctc gac ccc tgg ggc cag ggc acc ctg gtc 432
 Gly Ser Cys Tyr Asp Trp Leu Asp Pro Trp Gly Gln Gly Thr Leu Val
 130 135 140

40 acc gtc tgc agt gga ggc ggc ggt tca ggc gga ggt ggc tct ggc ggt 480
 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
 145 150 155 160

45 ggc gga agt gca ctt gac atc cag atg acc cag tct cca tct tcc gtg 528
 Gly Gly Ser Ala Leu Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val
 50 165 170 175

55 tct gct tct gta ggg gac aga gtc acc atc act tgt cgg gcg agt cag 576
 Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln
 180 185 190

gat att agc acc tgg tta gcc tgg tat cag cag aaa cca ggg aga gcc 624
 Asp Ile Ser Thr Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Arg Ala
 5 195 200 205
 cct aag ctc ctg atc tat gct gca tcc agt ttg caa agt ggg gtc cca 672
 10 Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro
 210 215 220
 tca agg ttc agc ggc agt ggg tct ggg aca gaa ttc act ctc aca atc 720
 15 Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile
 225 230 235 240
 20 agc agc ctg cag cct gaa gat ttt gca act tat tac tgt cta cag cat 768
 Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His
 25 245 250 255
 gat agt tac ccc ttc tct ttc ggc cct ggg acc aag gtg gaa atc aaa 816
 Asp Ser Tyr Pro Phe Ser Phe Gly Pro Gly Thr Lys Val Glu Ile Lys
 30 260 265 270
 cgt gcg gcc gca gag cag aag ctg atc agc gaa gag gat ctg ggc tcg 864
 35 Arg Ala Ala Ala Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Gly Ser
 275 280 285
 agg tcg acc cac cat gcg cat cac cac gcc gca tag 900
 40 Arg Ser Thr His His Ala His His His Ala Ala
 290 295
 45 <210> 38
 <211> 900
 <212> DNA
 50 <213> Homo sapiens
 <400> 38
 55 gtg aaa aaa tta tta ttc gca att cct tta gtt gtt cct ttc tat gcg 48

Val Lys Lys Leu Leu Phe Ala Ile Pro Leu Val Val Pro Phe Tyr Ala
 1 5 10 15
 gcc cag ccg gcc atg gcc gag gtg cag ctg gtg gag tct ggg gct gag 96
 Ala Gln Pro Ala Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu
 10 20 25 30
 gtg aag aag cct ggg tcc tcg gtg aag gtc tcc tgc aag gct tct gga 144
 Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly
 15 35 40 45
 ggc acc tac atc gac caa cct atc ggc tgg gtg cga cag gcc cct gga 192
 20 Gly Thr Tyr Ile Asp Gln Pro Ile Gly Trp Val Arg Gln Ala Pro Gly
 50 55 60
 caa ggg ctt gag tgg atg gga ggg atc atc cct ctc tct ggt ccg cca 240
 Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Leu Ser Gly Pro Pro
 25 65 70 75 80
 cac tac gca cag aag ttc cag ggc aaa gtc tcg att acc gcg gac gag 288
 30 His Tyr Ala Gln Lys Phe Gln Gly Lys Val Ser Ile Thr Ala Asp Glu
 35 85 90 95
 tcc acg agc aca gct tac ctg gaa ctg acc agc ctc aca tct gag gac 336
 Ser Thr Ser Thr Ala Tyr Leu Glu Leu Thr Ser Leu Thr Ser Glu Asp
 40 100 105 110
 acg gcc gta tat tac tgt gcg agg gtc ctt agg ggt tat tgt cgt cgt 384
 45 Thr Ala Val Tyr Tyr Cys Ala Arg Val Leu Arg Gly Tyr Cys Arg Arg
 115 120 125
 ggt tcc tgc tat gac tgg ctc gac ccc tgg ggc cag ggc acc ctg gtc 432
 50 Gly Ser Cys Tyr Asp Trp Leu Asp Pro Trp Gly Gln Gly Thr Leu Val
 130 135 140
 55 acc gtc tcg agt gga ggc ggc ggt tca ggc gga ggt ggc tct ggc ggt 480

Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
 5 145 150 155 160
 ggc gga agt gca ctt gac atc gtg atg acc cag tct cca tcc tcc ctg 528
 Gly Gly Ser Ala Leu Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu
 10 165 170 175
 tct gca tct gta gga gac aca gtc acc atc tct tgc cgg gca agt cag 576
 Ser Ala Ser Val Gly Asp Thr Val Thr Ile Ser Cys Arg Ala Ser Gln
 15 180 185 190
 agc att tcc aac ttt tta aac tgg tat cgg cag aaa cca gga aag gcc 624
 Ser Ile Ser Asn Phe Leu Asn Trp Tyr Arg Gln Lys Pro Gly Lys Ala
 20 195 200 205
 cct gaa ctg atg att tat gct gcg tcc aga ctg caa cgt ggg gac cca 672
 Pro Glu Leu Met Ile Tyr Ala Ala Ser Arg Leu Gln Arg Gly Asp Pro
 25 210 215 220
 tca agg ttt agt ggc agt gga tct ggg aca gaa ttc agt ctc acc atc 720
 Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Ser Leu Thr Ile
 30 225 230 235 240
 agc ggt ctg cag cct gag gat tct gca acc tat cac tgt caa cag agt 768
 Ser Gly Leu Gln Pro Glu Asp Ser Ala Thr Tyr His Cys Gln Gln Ser
 35 245 250 255
 tac agt acc aat ccc acg ttc ggc ggg ggg acc aag gtg gag atc aaa 816
 Tyr Ser Thr Asn Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 40 260 265 270
 cgt gcg gcc gca gag cag aag ctg atc agc gaa gag gat ctg ggc tcg 864
 Arg Ala Ala Ala Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Gly Ser
 45 275 280 285
 agg tgc acc cac cat gcg cat cac cac gcc gca tag 900
 50 55

Arg Ser Thr His His Ala His His His Ala Ala

290

295

<210> 39

<211> 915

<212> DNA

<213> Homo sapiens

<400> 39

gtg aaa aaa tta tta ttc gca att cct tta gtt gtt cct ttc tat gcg 48

Val Lys Lys Leu Leu Phe Ala Ile Pro Leu Val Val Pro Phe Tyr Ala

1 5 10 15

gcc cag ccg gcc atg gcc gag gtg cag ctg gtg gag tct ggg gct gag 96

Ala Gln Pro Ala Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu

20 25 30

gtg aag aag cct ggg tcc tcg gtg aag gtc tcc tgc aag gct tct gga 144

Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly

35 40 45

ggc acc tac atc gac caa cct atc ggc tgg gtg cga cag gcc cct gga 192

Gly Thr Tyr Ile Asp Gln Pro Ile Gly Trp Val Arg Gln Ala Pro Gly

50 55 60

caa ggg ctt gag tgg atg gga ggg atc atc cct ctc tct ggt ccg cca 240

Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Leu Ser Gly Pro Pro

65 70 75 80

cac tac gca cag aag ttc cag ggc aaa gtc tcg att acc gcg gac gag 288

His Tyr Ala Gln Lys Phe Gln Gly Lys Val Ser Ile Thr Ala Asp Glu

85 90 95

tcc acg agc aca gct tac ctg gaa ctg acc agc ctc aca tct gag gac 336

Ser Thr Ser Thr Ala Tyr Leu Glu Leu Thr Ser Leu Thr Ser Glu Asp

	100	105	110	
5	acg gcc gta tat tac tgt gcg agg gtc ctt agg ggt tat tgt cgt cgt			384
	Thr Ala Val Tyr Tyr Cys Ala Arg Val Leu Arg Gly Tyr Cys Arg Arg			
	115	120	125	
10	ggt tcc tgc tat gac tgg ctc gac ccc tgg ggc cag ggc acc ctg gtc			432
	Gly Ser Cys Tyr Asp Trp Leu Asp Pro Trp Gly Gln Gly Thr Leu Val			
15	130	135	140	
	acc gtc tcg agt gga ggc ggc ggt tca ggc gga ggt ggc tct ggc ggt			480
	Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly			
20	145	150	155	160
	ggc gga agt gca ctt cag gct gtg ctc act cag ccg tcc tca gtg tct			528
25	Gly Gly Ser Ala Leu Gln Ala Val Leu Thr Gln Pro Ser Ser Val Ser			
	165	170	175	
30	ggg ccc cca ggg cag agg gtc acc atc tcc tgc act ggg agc agc tcc			576
	Gly Pro Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser			
	180	185	190	
35	aac atc ggg gca ggt tat gat gta cac tgg tac cag cag ctt cca gga			624
	Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly			
40	195	200	205	
	aca gcc ccc aaa ctc ctc atc tat ggt aac aac aat cgg ccc tca ggg			672
	Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Asn Asn Arg Pro Ser Gly			
45	210	215	220	
	gtc cct gac cga ttc tct ggc tcc aag tct ggc acc tca gcc tcc ctg			720
	Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu			
50	225	230	235	240
	gcc atc act ggg ctc cag gct gag gat gag gct gat tat tac tgc cag			768
55	Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln			

	245	250	255	
5	tcc tat gac agc agc ctg agt ggg ttt gag gtc ttc gga acc ggg acc			816
	Ser Tyr Asp Ser Ser Leu Ser Gly Phe Glu Val Phe Gly Thr Gly Thr			
	260	265	270	
10	aag gtg gag atc aaa cgt gcg gcc gca gag cag aag ctg atc agc gaa			864
	Lys Val Glu Ile Lys Arg Ala Ala Ala Glu Gln Lys Leu Ile Ser Glu			
	275	280	285	
15	gag gat ctg ggc tcg agg tcg acc cac cat gcg cat cac cac gcc gca			912
	Glu Asp Leu Gly Ser Arg Ser Thr His His Ala His His His Ala Ala			
20	290	295	300	
	tag			915
25	<210> 40			
	<211> 1428			
	<212> DNA			
30	<213> Homo sapiens			
	<400> 40			
35	atg aaa cac ctg tgg ttc ttc ctc ctg ctg gtg gca gct ccc aga tgg			48
	Met Lys His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala Pro Arg Trp			
	1 5 10 15			
40	gtc ctg tcc cag gtg cag ctg gtg cag tct ggg gct gag gtg aag aag			96
	Val Leu Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys			
45	20 25 30			
	cct ggg tcc tcg gtg aag gtc tcc tgc aag gct tct gga ggc acc tac			144
	Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Tyr			
50	35 40 45			
	atc gac caa cct atc ggc tgg gtg cga cag gcc cct gga caa ggg ctt			192
55	Ile Asp Gln Pro Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu			

	50	55	60	
5	gag tgg atg gga ggg atc atc cct ctc tct ggt ccg cca cac tac gca			240
	Glu Trp Met Gly Gly Ile Ile Pro Leu Ser Gly Pro Pro His Tyr Ala			
	65	70	75	80
10	cag aag ttc cag ggc aaa gtc tcg att acc gcg gac gag tcc acg agc			288
	Gln Lys Phe Gln Gly Lys Val Ser Ile Thr Ala Asp Glu Ser Thr Ser			
15	85	90	95	
	aca gct tac ctg gaa ctg acc agc ctc aca tct gag gac acg gcc gta			336
	Thr Ala Tyr Leu Glu Leu Thr Ser Leu Thr Ser Glu Asp Thr Ala Val			
20	100	105	110	
	tat tac tgt gcg agg gtc ctt agg ggt tat tgt cgt cgt ggt tcc tgc			384
25	Tyr Tyr Cys Ala Arg Val Leu Arg Gly Tyr Cys Arg Arg Gly Ser Cys			
	115	120	125	
30	tat gac tgg ctc gac ccc tgg ggc cag ggc acc ctg gtc acc gtc tcg			432
	Tyr Asp Trp Leu Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser			
	130	135	140	
35	agt gct agt acc aag ggc cca tcc gtc ttc ccc ctg gca ccc tcc tcc			480
	Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser			
40	145	150	155	160
	aag agc acc tct ggg ggc aca gcg gcc ctg ggc tgc ctg gtc aag gac			528
	Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp			
45	165	170	175	
	tac ttc cct gaa ccg gtg acg gtg tcg tgg aac tca ggc gcc ctg acc			576
50	Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr			
	180	185	190	
55	agc ggc gtg cac acc ttc ccg gct gtc cta cag tcc tca gga ctc tac			624
	Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr			

	195	200	205	
5	tcc ctc agc agc gtg gtg acc gtg ccc tcc agc agc ttg ggc acc cag			672
	Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln			
	210	215	220	
10	acc tac atc tgc aac gtg aat cac aag ccc agc aac acc aag gtg gac			720
	Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp			
15	225	230	235	240
	aag aaa gtt gag ccc aaa tct tgt gac aaa act cac aca tgc cca ccg			768
	Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro			
20		245	250	255
	tgc cca gca cct gaa ctc ctg ggg gga ccg tca gtc ttc ctc ttc ccc			816
25	Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro			
	260	265	270	
30	cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct gag gtc aca			864
	Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr			
	275	280	285	
35	tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc aag ttc aac			912
	Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn			
40	290	295	300	
	tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg			960
	Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg			
45	305	310	315	320
	gag gag cag tac aac agc acg tac cgg gtg gtc agc gtc ctc acc gtc			1008
	Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val			
50		325	330	335
	ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc			1056
55	Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser			

5 340 345 350
 aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa 1104
 Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys
 10 355 360 365
 ggg cag ccc cga gaa cca cag gtg tac acc ctg ccc cca tcc cgg gat 1152
 Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp
 15 370 375 380
 gag ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc 1200
 Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe
 20 385 390 395 400
 tat ccc agc gac atc gcc gtg gag tgg gag agc aat ggg cag ccg gag 1248
 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu
 25 405 410 415
 aac aac tac aag acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc 1296
 Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe
 30 420 425 430
 ttc ctc tac agc aag ctc acc gtg gac aag agc agg tgg cag cag ggg 1344
 Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly
 35 435 440 445
 aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac aac cac tac 1392
 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr
 40 450 455 460
 acg cag aag agc ctc tcc ctg tct ccg ggt aaa tga 1428
 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Stop
 45 465 470 475
 <210> 41
 50 475 480 485
 <211> 720

<212> DNA

<213> Homo sapiens

<400> 41

atg gcg ttg cag acc cag gtc ttc att tct ctg ttg ctc tgg atc tct 48
 5
 Met Ala Leu Gln Thr Gln Val Phe Ile Ser Leu Leu Leu Trp Ile Ser
 10
 1 5 10 15
 ggt gcc tac ggg gac atc cag atg acc cag tct cca tcc tcc ctg tct 96
 15
 Gly Ala Tyr Gly Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser
 20
 20 25 30
 gca tct gta gga gac aga gtc acc atc act tgc cag gcg agt cag gac 144
 25
 Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp
 35
 35 40 45
 att agc aac tat tta aat tgg tat cag cag aaa cca ggg aaa gcc cct 192
 30
 Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
 50
 50 55 60
 aag ctc ctg ctc tat gct aca tcc aga ttg tac agt ggg gtc cca tcc 240
 35
 Lys Leu Leu Leu Tyr Ala Thr Ser Arg Leu Tyr Ser Gly Val Pro Ser
 65
 65 70 75 80
 agg ttc agt ggc agt gga tct ggg aca gat ttc act ctc agc atc agc 288
 40
 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Ser
 85
 85 90 95
 agc ctg cag cct gaa gat ttt gca act tac tat tgt caa cag act aag 336
 45
 Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Lys
 100
 100 105 110
 agt ttc ccc ctc act ttc ggc ggg ggg acc aag gtg gaa atc aaa cgt 384
 50
 Ser Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg
 55
 115 120 125

acc gtg gaa atc aaa cga act gtg gct gca cca tct gtc ttc atc ttc 432
 5 Thr Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe
 130 135 140
 ccg cca tct gat gag cag ttg aaa tct gga act gcc tct gtt gtg tgc 480
 10 Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys
 145 150 155 160
 ctg ctg aat aac ttc tat ccc aga gag gcc aaa gta cag tgg aag gtg 528
 15 Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val
 165 170 175
 20 gat aac gcc ctc caa tcg ggt aac tcc cag gag agt gtc aca gag cag 576
 Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln
 25 180 185 190
 gac agc aag gac agc acc tac agc ctc agc agc acc ctg acg ctg agc 624
 30 Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser
 195 200 205
 aaa gca gac tac gag aaa cac aaa gtc tac gcc tgc gaa gtc acc cat 672
 35 Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His
 210 215 220
 cag ggc ctg agc tcg ccc gtc aca aag agc ttc aac agg gga gag tgt 720
 40 Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
 225 230 235 240
 45 <210> 42
 <211> 11
 <212> PRT
 50 <213> Homo sapiens
 <400> 42
 55 Arg Ala Asn Gln Asn Ile Gly Asn Phe Leu Asn

	1	5	10
5	<210> 43		
	<211> 7		
	<212> PRT		
10	<213> Homo sapiens		
	<400> 43		
15	Ala Ala Ser Asn Leu Gln Ser		
	1	5	
20	<210> 44		
	<211> 9		
	<212> PRT		
25	<213> Homo sapiens		
	<400> 44		
30	Gln Gln Ser His Asn Ile Pro Leu Thr		
	1	5	
35	<210> 45		
	<211> 11		
	<212> PRT		
40	<213> Homo sapiens		
	<400> 45		
45	Arg Ala Ser Gln Ser Ile Asn Asn Tyr Leu Asn		
	1	5	10
50	<210> 46		
	<211> 7		
	<212> PRT		
55	<213> Homo sapiens		
	<400> 46		

Ala Ala Ser Ser Leu Gln Ser

5

1 5

<210> 47

10

<211> 10

<212> PRT

<213> Homo sapiens

15

<400> 47

Gln Gln Ser Tyr Asp Ser Thr Leu Phe Thr

20

1 5 10

<210> 48

25

<211> 11

<212> PRT

<213> Homo sapiens

30

<400> 48

Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn

35

1 5 10

<210> 49

<211> 7

40

<212> PRT

<213> Homo sapiens

45

<400> 49

Ala Ala Ser Ser Leu Gln Ser

50

1 5

<210> 50

<211> 9

55

<212> PRT

<213> Homo sapiens

<400> 50

5

Gln Gln Ser Tyr Ser Thr Pro Leu Thr

1 5

<210> 51

10

<211> 11

<212> PRT

15

<213> Homo sapiens

<400> 51

20

Arg Ala Ser Gln Arg Ile Ser Asn Tyr Leu Asn

1 5 10

<210> 52

25

<211> 7

<212> PRT

30

<213> Homo sapiens

<400> 52

Ala Ala Ser Asn Leu Gln Ser

35

1 5

<210> 53

40

<211> 9

<212> PRT

<213> Homo sapiens

45

<400> 53

Gln Gln Ser Tyr Thr Ile Pro Tyr Thr

50

1 5

<210> 54

55

<211> 111

<212> PRT

<213> Homo sapiens

<400> 54

Asp Val Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly

1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Asn Gln Asn Ile Gly Asn Phe

20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Pro Leu Ile

35 40 45

Tyr Ala Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Asp Phe Ser Leu Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser His Asn Ile Pro Leu

85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala

100 105 110

<210> 55

<211> 112

<212> PRT

<213> Homo sapiens

<400> 55

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly

1 5 10 15

Asp Arg Val Thr Met Thr Cys Arg Ala Ser Gln Ser Ile Asn Asn Tyr

20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile

35 40 45

Ser Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Asp Ser Thr Leu
 85 90 95
 Phe Thr Phe Gly Pro Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala
 100 105 110
 <210> 56
 <211> 111
 <212> PRT
 <213> Homo sapiens
 <400> 56
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
 20 25 30
 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
 85 90 95
 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala
 100 105 110

<210> 57

<211> 111

<212> PRT

<213> Homo sapiens

<400> 57

Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly

1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Arg Ile Ser Asn Tyr

20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Val

35 40 45

Tyr Ala Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro

65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Thr Ile Pro Tyr

85 90 95

Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Ala Ala Ala

100 105 110

<210> 58

<211> 333

<212> DNA

<213> Homo sapiens

<400> 58

gat gtt gtg atg act cag tct cca tcc tcc ctg tct gca tct gta ggg 48

Asp Val Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly

1 5 10 15

gac aga gtc acc atc act tgc cgg gca aat cag aac att ggt aat ttt 96
 Asp Arg Val Thr Ile Thr Cys Arg Ala Asn Gln Asn Ile Gly Asn Phe
 5 20 25 30
 tta aat tgg tat cag cag aaa cca ggg aaa gcc cct aag ccc ctg atc 144
 10 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Pro Leu Ile
 35 40 45
 tat gct gca tcc aat ttg caa agt ggg gtc cca tca agg ttc agt ggc 192
 15 Tyr Ala Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 agt gga tct ggg aca gat ttc agt ctc acc atc agc agt ctg caa cct 240
 20 Ser Gly Ser Gly Thr Asp Phe Ser Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 gaa gat ttt gca act tat tac tgt caa cag agt cac aat atc ccg ctc 288
 30 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser His Asn Ile Pro Leu
 85 90 95
 act ttc ggc gga ggg acc aag gtg gag atc aaa cgt gcg gcc gca 333
 35 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala
 100 105 110
 <210> 59
 40 <211> 336
 <212> DNA
 45 <213> Homo sapiens
 <400> 59
 50 gac atc cag atg acc cag tct cca tct tcc ctg tct gca tct gta gga 48
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 55 gac aga gtc acc atg act tgc cgg gca agt cag agt att aac aac tat 96

Asp Arg Val Thr Met Thr Cys Arg Ala Ser Gln Ser Ile Asn Asn Tyr
 5 20 25 30
 tta aat tgg tat caa caa aaa cca ggg aaa gcc cct aag ctc ctg atc 144
 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 10 35 40 45
 tct gct gca tcc agt ttg caa agt ggg gtc cca tcg agg ttc agt ggc 192
 Ser Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 15 50 55 60
 agt gga tct ggg aca gat ttc act ctc acc atc acc agt ctg caa cct 240
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Ser Leu Gln Pro
 20 65 70 75 80
 gag gat ttt gca act tac tac tgt caa cag agt tac gat tcc acc cta 288
 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Asp Ser Thr Leu
 25 85 90 95
 ttc act ttc ggc cct ggg acc aag gtg gaa atc aaa cgt gcg gcc gca 336
 Phe Thr Phe Gly Pro Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala
 30 100 105 110
 <210> 60
 <211> 333
 40 <212> DNA
 <213> Homo sapiens
 45 <400> 60
 gac atc cag atg acc cag tct cca tcc tcc ctg tct gca tct gta gga 48
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 50 1 5 10 15
 gac aga gtc acc atc act tgc cgg gca agt cag agc att agc agc tat 96
 55 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr

	20	25	30	
5	tta aat tgg tat cag cag aaa cca ggg aaa gcc cct aag ctc ctg atc			144
	Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile			
	35	40	45	
10	tat gct gca tcc agt ttg caa agt ggg gtc cca tca agg ttc agt ggc			192
	Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly			
	50	55	60	
15	agt gga tct ggg aca gat ttc act ctc acc atc agc agt ctg caa cct			240
	Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro			
20	65	70	75	80
	gaa gat ttt gca act tac tac tgt caa cag agt tac agt acc ccg ctc			288
25	Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu			
	85	90	95	
30	act ttc ggc gga ggg acc aag gtg gag atc aaa cgt gcg gcc gca			333
	Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala			
	100	105	110	
35	<210> 61			
	<211> 333			
	<212> DNA			
40	<213> Homo sapiens			
	<400> 61			
45	gac atc gtg atg acc cag tct cca tcc tcc ctg tct gca tct gta gga			48
	Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly			
	1	5	10	15
50	gac aga gtc acc atc act tgc cgg gca agt cag cgc att agc aac tat			96
	Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Arg Ile Ser Asn Tyr			
55	20	25	30	

tta aat tgg tat cag cag aaa cca ggg aaa gcc cct aag ctc ctg gtc 144
 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Val
 5 35 40 45
 tat gct gca tct aat ttg caa agt ggg gtc cca tca agg ttc agt ggc 192
 10 Tyr Ala Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 agt gga tct ggg aca gat ttc act ctc acc atc agc agt ctg caa cct 240
 15 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 gaa gat ttt gca act tac tac tgt caa cag agt tac act att ccg tac 288
 20 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Thr Ile Pro Tyr
 85 90 95
 act ttt ggc cag ggg acc aag ctg gag atc aaa cgt gcg gcc gca 333
 25 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Ala Ala Ala
 100 105 110
 <210> 62
 35 <211> 900
 <212> DNA
 <213> Homo sapiens
 40 <400> 62
 gtg aaa aaa tta tta ttc gca att cct tta gtt gtt cct ttc tat gcg 48
 45 Val Lys Lys Leu Leu Phe Ala Ile Pro Leu Val Val Pro Phe Tyr Ala
 1 5 10 15
 gcc cag ccg gcc atg gcc gag gtg cag ctg gtg gag tct ggg gct gag 96
 50 Ala Gln Pro Ala Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu
 20 25 30
 55 gtg aag aag cct ggg tcc tcg gtg aag gtc tcc tgc aag gct tct gga 144

Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly
 35 40 45
 5 ggc acc tac atc gac caa cct atc ggc tgg gtg cga cag gcc cct gga 192
 Gly Thr Tyr Ile Asp Gln Pro Ile Gly Trp Val Arg Gln Ala Pro Gly
 10 50 55 60
 caa ggg ctt gag tgg atg gga ggg atc atc cct ctc tct ggt ccg cca 240
 Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Leu Ser Gly Pro Pro
 15 65 70 75 80
 cac tac gca cag aag ttc cag ggc aaa gtc tcg att acc gcg gac gag 288
 20 His Tyr Ala Gln Lys Phe Gln Gly Lys Val Ser Ile Thr Ala Asp Glu
 85 90 95
 25 tcc acg agc aca gct tac ctg gaa ctg acc agc ctc aca tct gag gac 336
 Ser Thr Ser Thr Ala Tyr Leu Glu Leu Thr Ser Leu Thr Ser Glu Asp
 100 105 110
 30 acg gcc gta tat tac tgt gcg agg gtc ctt agg ggt tat tgt cgt cgt 384
 Thr Ala Val Tyr Tyr Cys Ala Arg Val Leu Arg Gly Tyr Cys Arg Arg
 35 115 120 125
 ggt tcc tgc tat gac tgg ctc gac ccc tgg ggc cag ggc acc ctg gtc 432
 Gly Ser Cys Tyr Asp Trp Leu Asp Pro Trp Gly Gln Gly Thr Leu Val
 40 130 135 140
 acc gtc tcg agt gga ggc ggc ggt tca ggc gga ggt ggc tct ggc ggt 480
 45 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
 145 150 155 160
 50 ggc gga agt gca ctt gat gtt gtg atg act cag tct cca tcc tcc ctg 528
 Gly Gly Ser Ala Leu Asp Val Val Met Thr Gln Ser Pro Ser Ser Leu
 165 170 175
 55 tct gca tct gta ggg gac aga gtc acc atc act tgc cgg gca aat cag 576

Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Asn Gln
 5 180 185 190
 aac att ggt aat ttt tta aat tgg tat cag cag aaa cca ggg aaa gcc 624
 Asn Ile Gly Asn Phe Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala
 10 195 200 205
 cct aag ccc ctg atc tat gct gca tcc aat ttg caa agt ggg gtc cca 672
 Pro Lys Pro Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser Gly Val Pro
 15 210 215 220
 tca agg ttc agt ggc agt gga tct ggg aca gat ttc agt ctc acc atc 720
 Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Thr Ile
 20 225 230 235 240
 agc agt ctg caa cct gaa gat ttt gca act tat tac tgt caa cag agt 768
 Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser
 25 245 250 255
 cac aat atc ccg ctc act ttc ggc gga ggg acc aag gtg gag atc aaa 816
 His Asn Ile Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 30 260 265 270
 cgt gcg gcc gca gag cag aag ctg atc agc gaa gag gat ctg ggc tcg 864
 Arg Ala Ala Ala Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Gly Ser
 35 275 280 285
 agg tcg acc cac cat gcg cat cac cac gcc gca tag 900
 40 290 295 300
 Arg Ser Thr His His Ala His His His Ala Ala Stop
 45 290 295 300
 50 <210> 63
 <211> 903
 <212> DNA
 55 <213> Homo sapiens

<400> 63

5 gtg aaa aaa tta tta ttc gca att cct tta gtt gtt cct ttc tat gcg 48
 Val Lys Lys Leu Leu Phe Ala Ile Pro Leu Val Val Pro Phe Tyr Ala
 1 5 10 15
 10 gcc cag ccg gcc atg gcc gag gtg cag ctg gtg gag tct ggg gct gag 96
 Ala Gln Pro Ala Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu
 20 25 30
 15 gtg aag aag cct ggg tcc tcg gtg aag gtc tcc tgc aag gct tct gga 144
 Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly
 35 40 45
 20 ggc acc tac atc gac caa cct atc ggc tgg gtg cga cag gcc cct gga 192
 Gly Thr Tyr Ile Asp Gln Pro Ile Gly Trp Val Arg Gln Ala Pro Gly
 50 55 60
 25 caa ggg ctt gag tgg atg gga ggg atc atc cct ctc tct ggt ccg cca 240
 Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Leu Ser Gly Pro Pro
 65 70 75 80
 30 cac tac gca cag aag ttc cag ggc aaa gtc tcg att acc gcg gac gag 288
 His Tyr Ala Gln Lys Phe Gln Gly Lys Val Ser Ile Thr Ala Asp Glu
 85 90 95
 35 tcc acg agc aca gct tac ctg gaa ctg acc agc ctc aca tct gag gac 336
 Ser Thr Ser Thr Ala Tyr Leu Glu Leu Thr Ser Leu Thr Ser Glu Asp
 100 105 110
 40 acg gcc gta tat tac tgt gcg agg gtc ctt agg ggt tat tgt cgt cgt 384
 Thr Ala Val Tyr Tyr Cys Ala Arg Val Leu Arg Gly Tyr Cys Arg Arg
 115 120 125
 45 ggt tcc tgc tat gac tgg ctc gac ccc tgg ggc cag ggc acc ctg gtc 432
 Gly Ser Cys Tyr Asp Trp Leu Asp Pro Trp Gly Gln Gly Thr Leu Val

	130	135	140	
5	acc gtc tcg agt gga ggc ggc ggt tca ggc gga ggt ggc tct ggc ggt			480
	Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly			
	145	150	155	160
10	ggc gga agt gca ctt gac atc cag atg acc cag tct cca tct tcc ctg			528
	Gly Gly Ser Ala Leu Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu			
	165	170	175	
15	tct gca tct gta gga gac aga gtc acc atg act tgc cgg gca agt cag			576
	Ser Ala Ser Val Gly Asp Arg Val Thr Met Thr Cys Arg Ala Ser Gln			
	180	185	190	
20	agt att aac aac tat tta aat tgg tat caa caa aaa cca ggg aaa gcc			624
	Ser Ile Asn Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala			
	195	200	205	
25	cct aag ctc ctg atc tct gct gca tcc agt ttg caa agt ggg gtc cca			672
	Pro Lys Leu Leu Ile Ser Ala Ala Ser Ser Leu Gln Ser Gly Val Pro			
	210	215	220	
30	tcg agg ttc agt ggc agt gga tct ggg aca gat ttc act ctc acc atc			720
	Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile			
	225	230	235	240
35	acc agt ctg caa cct gag gat ttt gca act tac tac tgt caa cag agt			768
	Thr Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser			
	245	250	255	
40	tac gat tcc acc cta ttc act ttc ggc cct ggg acc aag gtg gaa atc			816
	Tyr Asp Ser Thr Leu Phe Thr Phe Gly Pro Gly Thr Lys Val Glu Ile			
	260	265	270	
45	aaa cgt gcg gcc gca gag cag aag ctg atc agc gaa gag gat ctg ggc			864
	Lys Arg Ala Ala Ala Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Gly			

	275	280	285	
5	tcg agg	tcg acc	cac cat	gcg cat
			cac cac	gcc gca
			tag	903
	Ser Arg	Ser Thr	His His	Ala His
			His His	Ala Ala
			Stop	
	290	295	300	
10	<210> 64			
	<211> 900			
15	<212> DNA			
	<213> Homo sapiens			
	<400> 64			
20	gtg aaa	aaa tta	tta ttc	gca att
			cct tta	gtt gtt
			cct ttc	tat gcg
				48
	Val Lys	Lys Leu	Leu Phe	Ala Ile
			Pro Leu	Val Val
			Pro Phe	Tyr Ala
25	1	5	10	15
	gcc cag	ccg gcc	atg gcc	gag gtg
			cag ctg	gtg gag
			tct ggg	gct gag
				96
	Ala Gln	Pro Ala	Met Ala	Glu Val
			Gln Leu	Val Glu
			Ser Gly	Ala Glu
30	20	25	30	
	gtg aag	aag cct	ggg tcc	tcg gtg
			aag gtc	tcc tgc
			aag gct	tct gga
				144
35	Val Lys	Lys Pro	Gly Ser	Ser Val
			Lys Val	Ser Cys
			Lys Ala	Ser Gly
	35	40	45	
40	ggc acc	tac atc	gac caa	cct atc
			ggc tgg	gtg cga
			cag gcc	cct gga
				192
	Gly Thr	Tyr Ile	Asp Gln	Pro Ile
			Gly Trp	Val Arg
			Gln Ala	Pro Gly
45	50	55	60	
	caa ggg	ctt gag	tgg atg	gga ggg
			atc atc	cct etc
			tct ggt	ccg cca
				240
	Gln Gly	Leu Glu	Trp Met	Gly Gly
			Ile Ile	Pro Leu
			Ser Gly	Pro Pro
50	65	70	75	80
	cac tac	gca cag	aag ttc	cag ggc
			aaa gtc	tcg att
			acc gcg	gac gag
				288
	His Tyr	Ala Gln	Lys Phe	Gln Gly
			Lys Val	Ser Ile
			Thr Ala	Asp Glu
55	85	90	95	

	tcc acg agc aca gct tac ctg gaa ctg acc agc ctc aca tct gag gac	336
5	Ser Thr Ser Thr Ala Tyr Leu Glu Leu Thr Ser Leu Thr Ser Glu Asp	
	100 105 110	
10	acg gcc gta tat tac tgt gcg agg gtc ctt agg ggt tat tgt cgt cgt	384
	Thr Ala Val Tyr Tyr Cys Ala Arg Val Leu Arg Gly Tyr Cys Arg Arg	
	115 120 125	
15	ggc tcc tgc tat gac tgg ctc gac ccc tgg ggc cag ggc acc ctg gtc	432
	Gly Ser Cys Tyr Asp Trp Leu Asp Pro Trp Gly Gln Gly Thr Leu Val	
20	130 135 140	
	acc gtc tcg agt gga ggc ggc ggt tca ggc gga ggt ggc tct ggc ggt	480
	Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly	
25	145 150 155 160	
	ggc gga agt gca ctt gac atc cag atg acc cag tct cca tcc tcc ctg	528
	Gly Gly Ser Ala Leu Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu	
30	165 170 175	
	tct gca tct gta gga gac aga gtc acc atc act tgc cgg gca agt cag	576
35	Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln	
	180 185 190	
40	agc att agc agc tat tta aat tgg tat cag cag aaa cca ggg aaa gcc	624
	Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala	
	195 200 205	
45	cct aag ctc ctg atc tat gct gca tcc agt ttg caa agt ggg gtc cca	672
	Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro	
50	210 215 220	
	tca agg ttc agt ggc agt gga tct ggg aca gat ttc act ctc acc atc	720
	Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile	
55	225 230 235 240	

EP 1 256 348 A1

agc agt ctg caa cct gaa gat ttt gca act tac tac tgt caa cag agt 768
 Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser
 5 245 250 255
 tac agt acc ccg ctc act ttc ggc gga ggg acc aag gtg gag atc aaa 816
 10 Tyr Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 260 265 270
 cgt gcg gcc gca gag cag aag ctg atc agc gaa gag gat ctg ggc tcg 864
 15 Arg Ala Ala Ala Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Gly Ser
 275 280 285
 20 agg tcg acc cac cat gcg cat cac cac gcc gca tag 900
 Arg Ser Thr His His Ala His His His Ala Ala Stop
 25 290 295 300
 <210> 65
 <211> 900
 30 <212> DNA
 <213> Homo sapiens
 35 <400> 65
 gtg aaa aaa tta tta ttc gca att cct tta gtt gtt cct ttc tat gcg 48
 Val Lys Lys Leu Leu Phe Ala Ile Pro Leu Val Val Pro Phe Tyr Ala
 40 1 5 10 15
 gcc cag ccg gcc atg gcc gag gtg cag ctg gtg gag tct ggg gct gag 96
 45 Ala Gln Pro Ala Met Ala Glu Val Gln Leu Val Glu Ser Gly Ala Glu
 20 25 30
 50 gtg aag aag cct ggg tcc tcg gtg aag gtc tcc tgc aag gct tct gga 144
 Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly
 35 40 45
 55 ggc acc tac atc gac caa cct atc ggc tgg gtg cga cag gcc cct gga 192

Gly Thr Tyr Ile Asp Gln Pro Ile Gly Trp Val Arg Gln Ala Pro Gly
 5 50 55 60
 caa ggg ctt gag tgg atg gga ggg atc atc cct ctc tct ggt ccg cca 240
 Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Leu Ser Gly Pro Pro
 10 65 70 75 80
 cac tac gca cag aag ttc cag ggc aaa gtc tcg att acc gcg gac gag 288
 His Tyr Ala Gln Lys Phe Gln Gly Lys Val Ser Ile Thr Ala Asp Glu
 15 85 90 95
 tcc acg agc aca gct tac ctg gaa ctg acc agc ctc aca tct gag gac 336
 Ser Thr Ser Thr Ala Tyr Leu Glu Leu Thr Ser Leu Thr Ser Glu Asp
 20 100 105 110
 acg gcc gta tat tac tgt gcg agg gtc ctt agg ggt tat tgt cgt cgt 384
 Thr Ala Val Tyr Tyr Cys Ala Arg Val Leu Arg Gly Tyr Cys Arg Arg
 25 115 120 125
 ggt tcc tgc tat gac tgg ctc gac ccc tgg ggc cag ggc acc ctg gtc 432
 Gly Ser Cys Tyr Asp Trp Leu Asp Pro Trp Gly Gln Gly Thr Leu Val
 30 130 135 140
 acc gtc tcg agt gga ggc ggc ggt tca ggc gga ggt ggc tct ggc ggt 480
 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
 35 145 150 155 160
 ggc gga agt gca ctt gac atc gtg atg acc cag tct cca tcc tcc ctg 528
 Gly Gly Ser Ala Leu Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu
 40 165 170 175
 tct gca tct gta gga gac aga gtc acc atc act tgc cgg gca agt cag 576
 Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln
 45 180 185 190
 cgc att agc aac tat tta aat tgg tat cag cag aaa cca ggg aaa gcc 624
 55

Arg Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala
 195 200 205
 5 cct aag ctc ctg gtc tat gct gca tct aat ttg caa agt ggg gtc cca 672
 Pro Lys Leu Leu Val Tyr Ala Ala Ser Asn Leu Gln Ser Gly Val Pro
 10 210 215 220
 tca agg ttc agt ggc agt gga tct ggg aca gat ttc act ctc acc atc 720
 Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
 15 225 230 235 240
 agc agt ctg caa cct gaa gat ttt gca act tac tac tgt caa cag agt 768
 20 Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser
 245 250 255
 25 tac act att ccg tac act ttt ggc cag ggg acc aag ctg gag atc aaa 816
 Tyr Thr Ile Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
 260 265 270
 30 cgt gcg gcc gca gag cag aag ctg atc agc gaa gag gat ctg ggc tcg 864
 Arg Ala Ala Ala Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Gly Ser
 35 275 280 285
 agg tcg acc cac cat gcg cat cac cac gcc gca tag 900
 40 Arg Ser Thr His His Ala His His His Ala Ala Stop
 290 295 300
 <210> 66
 45 <211> 59
 <212> DNA
 <213> Artificial Sequence
 50 <220>
 <223> Primer
 55 <400> 66

ccctgatcag aattcgcagg atccctcgag actagtgatg atcgggccag atatacgcg 59

<210> 67

<211> 51

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 67

ccctgatcaa gatctgctag cgtcgactcc ccagcatgcc tgctgctatt g 51

<210> 68

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 68

ccccagatct ctattccttt gccctcggac gag 33

<210> 69

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 69

ccccagctt atgaaaaagc ctgaactcac cgcg 34

<210> 70

<211> 26

<212> DNA
 <213> Artificial Sequence
 5 <220>
 <223> Primer
 10 <400> 70
 cccgccggct ggggtgtggcg gaccgc 26
 <210> 71
 15 <211> 29
 <212> DNA
 20 <213> Artificial Sequence
 <220>
 25 <223> Primer
 <400> 71
 ccctctaga aagtatagga acttcaagc 29
 30 <210> 72
 <211> 45
 35 <212> DNA
 <213> Artificial Sequence
 <220>
 40 <223> Primer
 <400> 72
 45 ccccaagctt ctcgagacta gtaccaaggg cccatcggtc ttccc 45
 <210> 73
 50 <211> 41
 <212> DNA
 <213> Artificial Sequence
 55 <220>

<223> Primer

5

<400> 73

ccccgggccc tctagtagct ttcatttacc cggagacagg g 41

<210> 74

10

<211> 92

<212> DNA

15

<213> Artificial Sequence

<220>

<223> Primer

20

<400> 74

cccaagcttc accatgaaac acctgtggtt ctcctcctg ctggtggcag ctcccagatg 60

25

ggtcctgtcc caggtgcagc tggcgcagtc tg

<210> 75

<211> 33

30

<212> DNA

<213> Artificial Sequence

35

<220>

<223> Primer

<400> 75

40

cccgctagca ctcgagacgg tgaccagggt gcc 33

<210> 76

45

<211> 45

<212> DNA

<213> Artificial Sequence

50

<220>

<223> Primer

55

<400> 76

ccccagagct agtcctgcag gcggggaat gtgcgcggaa ccct 45
 <210> 77
 5 <211> 39
 <212> DNA
 10 <213> Artificial Sequence
 <220>
 <223> Primer
 15 <400> 77
 ccccgctagc ctgcaagtca ttctgaacct cagcgtccc 39
 20 <210> 78
 <211> 49
 25 <212> DNA
 <213> Artificial Sequence
 <220>
 30 <223> Primer
 <400> 78
 35 cccaagctt ctagagtga cgtaccgtg gaaatcaaac gaactgtg 49
 <210> 79
 <211> 45
 40 <212> DNA
 <213> Artificial Sequence
 45 <220>
 <223> Primer
 <400> 79
 50 ccccgggccc tctagcgccc gcctaacct ctcccctgtt gaagc 45
 <210> 80
 55 <211> 96

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 80

cccaagcttc accatggcgt tgcagaccca ggtcttcatt tctctgttgc tctggatctc 60

tggtgcctac ggggacatcc agatgaccca gtctcc

<210> 81

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 81

ccccgtacgt ttgatttcca ccttgggtccc cccg 34

Claims

1. A substance which inhibits the binding between E2/NS1 protein of hepatitis C virus and a cell infectious with hepatitis C virus, a cell expressing CD81, or CD81.
2. The substance of claim 1 which inhibits, upon binding to a region having a positively charged regions of E2/NS1 protein of hepatitis C virus, the binding between E2/NS1 protein of hepatitis C virus and a cell infectious with hepatitis C virus, a cell expressing CD81, or CD81.
3. The substance of claim 1 or 2 wherein E2/NS1 protein of hepatitis C virus is a protein prepared by adding a substance capable of recognizing E2/NS1 protein to E2/NS1 protein of hepatitis C virus.
4. The substance of any one of claims 1 to 3 wherein E2/NS1 protein of hepatitis C virus is a protein prepared by adding a substance capable of detecting E2/NS1 protein by a fluorescence method or a luminescence method to E2/NS1 protein of hepatitis C virus.
5. The substance of any one of claims 1 to 4 wherein E2/NS1 protein of hepatitis C virus is a protein prepared by adding a tag to E2/NS1 protein of hepatitis C virus.
6. The substance of claim 5 wherein E2/NS1 protein of hepatitis C virus is a protein prepared by adding a tag to the C-terminus of E2/NS1 protein of hepatitis C virus.

EP 1 256 348 A1

7. The substance of any one of claims 1 to 6 wherein a cell expressing CD81 is a cell which expresses human CD81.
8. The substance of any one of claims 1 to 7 wherein CD81 is human CD81 and expressed by solubilized form.
- 5 9. The substance of any one of claims 1 to 8 which has an association constant to E2/NS1 protein of hepatitis C virus is higher than 10^8 , or a dissociation constant to E2/NS1 protein of hepatitis C virus is lower than 10^{-8} .
- 10 10. The substance of claim 9 which has an association constant to E2/NS1 protein of hepatitis C virus is higher than 10^9 , or a dissociation constant to E2/NS1 protein of hepatitis C virus is lower than 10^{-9} .
11. The substance of any one of claims 1 to 10 which is a protein, sulfated polysaccharide, or a low molecular weight compound.
12. The substance of claim 11 wherein a protein is an antibody.
13. The substance of claim 12 wherein an antibody is derived from the B cell of a patient who recovered from hepatitis C.
14. The substance of claim 13 wherein an antibody is derived from genes in the B cell of a patient who recovered from hepatitis C.
- 20 15. The substance of claim 13 or 14 wherein a patient is recovered from hepatitis C without any antiviral treatment and the B cell is peripheral blood mononuclear cell.
- 25 16. An antibody wherein CDR-1, CDR-2, and CDR-3 of a variable region of the H chain respectively comprise amino acid sequences shown by SEQ ID NOS: 1, 2, and 3 in the Sequence Listing or the amino acid sequences having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequences shown by SEQ ID NOS: 1, 2, and 3, and which has an affinity to E2/NS1 protein of hepatitis C virus.
- 30 17. The antibody of claim 16 which comprises an amino acid sequence shown by SEQ ID NO: 16 or 34 in the Sequence Listing or the amino acid sequence having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequence shown by SEQ ID NO: 16 or 34.
- 35 18. An antibody wherein CDR-1, CDR-2, and CDR-3 of a variable region of the L chain respectively comprise amino acid sequences shown by SEQ ID NOS: 4, 5, and 6 in the Sequence Listing or the amino acid sequences having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequences shown by SEQ ID NOS: 4, 5, and 6, and which has an affinity to E2/NS1 protein of hepatitis C virus.
- 40 19. The antibody of claim 18 which comprises an amino acid sequence shown by SEQ ID NO: 17 in the Sequence Listing or the amino acid sequence having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequence shown by SEQ ID NO: 17.
- 45 20. An antibody wherein CDR-1, CDR-2, and CDR-3 of a variable region of the L chain respectively comprise amino acid sequences shown by SEQ ID NOS: 7, 8, and 9 in the Sequence Listing or the amino acid sequences having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequences shown by SEQ ID NOS: 7, 8, and 9, and which has an affinity to E2/NS1 protein of hepatitis C virus.
- 50 21. The antibody of claim 20 which comprises an amino acid sequence shown by SEQ ID NO: 18 in the Sequence Listing or the amino acid sequence having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequence shown by SEQ ID NO: 18.
- 55 22. An antibody wherein CDR-1, CDR-2, and CDR-3 of a variable region of the L chain respectively comprise amino acid sequences shown by SEQ ID NOS: 10, 11, and 12 in the Sequence Listing or the amino acid sequences having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequences shown by SEQ ID NOS: 10, 11, and 12, and which has an affinity to E2/NS1 protein of hepatitis C virus.
23. The antibody of claim 22 which comprises an amino acid sequence shown by SEQ ID NO: 19 in the Sequence Listing or the amino acid sequence having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequence shown by SEQ ID NO: 19.

EP 1 256 348 A1

- 5
24. An antibody wherein CDR-1, CDR-2, and CDR-3 of a variable region of the L chain respectively comprise amino acid sequences shown by SEQ ID NOS: 13, 14, and 15 in the Sequence Listing or the amino acid sequences having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequences shown by SEQ ID NOS: 13, 14, and 15, and which has an affinity to E2/NS1 protein of hepatitis C virus.
- 10
25. The antibody of claim 24 which comprises an amino acid sequence shown by SEQ ID NO: 20 in the Sequence Listing or the amino acid sequence having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequence shown by SEQ ID NO: 20.
- 15
26. An antibody wherein CDR-1, CDR-2, and CDR-3 of a variable region of the L chain respectively comprise amino acid sequences shown by SEQ ID NOS: 42, 43, and 44 in the Sequence Listing or the amino acid sequences having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequences shown by SEQ ID NOS: 42, 43, and 44, and Which has an affinity to E2/NS1 protein of hepatitis C virus.
- 20
27. The antibody of claim 26 which comprises an amino acid sequence shown by SEQ ID NO: 54 in the Sequence Listing or the amino acid sequence having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequence shown by SEQ ID NO: 54.
- 25
28. An antibody wherein CDR-1, CDR-2, and CDR-3 of a variable region of the L chain respectively comprise amino acid sequences shown by SEQ ID NOS: 45, 46, and 47 in the Sequence Listing or the amino acid sequences having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequences shown by SEQ ID NOS: 45, 46, and 47, and which has an affinity to E2/NS1 protein of hepatitis C virus.
- 30
29. The antibody of claim 28 which comprises an amino acid sequence shown by SEQ ID NO: 55 in the Sequence Listing or the amino acid sequence having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequence shown by SEQ ID NO: 55.
- 35
30. An antibody wherein CDR-1, CDR-2, and CDR-3 of a variable region of the L chain respectively comprise amino acid sequences shown by SEQ ID NOS: 48, 49, and 50 in the Sequence Listing or the amino acid sequences having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequences shown by SEQ ID NOS: 48, 49, and 50, and which has an affinity to E2/NS1 protein of hepatitis C virus.
- 40
31. The antibody of claim 30 which comprises an amino acid sequence shown by SEQ ID NO: 56 in the Sequence Listing or the amino acid sequence having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequence shown by SEQ ID NO: 56.
- 45
32. An antibody wherein CDR-1, CDR-2, and CDR-3 of a variable region of the L chain respectively comprise amino acid sequences shown by SEQ ID NOS: 51, 52, and 53 in the Sequence Listing or the amino acid sequences having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequences shown by SEQ ID NOS: 51, 52, and 53, and which has an affinity to E2/NS1 protein of hepatitis C virus.
- 50
33. The antibody of claim 32 which comprises an amino acid sequence shown by SEQ ID NO: 57 in the Sequence Listing or the amino acid sequence having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequence shown by SEQ ID NO: 57.
- 55
34. An antibody which comprises, as an amino acid sequence of a heavy chain, an amino acid sequences shown by SEQ ID NO: 40 in the Sequence Listing or the amino acid sequences having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequences shown by SEQ ID NO: 40, and which has an affinity to E2/NS1 protein of hepatitis C virus.
35. An antibody which comprises, as an amino acid sequence of a light chain, an amino acid sequences shown by SEQ ID NO: 41 in the Sequence Listing or the amino acid sequences having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequences shown by SEQ ID NO: 41, and which has an affinity to E2/NS1 protein of hepatitis C virus.
36. A single-chain antibody having an affinity to E2/NS1 protein of hepatitis C virus, which comprises an amino acid sequence shown by SEQ ID NO: 26, 27, 28, or 29 in the Sequence Listing or the amino acid sequence having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequence shown by SEQ


EP 1 256 348 A1

ID NO: 26, 27, 28, or 29.


- 5 37. A single-chain antibody having an affinity to E2/NS1 protein of hepatitis C virus, which comprises an amino acid sequence shown by SEQ ID NO: 36, 37, 38, or 39 in the Sequence Listing or the amino acid sequence having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequence shown by SEQ ID NO: 36, 37, 38, or 39.
- 10 38. A single-chain antibody having an affinity to E2/NS1 protein of hepatitis C virus, which comprises an amino acid sequence shown by SEQ ID NO: 62, 63, 64, or 65 in the Sequence Listing or the amino acid sequence having a deletion, a substitution, or an addition of one or several amino acids in the amino acid sequence shown by SEQ ID NO: 62, 63, 64, or 65.
- 15 39. A nucleic acid which encodes the antibody of any of claims 16 to 38.
- 20 40. The nucleic acid of claim 39 which comprises a nucleotide sequence shown by any of SEQ ID NO: 21, 22, 23, 24, 25, 35, 58, 59, 60, or 61 in the Sequence Listing.
- 25 41. The nucleic acid of claim 39 which comprises a nucleotide sequence shown by SEQ ID NO: 40 or 41 in the Sequence Listing.
- 30 42. The nucleic acid of claim 39 which comprises a nucleotide sequence shown by any of SEQ ID NO: 26, 27, 28, or 29 in the Sequence Listing.
- 35 43. The nucleic acid of claim 39 which comprises a nucleotide sequence shown by any of SEQ ID NO: 36, 37, 38, or 39 in the Sequence Listing.
- 40 44. The nucleic acid of claim 39 which comprises a nucleotide sequence shown by any of SEQ ID NO: 62, 63, 64, or 65 in the Sequence Listing.
- 45 45. A method for producing an antibody using the nucleic acid of any of claims 39 to 44.
- 50 46. A recombinant antibody which can be obtained by the method of claim 45 and has an affinity to E2/NS1 protein of hepatitis C virus.
- 55 47. The recombinant antibody of claim 46 wherein the Fc region is of a human type.
48. The recombinant antibody of claim 46 or 47 which is a single-strand antibody.
49. A medicament which comprises the substance of any of claims 1 to 15 as an active ingredient.
- 50 50. A medicament which comprises the antibody of any of claims 16 to 38 as an active ingredient.
51. A medicament which comprises the recombinant antibody of any of claims 46 to 48 as an active ingredient.
52. A medicament of any of claims 49 to 51 for treating and/or preventing hepatitis C.
53. A medicament of any of claims 49 to 51 for diagnosing hepatitis C.
54. An anti-HCV agent which comprises the substance of any of claims 1 to 15 as an active ingredient.
- 50 55. An anti-HCV agent which comprises the antibody of any of claims 16 to 38 as an active ingredient.
56. An anti-HCV agent which comprises the recombinant antibody of any of claims 46 to 48.
- 55 57. A method for obtaining a sequence of the variable region of the antibody binding to E2/NS 1 wherein the B cell of a patient who recovered from hepatitis C is stimulated to express mRNA of the antibody against E2/NS1 protein of hepatitis C virus, and thereby mRNA of the antibody and cDNA of the antibody are obtained from the B cell.

58. The method for obtaining a sequence of the variable region of the antibody according to claim 57, wherein a patient who recovered from hepatitis C is one who recovered without antiviral treatment and the B cell is a peripheral blood mononuclear cell.
- 5 59. An antibody having a sequence of the variable region obtained by the method of claims 57 or 58.
60. A method for screening a substance which inhibits the binding between E2/NS1 of hepatitis C virus and a cell infectious with hepatitis C, a cell expressing CD81, or CD81, which comprises steps of: contacting E2/NS1 of hepatitis C virus with a cell infectious with hepatitis C, a cell expressing CD81, or CD81 in the presence and absence of a test substance; and comparing the bindings between E2/NS1 of hepatitis C virus and the cell infectious with hepatitis C, the cell expressing CD81, or CD81 in the presence and absence of a test substance.
- 10
61. The screening method of claim 60 wherein E2/NS1 protein of hepatitis C virus is a protein prepared by adding a substance capable of recognizing E2/NS1 protein to E2/NS1 protein of hepatitis C virus.
- 15
62. The screening method of claim 60 or 61 wherein E2/NS1 protein of hepatitis C virus is a protein prepared by adding a substance capable of detecting E2/NS1 protein by a fluorescence method or a luminescence method to E2/NS1 protein of hepatitis C virus.
- 20
63. The screening method of any of claims 60 to 62 wherein E2/NS1 protein of hepatitis C virus is a protein prepared by adding a tag to E2/NS1 protein of hepatitis C virus.
64. The screening method of claims 63 wherein E2/NS1 protein of hepatitis C virus is a protein prepared by adding a tag to the C-terminus of E2/NS1 protein of hepatitis C virus.
- 25
65. The screening method of any of claims 60 to 63 wherein the cell expressing CD81 is a cell which expresses human CD81.
66. The screening method of any of claims 60 to 63 wherein CD81 is human CD81 and expressed by solubilized form.
- 30
67. A screening method of any of claims 60 to 66 wherein the test substance is a protein, sulfated polysaccharides, or a low molecular weight compound.
68. A substance which inhibits the binding between E2/NS1 protein of hepatitis C virus and the cell infectious with hepatitis C, the cell expressing CD81, or CD81, which is obtained by the screening method of any of claims 60 to 67.
- 35
69. A substance which inhibits a life cycle of hepatitis C virus, which is obtained by the screening method which comprises steps of assaying the binding between a cell infectious with HCV and a cell expressing HCV protein in the presence and absence of the test substance, and comparing it with the binding in the absence of the test substance.
- 40
70. A substance which inhibits a life cycle of hepatitis C virus, which is obtained by the screening method which comprises steps of, after the cell infectious with HCV has bound with the HCV protein expressing cell in the presence or absence of the test substance, assaying the fusion between the cell infectious with HCV and the HCV protein expressing cell, and comparing it with the fusion in the absence of the test substance.
- 45
71. The substance which inhibits a life cycle of hepatitis C virus according to claim 69 or 70, wherein the test substance is a protein, sulfated polysaccharides, or a low molecular weight compound.
72. An anti-HCV agent which comprises the substance of any of claims 68 to 71 as an active ingredient.
- 50
73. A method for producing the anti-HCV agent which comprises formulating the anti-HCV agent using the substance of any of claims 68 to 71.
74. The method for producing the anti-HCV agent according to claim 73, which comprises a step of confirming the inhibition of proliferation of hepatitis C virus by the screening method of any of claims 68 to 71.
- 55

Fig. 1



Measurement of NOB activity of scFv



Confirmation of neutralizing activity of heparin




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8





Fig. 9



INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP01/00967

<p>A. CLASSIFICATION OF SUBJECT MATTER Int.Cl⁷ A61K 31/737, 38/17, 39/395, A61K 45/00, A61P 31/20, C07K 16/10, C12N 15/09, G01N 33/50, 33/53, 33/576</p> <p>According to International Patent Classification (IPC) or to both national classification and IPC</p>																				
<p>B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Int.Cl⁷ A61K 31/737, 38/17, 39/395, A61K 45/00, A61P 31/20, C07K 16/10, C12N 15/09, G01N 33/50, 33/53, 33/576</p> <p>Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched</p> <p>Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) JICST FILE (JOIS), MEDLINE (STN), WPI (DIALOG), BIOSIS (DIALOG)</p>																				
<p>C. DOCUMENTS CONSIDERED TO BE RELEVANT</p> <table border="1"> <thead> <tr> <th>Category*</th> <th>Citation of document, with indication, where appropriate, of the relevant passages</th> <th>Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td>X/Y</td> <td>PILERI P., et al., "Binding of hepatitis C virus to CD81", Science (1998) vol.282, pp.938-941</td> <td>1,3-8/9-74</td> </tr> <tr> <td>Y</td> <td>WO, 99/18198, A1 (CHIRON S.P.A.), 15 April, 1999 (15.04.99) & AU, 9893633, A & EP, 1021534, A1</td> <td>9-74</td> </tr> <tr> <td>Y</td> <td>Hide KIKUCHI, "Ketsueki Baikai Kansensho HCV", Rinshou to Kenkyu (1999) Vol.76, No.7, pp.1260-1266</td> <td>9-74</td> </tr> <tr> <td>PX</td> <td>Tobias Allander, et al., "Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81", Journal of General Virology (October 2000) Vol.81, No.10, pp.2451-2459</td> <td>1,3-74</td> </tr> <tr> <td>A</td> <td>Mike Flint, et al., "Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein", Journal of Virology (1999) Vol.73, No.8, pp.6782-6790</td> <td>1-74</td> </tr> </tbody> </table>			Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	X/Y	PILERI P., et al., "Binding of hepatitis C virus to CD81", Science (1998) vol.282, pp.938-941	1,3-8/9-74	Y	WO, 99/18198, A1 (CHIRON S.P.A.), 15 April, 1999 (15.04.99) & AU, 9893633, A & EP, 1021534, A1	9-74	Y	Hide KIKUCHI, "Ketsueki Baikai Kansensho HCV", Rinshou to Kenkyu (1999) Vol.76, No.7, pp.1260-1266	9-74	PX	Tobias Allander, et al., "Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81", Journal of General Virology (October 2000) Vol.81, No.10, pp.2451-2459	1,3-74	A	Mike Flint, et al., "Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein", Journal of Virology (1999) Vol.73, No.8, pp.6782-6790	1-74
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																		
X/Y	PILERI P., et al., "Binding of hepatitis C virus to CD81", Science (1998) vol.282, pp.938-941	1,3-8/9-74																		
Y	WO, 99/18198, A1 (CHIRON S.P.A.), 15 April, 1999 (15.04.99) & AU, 9893633, A & EP, 1021534, A1	9-74																		
Y	Hide KIKUCHI, "Ketsueki Baikai Kansensho HCV", Rinshou to Kenkyu (1999) Vol.76, No.7, pp.1260-1266	9-74																		
PX	Tobias Allander, et al., "Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81", Journal of General Virology (October 2000) Vol.81, No.10, pp.2451-2459	1,3-74																		
A	Mike Flint, et al., "Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein", Journal of Virology (1999) Vol.73, No.8, pp.6782-6790	1-74																		
<p><input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.</p>																				
<p>* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family</p>																				
<p>Date of the actual completion of the international search 07 May, 2001 (07.05.01)</p>		<p>Date of mailing of the international search report 15 May, 2001 (15.05.01)</p>																		
<p>Name and mailing address of the ISA/ Japanese Patent Office</p>		<p>Authorized officer</p>																		
<p>Facsimile No.</p>		<p>Telephone No.</p>																		

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP01/00967

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Mike Flint, et al., "Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein", Journal of Virology (January 2000) Vol.74, No.2, pp.702-709	1-74

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

专利名称(译)	丙型肝炎的补救措施		
公开(公告)号	EP1256348A4	公开(公告)日	2005-07-27
申请号	EP2001904385	申请日	2001-02-13
[标]申请(专利权)人(译)	日本国立感染症研究所		
申请(专利权)人(译)	三菱制药株式会社 日本成为代表的总干事国立传染病的		
当前申请(专利权)人(译)	三菱制药株式会社 日本成为代表的总干事国立传染病的		
[标]发明人	ITAMI SEIMA C O MITSUBISHI PHARMA CORPORATION SEKI MAKOTO C O MITSUBISHI PHARMA CORPORATION MATSUURA YOSHIHARU MIYAMURA TATSUO		
发明人	ITAMI, SEIMA C/O MITSUBISHI PHARMA CORPORATION SHIBUI, TATSUROU C/O MITSUBISHI PHARMA CORPORATION SEKI, MAKOTO C/O MITSUBISHI PHARMA CORPORATION YOTSUMOTO, YOSHIHISA C/O MITSUBISHI PHARMA CORP. MATSUURA, YOSHIHARU MIYAMURA, TATSUO		
IPC分类号	A61K31/737 A61P31/20 C07K16/10 C12N5/02 A61K38/17 A61K39/395 A61K45/00 C12N15/09 G01N33/50 G01N33/53 G01N33/576		
CPC分类号	A61K31/737 A61K2039/505 C07K16/109 C07K2317/21 C07K2317/622		
优先权	2000034906 2000-02-14 JP		
其他公开文献	EP1256348A1 EP1256348B1		
外部链接	Espacenet		

摘要(译)

本发明提供抑制丙型肝炎病毒的E2 / NS1蛋白与感染丙型肝炎病毒的细胞，表达CD81或CD81的细胞之间结合的物质。本发明可提供具有抗病毒作用的新型药物，例如对HCV感染的抑制作用。